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Abstract
Cardiac remodeling and dysfunction occur prior to the onset of heart failure. Altered
regulation of cardiac function by the autonomic nervous system has been implicated in
the progression of heart disease. Both altered sympathetic and parasympathetic tone
contribute to cardiac disease; however, the role of the parasympathetic nervous system,
and specifically acetylcholine (ACh), in cardiac dysfunction has not been fully
elucidated. In these studies, we sought to determine whether changes in neuronal and/or
non-neuronal ACh release regulate cardiac activity and alter the progression of cardiac
remodeling and dysfunction. A systemic decrease in the expression of the vesicular
acetylcholine transporter (VAChT), the protein responsible for packaging ACh, led to the
development

of

significant

ventricular

dysfunction

coupled

with

significant

transcriptional changes in cardiac tissue. Furthermore, we identified that murine
cardiomyocytes possess an intrinsic cholinergic system, which prevents hypertrophy and
molecular remodeling in cardiomyocytes in response to hyperadrenergic stimulation, in
vitro. In addition, this cardiac non-neuronal cholinergic system (NNCS) is also critical in
regulating heart activity and remodeling, in vivo. Inhibition of cardiomyocyte-specific
ACh secretion led to delayed heart rate recovery following physiological stress, including
exercise, as well as significant ventricular remodeling. Cardiomyocytes lacking the
intrinsic cholinergic system displayed hypertrophy and molecular remodeling. This
NNCS also plays a significant role under pathological conditions as chronic treatment
with angiotensin II led to enhanced cardiac remodeling and ventricular dysfunction in
mice lacking the NNCS. Additionally, this intrinsic cholinergic system in the heart is also
present in human cardiomyocytes, suggesting the conserved expression of prototypic
markers of the cholinergic system in man. This system might be of functional
significance in cardiac disease as failing human cardiomyocytes exhibit increased
VAChT expression, which likely leads to an increase in ACh secretion directly from
cardiomyocytes. The increase in VAChT expression may play a protective role in heart
failure, as overexpression of VAChT in mice did not reveal adverse phenotypes under
physiological conditions. Our data suggest that both neuronal and non-neuronal ACh are

ii

critical in maintaining cardiac homeostasis and deficient cholinergic signaling contributes
to ventricular remodeling and cardiac dysfunction.
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Introduction

Acetylcholine (ACh), a phylogenetically ancient signaling molecule, was first identified
by Otto Loewi in 1921 as the molecule secreted from the Vagus nerve which acts as the
main mediator of chemical synaptic transmission in the parasympathetic nervous system.
Since its discovery, it has been implicated in the regulation of many physiological
functions in both the central and peripheral nervous systems. The parasympathetic
nervous system (PSNS) regulates the heart via the Vagus nerves, which mainly innervate
the atria, with some sparse ventricular innervation, [1] and play a crucial role in
regulating several aspects of cardiac physiology.
Cholinergic signaling leads to a reduction in heart rate, the contractile forces of the atria
and the conduction velocity of both the sinoatrial and atrioventricular nodes. Past
evidence suggests that, under physiological conditions, parasympathetic tone is the main
regulator of heart rate and cardiac activity [2, 3]. Therefore, it is likely that, under
pathological conditions, cholinergic tone is required to balance sympathetic signaling and
prevent a number of known adverse effects associated with increased sympathetic
signaling. This may serve to prevent cardiomyocyte remodeling associated with over
activation of the sympathetic system, as observed during the activation of neurohumoral
responses in heart failure. However, it is unknown whether modulation of cholinergic
activity can serve as a new target for the treatment of cardiac disease by delaying the
progression of cardiac dysfunction associated with heart failure.

1.1 The heart failure syndrome
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Heart failure (HF) is not a disease; rather, it can be characterized as a progressive
syndrome and the final outcome of a number of different acute and chronic conditions. It
is characterized by significant damage and weakening of the cardiac muscle leading to
decreased cardiac output. The prevalence of HF is very high with more that 5.1 million
people over the age of 20 suffering from HF in the US alone [4]. Despite significant
advancements in clinical care of HF patients, this syndrome continues to be an important
contributor to high morbidity (greater than 1 million hospital discharges), mortality
(greater than 50,000 deaths) and economic burden ($30.7 billion) in the US, according to
the latest update on heart disease and stroke [4].
Although heart failure leads to significant changes in the cardiac muscle, robust defects
are also observed in other organs that can be affected by many of the physiological
changes associated with the progression of the HF syndrome. This includes an increase in
fluid retention in the lungs, which worsens as the left ventricular function declines and
there is a greater increase in pulmonary venous pressure [5, 6]. This accumulation of fluid
in the lungs leads to impairment of gas exchange and contributes to the clinical symptoms
of heart failure, which include shortness of breath, especially during strenuous work [7,
8] and even correlates with prognosis in heart failure patients [9]. In addition, the
decrease in cardiac output during heart failure has a pronounced effect on the kidneys,
which begin to retain salt and water [10]. This further exacerbates the pathophysiological
response as it leads to an increase in preload and thereby places further strain on the
failing cardiac muscle.
Clinically, heart failure is associated with a progressive decline in cardiac function, which
leads to increased morbidity and mortality. Furthermore, it is important to note that the
significant molecular and structural remodeling processes, which are initially activated in
order to maintain homeostatic cardiac function, lead to a further aggravation of cardiac
remodeling.
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1.2 Regulation of cardiac hemodynamics

In a healthy heart, there is a fine balance between the mechanisms regulating the filling
and ejection phases of cardiac contractility. Cardiac performance is mainly determined by
five key mechanisms which are active in the cardiovascular system; heart rate, inotropy,
lusitropy, preload and afterload. These mechanisms are intricately connected and, as
such, defects in any of these will lead to a rapid and progressive decline in the function of
the entire heart.
The heart rate is determined by both sympathetic and parasympathetic signaling at the
pacemaker region of the SA node where the wave of depolarization leading to contraction
is initiated [11]. This wave is then propagated through the atria, the AV node and finally
the Purkinje system to induce contraction of atrial and ventricular tissue, in succession, to
produce systole [12].
Inotropy and lusitropy, which refer to the contraction and relaxation of ventricular tissue,
respectively, are mechanisms modulated by the biochemical and biophysical properties of
ventricular cardiomyocytes. As such, they are drastically sensitive to the molecular
changes that occur in cardiomyocytes during heart disease. These mechanisms can be
considerably influenced by several different variables including changes in calcium reuptake into the sarcoplasmic reticulum (SR) [13], as well as changes in the calcium
sensitivity of contractile proteins, including troponin [14, 15]. In addition, changes in
cytoskeletal proteins [16] and ventricular geometry (e.g. thickness of the ventricular
walls) can also have a significant effect on the contractile ability of the myocardium [17].
Although heart rate, inotropy and lusitropy are all regulated by the cardiac muscle, both
preload and afterload are modulated by changes in venous blood flow. Preload is a
measure of the amount of blood returning to the heart from venous circulation. Afterload
refers to the amount of blood remaining in the heart following the end of systole and can
change depending on arterial pressure, especially in the aorta. Under physiological
conditions, there is a fine interplay between venous return of blood to the heart and
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cardiac output. Stroke volume is increased when more blood returns to the heart and can
be decreased when the amount of venous return is low enough to reduce atrial pressure
[18, 19].
Many of these mechanisms, which regulate cardiac output in a healthy heart, appear to be
altered in heart failure and lead to the observed hemodynamic abnormalities. The initial
insult can play a large part in determining the specific hemodynamic changes that will
occur and, therefore, characterize the type of heart failure observed in patients. There are
several distinct manifestations of the heart failure syndrome and these are classified
according to whether the initial abnormality affects the hemodynamic parameters during
systole or diastole.

1.2.1

Systolic and diastolic heart failure

Systolic heart failure is caused by several different initial insults, including myocardial
infarctions, can lead to damage of the ventricular walls [20]. Ventricular wall damage is
associated with enlargement of the ventricles and molecular remodeling of the cardiac
myocytes, which leads to cardiomyocyte elongation and reduced myocyte shortening
capacity [21, 22]. Conditions that damage or weaken the myocardium can serve as the
initial trigger for cardiomyocyte remodeling and the molecular changes associated with
altered myocyte function lead to an overall decrease in ventricular ejection fraction and
systolic heart failure [23, 24]. These include insults that have a regional effect (e.g.
myocardial infarction), or an effect on the entire cardiac muscle (e.g. viral and toxic
myocarditis) [20, 25, 26]. All of these insults lead to an increase in ventricular cavity
volume due to an elongation of cardiomyocytes (i.e. eccentric hypertrophy) [27]. The
changes in the architectural and anatomical structure of the heart in systolic heart failure
lead to inefficient contraction of the ventricular muscle and result in impaired ventricular
ejection.
Conversely, diastolic heart failure is caused by reduced ventricular cavity size, which
often results from thickening of the ventricular cardiomyocytes [28]. Although
ventricular cavity volume is significantly increased in systolic heart failure, it often
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appears to be unaltered, or minimally changed, in patients with diastolic heart failure [29,
30]. This is partly due to the fact that hypertrophic cardiomyopathies, such as
hypertension and diabetes, are the leading cause of diastolic HF [29]. The
cardiomyocytes undergo concentric, as opposed to eccentric, hypertrophy in diastolic HF
and a thickening, rather than elongation, of cardiac myocytes is observed [27]. In
diastolic HF, there is decreased ventricular compliance during diastole due to thickening
of the ventricular walls and this increase in rigidity of the ventricular walls results in
abnormal relaxation and passive stiffness [31]. Diastolic heart failure leads to a
subsequent increase in venous pressure, which ultimately affects pulmonary pressure and
promotes the development of pulmonary edema, a clinical symptom often observed in
patients with diastolic HF [32].

1.3 Hemodynamic changes in heart failure

It is important to recognize that several mechanisms contribute to impaired cardiac
function in heart failure. Systolic and diastolic dysfunction cannot simply be linked to
changes in inotropy or lusitropy, respectively. Rather, the activation of neurohumoral
mechanisms meant to maintain cardiac output leads to altered ventricular hemodynamics
through a variety of pathways and contributes to a very complex heart failure phenotype.
Depending on whether the initial insult leads to systolic or diastolic HF, the myocardium
responds by undergoing either eccentric or concentric hypertrophy, respectively.
Eccentric hypertrophy leads to impairment in ventricular filling and a decrease in EDV
due to the fact that left ventricular dilation increases wall stress during diastole [33, 34].
Furthermore, it leads to inefficient ejection of blood during systole as the altered structure
of the myocardium and increased ventricular diameter contribute to further mechanical
disadvantage. The extent of contractile dysfunction associated with eccentric hypertrophy
can also be affected by the presence of fibrosis following myocardial damage, which
leads to cardiomyocyte necrosis and decreases myocardial compliance during all phases
of the cardiac cycle [35, 36].
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This enhanced fibrotic response also plays a significant role in heart failure associated
with concentric hypertrophy [37], in which the thickening of the cardiomyocytes, and
thus the ventricles, leads to impairment in both the filling and ejection capacity of the
heart [38]. This is due to the decrease in ventricular volume associated with concentric
hypertrophy, which has the effect of reducing stroke volume and increasing end diastolic
pressure. Over time, the reduced ventricular compliance associated with concentric
hypertrophy and diastolic dysfunction results in systolic dysfunction and the onset of
heart failure. Regardless of the initial dysfunction, cardiac remodeling and hypertrophy
often progress to ventricular dilation and a severe decline in cardiac output (Fig. 1.1).
Following initial cardiac remodeling and reduction in ventricular contractility and
ejection, increased residual blood volume (i.e. end-systolic volume) leads to an increase
in end-diastolic volume, which activates hemodynamic responses involved in altering
both preload and afterload to maintain homeostatic cardiac output. In the event of
impaired ventricular filling, as is observed in diastolic dysfunction, vasoconstriction and
fluid retention in the kidneys are activated in order to increase preload and afterload,
respectively [39].
The hemodynamic abnormalities observed in HF patients can be altered by neurohumoral
responses including vasoconstriction, fluid retention and changes in proliferative
signaling. However, these responses tend to have maladaptive long-term consequences,
which lead to a progressive decline in cardiac function and greater myocardial
remodeling in heart failure.

1.4 Neurohumoral responses to decreased cardiac output

The initial changes in ventricular hemodynamics, including reduced arterial filling and
increased accumulation of blood in venous circulation, activate the neurohumoral
response in order to maintain cardiac homeostasis. Although these responses are critical
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Figure 1.1 - Progression of cardiac remodeling in heart failure. (1) A healthy heart
can regulate short-term changes in cardiac output and has the ability to maintain the
metabolic demands of the body. (2) The presence of cardiovascular stressors or disease
leads to activation of neurohumoral responses to maintain ventricular hemodynamics,
which results in pathological hypertrophy associated with the activation of various
molecular remodeling processes. (3) Prolonged hypertrophy and activation of
neurohumoral responses, including enhanced sympathetic tone, leads to ventricular
dilation characterized by an enlargement of the ventricular cavity. This leads to a further
decline in cardiac output and heart failure.
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Figure 1.1 - Progression of cardiac remodeling in heart failure.
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in regulating cardiac function during the short-term, they can also exacerbate and
enhance the progression of heart failure.
Interestingly, the decrease in arterial filling observed following the initial cardiac insult
activates pathways, which lead to an increase in cardiac output, vasoconstriction of blood
vessels and fluid retention in the kidneys through inhibition of sodium and water
excretion [40]. These responses are commonly activated when the cardiovascular system
is challenged over the short-term through either exercise or increased blood loss, as seen
during hemorrhaging [41, 42]. However, in heart failure, as cardiac function
progressively declines, this neurohumoral response persists and becomes maladaptive.
In addition to these changes to the cardiovascular system, long-term changes, including
transcriptional changes that can alter cardiomyocyte function and signaling, also take
place concurrently. Furthermore, the activation of pro-inflammatory responses play a
significant role in altering the progression of heart failure [43, 44] and can evolve slowly
over months and years following the initial induction of cardiac disease.

1.4.1

Cardiac stimulation to increase cardiac output

Similar to the neurohumoral response observed in exercise, the increase in cardiac output
in heart failure is modulated by activation of autonomic centers in the brainstem. In
response to decreased arterial filling, activation of the baroreceptor reflex leads to a
subsequent increase in sympathetic activity and reduction in parasympathetic tone [45,
46]. This increase in noradrenergic signaling leads to an increase in ventricular ejection
by enhancing inotropic responses, augmenting ventricular filling by affecting lusitropy
and also increasing cardiac output by accelerating heart rate through its positive effects
on chronotropy [47, 48]. An increase in cardiac contractility decreases end-systolic
volume by enhancing ventricular ejection. Importantly, the positive effects on cardiac
contractility are not solely due to the effects of norepinephrine on cardiac myocytes;
rather, other regulatory mediators including angiotensin II [49], vasopressin [50] and
endothelin [51] also play minor roles in increasing the contractile response. Similarly,
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enhanced lusitropic responses can also increase cardiac output by increasing end diastolic
volume through greater myocardial relaxation during diastole [52].
Though these effects have a positive influence on cardiac output and maintain the
metabolic requirements of all tissues, the long-term activation of these responses leads to
a chronic cardiac energy deficit due to consistently elevated cardiac energy utilization
that accompanies increased chronotropic and inotropic responses. This leads to a
significant decrease in myocardial reserve ATP levels and is thought to contribute to
diastolic dysfunction [53] and increased susceptibility of the heart to stress [54].

1.4.2

Vasoconstriction to maintain blood pressure

In the event of reduced arterial filling, as seen in heart failure, a major neurohumoral
response involves activation of arterial vasoconstriction in order to increase peripheral
vascular resistance [55, 56]. This increase in vasoconstriction is activated through
sympathetic stimulation, which leads to the release of norepinephrine, downstream
activation of α1-adrenergic receptors on smooth muscle cells and increased blood
pressure [57]. During heart failure, this mechanism increases afterload in order to
maintain blood pressure. However, the reflex response to increase vasoconstriction can
lead to an increase in myocardial energy demand. This increase in energy expenditure is
due to the fact that the cardiac muscle must sustain greater contractility in order to
maintain normal cardiac output against greater resistance. This places further strain on
the damaged cardiac muscle and, once again, leads to a decline in cardiac function.
Aside from its negative effects on cardiac muscle, this increase in vasoconstriction also
has maladaptive effects in other organs as it leads to a reduction in the amount of blood
flow throughout the body. This can contribute to an enhancement of clinical symptoms in
patients with end-stage HF, including anemia [58].
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1.4.3

Fluid retention to maintain cardiac output

In the event of cardiogenic shock, which is observed under conditions of severe left
ventricular dysfunction (e.g. following myocardial infarction or myocarditis), there is a
significant and drastic decline in blood pressure [59]. In order to counteract this extreme
decrease in arterial filling, the kidneys retain salt and water. This restores blood volume
and increases preload, which can help maintain cardiac output even under conditions
where the myocardium is damaged [39]. However, due to the long-term deficits in
cardiac output observed in heart failure, these responses become detrimental because the
increase in preload further augments the problems associated with elevated systemic and
pulmonary venous pressures. In fact, sodium and water retention by the kidneys serves as
a cause for edema, one of the major clinical symptoms observed in heart failure [60]. In
severe HF, the significant decrease in cardiac output leads to a subsequent reduction in
glomerular filtration rate (GFR) and contributes to increased sodium retention, and hence
water retention, in the plasma [61]. Additionally, vasoconstriction of renal efferent
arterioles and increased sodium reabsorption by renal tubules also leads to significant
fluid retention in heart failure [61].

1.5 Mediators of the neurohumoral response

Many of the signaling cascades activated during the neurohumoral response contribute to
maintaining hemodynamic homeostasis; however, these cascades activate pathological
hypertrophy and lead to the progression of cardiac dysfunction and heart failure. The first
major neurohumoral response activated in heart failure involves a drastic increase in
secretion of norepinephrine by sympathetic nerves [62]. However, in addition to these
changes in sympathetic activity, there is also a marked activation of several other
signaling pathways.
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1.5.1

Renin-angiotensin-aldosterone system (RAAS)

The RAAS system plays a crucial role in modulating blood pressure and fluid retention
and can, therefore, be activated to maintain homeostasis during changes in blood volume,
as observed in heart failure [63]. Under conditions where blood volume is decreased,
renin gets secreted from juxtaglomerular cells in the kidneys into the plasma [64, 65].
Renin is then able to activate the conversion of the peptide angiotensinogen, which is
secreted from the liver, into angiotensin I [66, 67]. The subsequent conversion of
angiotensin I into angiotensin II occurs via the proteolytic actions of the angiotensinconverting enzyme (ACE) in both the blood, where it is found in high concentrations on
the surface of endothelial cells, as well as several tissues throughout the body [68-70].
Interestingly, the same enzyme which catalyzes the conversion of angiotensin I into
angiotensin II also hydrolyzes the peptide, bradykinin [71-73]. This protein serves as a
vasodilator due to its actions on endothelial cells in the vasculature where it induces the
production of NO, cAMP and prostacyclins [74-76]. As such, ACE can play a significant
role in modulating vascular tone because it can increase production of angiotensin II, a
vasoconstrictor, and concurrently hydrolyze the vasodilator, bradykinin.
Angiotensin II has emerged as a multifunctional cytokine that exerts its effect through
interaction with two G-protein coupled receptor (GPCR) subtypes, AT1 and AT2, which
regulate opposing responses [77, 78]. The levels of AT2 receptors are significantly lower
than AT1 receptors in adult tissues. Although the importance of AT2 receptors in heart
failure is not as well understood, angiotensin II appears to signal via this receptor subtype
to induce vasodilation and inhibition of cellular growth [79, 80]. AT1-dependent
signaling leads to potent vasoconstriction through direct effects on vascular smooth
muscle cells [81, 82]. In addition, it can also have a small effect on inotropy as it can
enhance myocardial contractility [83]. Finally, AT1 receptor signaling can also activate
cardiomyocyte hypertrophy, likely through both mechanical stretching as well as direct
effects on ventricular myocytes [84-86].
In addition to its effects in the cardiovascular system, angiotensin II also appears to
activate AT1 receptors in the paraventricular nucleus (PVN) of the hypothalamus and
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thereby regulate fluid balance and sympathetic drive in an animal model of congestive
heart failure [87]. Pharmacological inhibition of this receptor in the PVN reduces
neuronal firing and decreases sympathetic drive and volume accumulation [87].
Furthermore, angiotensin II also plays a major role in regulating fluid reabsorption in the
kidneys. It is able to stimulate the transcription and activity of Na+/H+ exchangers [88,
89] as well as induce hypertrophy of renal tubule cells [90, 91], which leads to an
increase in sodium reabsorption. As sodium absorption increases, water is subsequently
taken up from the urine by the tubules, which increases blood volume and facilitates the
angiotensin II-mediated increase in blood pressure [92].
Importantly, Ang II appears to have a critical function in several different pathways that
regulate the progression of pathological remodeling in cardiac disease. It has direct
effects via AT1 and AT2 receptors, but it can also stimulate the release of other
modulators of the cardiovascular system. These include aldosterone, vasopressin,
endothelin, nitric oxide, as well as catecholamines, including epinephrine and
norepinephrine.
In a healthy individual, aldosterone secretion is regulated by adrenocorticotropic
hormone (ACTH) from the anterior pituitary gland, which can then stimulate aldosterone
synthesis in the adrenal cortex [93]. In severe heart failure, the high concentration of
circulating angiotensin II serves as the major stimulator of aldosterone secretion,
especially in the left ventricle [94, 95]. Once produced, aldosterone is secreted into the
blood and can act on distal tubules to increase sodium and water reabsorption and
increase blood volume as well as blood pressure through this mechanism [93].

1.5.2

Vasopressin

Angiotensin II can also stimulate the release of the peptide hormone vasopressin from the
posterior pituitary gland, which is normally secreted in response to low blood volume
[96]. The major function of vasopressin is to increase water permeability of the renal
collecting ducts through V2 receptor-mediated regulation of aquaporin expression and
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distribution, thereby inhibiting water secretion and increasing blood volume [97, 98]. In
addition, it can also augment vasoconstriction by enhancing the effects of catecholamines
and thereby increasing blood pressure [99]. In heart failure, these potent effects of
vasopressin become maladaptive due to the fact that vasopressin secretion is constantly
elevated in response to increased levels of circulating Ang II as well as arterial
underfilling as a result of decreased cardiac output.

1.5.3

Nitric oxide (NO)

Nitric oxide is an important cellular signaling molecule in many different cell types
throughout the body, including endothelial cells in the vasculature [100]. It is
biosynthesized by three separate nitric oxide synthase (NOS) enzymes using the
precursor L-arginine [101, 102]. Interestingly, Ang II also plays a role in inducing
pathophysiological responses via NO signaling as exposure to angiotensin II can increase
eNOS transcription and NO production [103].
Two of the three isoforms of NOS, nNOS and eNOS, are constitutively active enzymes
and play a role in physiological signaling through autocrine/paracrine effects [104]. NO
induces its physiological effects, in particular vasodilation, through binding to soluble
guanylyl cyclases which leads to the production of cGMP and protein kinase G (PKG),
the protein which modulates reuptake of calcium into intracellular stores [105, 106].
Importantly, physiologically relevant concentrations of NO are maintained by eNOS and
nNOS, which are activated by calcium and calmodulin [104]. However, the inducible
form of NOS (iNOS), which is expressed in endothelial cells, smooth muscle cells as well
as macrophages can be activated by immunostimulatory cytokines or infection and
produce very high concentrations of NO in a calcium-independent manner [102, 104,
107].
Activation of iNOS in isolated cardiomyocytes by inflammatory mediators is able to
inhibit contractility [108]. In fact, experimental heart failure in rabbits has been shown to
increase levels of iNOS, which may contribute to contractile dysfunction due to increased
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production of superoxides in the heart [109]. iNOS-dependent superoxide production
may compound the increased oxidative stress observed due to the stimulatory effects of
Ang II on endothelial NADPH oxidase, which leads to the production of hydrogen
peroxide and superoxides [110-112]. Importantly, iNOS expression is significantly
increased in human heart failure, especially in dilated cardiomyopathy and ischemic heart
disease, which suggests a functional role for iNOS signaling in cardiac disease in humans
[113].

1.5.4

Endothelin

Angiotensin II can mediate secretion of the protein, endothelin, from endothelial cells in
the vasculature [114-116]. Endothelin-1 (ET-1) is the major isoform of endothelin in the
cardiovascular system and its release can be modulated through the actions of angiotensin
II, epinephrine [117], mechanical pressure [118, 119], and high shear stress along the
vessel walls [120]. Endothelins are very potent vasoconstrictors and mediate these effects
via the ETA GPCRs in a paracrine manner [121]. ETA receptors couple to Gq proteins in
vascular smooth muscle cells and binding of ET-1 to these receptors induces
vasoconstriction through activation of PLC to produce IP3 and DAG [122]. In addition to
its effects on vascular tone, ET-1 also increases cardiac contractility over the short-term
[117] while the long-term effects include induction of hypertrophic remodeling in
cardiomyocytes [123]. Furthermore, ET-1 has been shown to induce pro-inflammatory
responses in different tissues, including the myocardium [124, 125].
Under normal physiological conditions, vascular tone is maintained through a delicate
balance between vasodilators and vasoconstrictors, including ET-1. However, the drastic
changes observed in cardiac output during heart failure lead to significant activation of
several neurohumoral mechanisms. Importantly, it appears that the overactivation of the
sympathetic system that occurs early during the onset of heart failure plays a crucial role
in the activation of many of these compensatory mechanisms.
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1.5.5

Sympathetic hyperactivity

The autonomic nervous system is the main regulator of cardiac output. It is accepted that
chronic autonomic sympathetic/parasympathetic imbalance plays a crucial role in the
development of HF and is a critical modulator of the neurohumoral response [126-129].
Importantly, increased sympathetic tone, coupled with decreased parasympathetic drive,
is seen even in the early stages of CHF [130, 131].
Several lines of research implicate the over-activation of the sympathetic nervous system
in patients as a major contributor to cardiac remodeling [62, 132]. This is associated with
poorer prognosis and higher morbidity and mortality [133], as increased sympathetic tone
may help to preserve cardiac function initially, but then may contribute to remodeling
[128, 134]. The activation of neurohumoral mechanisms, including increased SNS
signaling, is a hallmark of heart failure resulting from homeostatic regulation following
the initial decrease in cardiac output [128, 134]. SNS hyperactivity is observed in several
cardiac diseases including hypertension, where patients display a significant increase in
SNS activity, a phenomenon which appears to contribute to altered blood pressure
regulation as well as left ventricular dysfunction [135]. Importantly, decreasing SNS
signaling through activation of the baroreflex has been shown to increase survival in an
animal model of chronic HF [136], thus suggesting that enhanced sympathetic signaling
plays a critical role in the progression of cardiac dysfunction.
Norepinephrine, secreted by the sympathetic nervous system, binds to adrenergic
receptors in the heart as well as the vasculature and kidneys. As such, it plays a
significant role in modulating maladaptive responses in heart failure. In the heart,
norepinephrine can bind to β1-adrenergic receptors, the major subtype in cardiac tissue,
and activate second messenger signaling via the stimulatory G-protein, Gs, which
activates adenylyl cyclase and cAMP production [137]. The noradrenergic-mediated
inotropic, lusitropic and chronotropic responses observed following activation of the β1
adrenergic receptor serve to maintain cardiac output [138], but also mediate pathological
cardiac hypertrophic responses and induce myocyte apoptosis, thus leading to further
weakening of the failing cardiac muscle [137, 139].
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In the vasculature, norepinephrine binds to α-adrenergic receptors, which are coupled to
Gq proteins. As such, activation of α1-adrenergic receptors activates production of IP3
and DAG, which induce vasoconstriction in vascular smooth muscle cells through IP3mediated calcium release from intracellular stores and activates DAG-mediated signaling
via protein kinase C (PKC) [140]. The arterial vasoconstriction mediated by
noradrenergic signaling can increase blood pressure and promote both sodium and fluid
retention in the kidneys.
Modulation of the autonomic nervous system has become an important target in
decreasing morbidity and mortality in heart failure patients. Currently, β-adrenergic
receptor blockers, in combination with angiotensin-converting enzyme inhibitors (ACEi)
and angiotensin receptor blockers (ARBs), are used as a first-line treatment for HF [141].
β-blockers work by inhibiting the effect of norepinephrine, released from sympathetic
neurons, on β-adrenergic receptors in both the heart and vasculature and can thereby
decrease heart rate and lower blood pressure through vasodilation. This reduces the
pressure placed on the heart and thus preserves cardiac function. The chronic use of βblockers has been quite successful and has been shown to increase cardiac function and
reduce left ventricular remodeling and mortality in patients, with third-generation nonselective β-blockers decreasing mortality more than second-generation β1-selective drugs
(34% vs. 40%, respectively) [142-144].
The importance of modulating sympathetic tone in left ventricular hypertrophy and
cardiomyopathy is further highlighted by the fact that autoantibodies against the β1adrenergic receptor are found in patients with both cardiac hypertrophy and dilated
cardiomyopathy [145, 146]. The cause and effect relationship between the production of
autoantibodies and cardiomyopathy has not yet been fully elucidated. However, the
presence of these autoantibodies has been shown to activate signaling cascades
downstream of β1-adrenergic signaling in cultured myocytes and may contribute to the
cardiac dysfunction observed in cardiomyopathy [147]. It is also possible that, in addition
to activation of signaling pathways downstream of adrenergic receptor activation, the
presence of these autoantibodies also leads to autoimmune-mediated cardiac damage.
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In addition to the positive effects observed following inhibition of direct actions of
sympathetic signaling in the heart, positive outcomes have been observed following renal
sympathetic denervation in patients with heart failure. Activation of the renal sympathetic
nerves in heart failure leads to increased peripheral vascular resistance and ventricular
remodeling, partly due to higher levels of angiotensin II. Renal denervation has shown
promise in human heart failure patients, as there was a trend towards improvement in
exercise capacity and LV hypertrophy [148, 149]. Furthermore, independent of its blood
pressure lowering effects, renal denervation has been shown to have a positive effect on
atrial fibrillation [150] and heart rate reduction [151], both of which have been shown to
play a critical role in reducing morbidity and mortality in HF patients.

1.6 Cellular and molecular abnormalities in response to
neurohumoral signaling

The activation of all the pathways that regulate neurohumoral signaling as well as the
chronic increase in cardiac volume, which occurs in order to compensate for
hemodynamic changes, leads to significant cellular and molecular abnormalities in failing
hearts. These cellular changes constitute the significant cardiomyocyte remodeling
observed in heart failure and lead to further defects in ventricular ejection during systole
and/or impaired filling of the ventricles during diastole. The abnormalities that contribute
to these defects can be characterized as functional changes wherein normal cardiac
proteins and structures responsible for proper functioning of the cardiac muscle are
altered. In addition, the changes at the cellular level also lead to changes in the
architectural structure of the heart, likely as the result of chronic exposure to
neurohumoral signaling at the level of the cardiac muscle.

1.6.1

Cardiac contraction and relaxation

The heart is composed of several different cell types, including endothelial cells,
fibroblasts as well as vascular smooth muscle cells and cardiomyocytes. There are several
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types of cardiomyocytes present in the heart, including specialized myocytes capable of
conducting action potentials that regulate chronotropy via intracellular cAMP signaling
[152]. In contrast, inotropy and lusitropy are dependent on the function of working
cardiomyocytes, which are organized in a branched network. Synchronous contraction is
maintained via specialized cell-cell junctions that allow action potentials to travel
between adjacent cardiomyocytes without interruption [153]. Due to the fact that cardiac
myocytes are highly active, contracting cells, nearly half the volume of these cells is
composed of contractile proteins organized in myofibrils. Much of the remaining cellular
volume is occupied by mitochondria, which provide the energy required for the
maintenance of cardiac work.
The myofibrils are composed of myofilaments, which contract in ventricular myocytes
following direct activation by the second messenger calcium (Ca2+) during systole [154]
(Fig. 1.2). Importantly, in order to maintain synchronous contraction of the entire
cardiomyocyte, tubular invaginations known as transverse tubules (T-tubules) are present
throughout the cell and allow for proper excitation-contraction coupling by regulating
calcium influx via the L-type Ca2+ channels [155-157]. Importantly, in heart failure,
where there is a decrease in systolic Ca2+ transients, there appears to be an upregulation
of L-type Ca2+ channel density as well as probability of opening, suggesting a response to
maintain intracellular Ca2+ currents (ICa,L) and preserve cardiac contractility [158, 159].
T-tubules also allow exposure to the extracellular environment and, in combination with
the plasma membrane, can mediate excitation-contraction coupling and regulate cell
signaling mediated by ligand binding to receptors on the extracellular face of the
membranes [160-163].
In addition to the T-tubules and plasma membrane, there are also subcellular structures
within the cardiomyocytes that play key roles in regulating excitation-contraction
coupling in these cells. One of these structures is the sarcoplasmic reticulum (SR), which
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Figure 1.2 - Mechanisms regulating calcium-induced calcium release and excitationcontraction coupling. (1) Action potentials and initiated at the SA node and travel along
the sarcolemma and activates voltage-gated L-type Ca2+ channels in T-tubules. (2) Ca2+
influx into the cytosol activates ryanodine receptors (RyRs) on the sarcoplasmic
reticulum (SR) and induces Ca2+ release from the SR. (3) Cytosolic Ca2+ binds to
Troponin C and induces contraction of myofilaments. (4) Following systolic contraction,
intracellular Ca2+ is transported back into the SR by the sarco/endoplasmic reticulum
ATPase (SERCA2a) where it is sequestered until the next contraction. Cytosolic Ca2+ is
also extruded from the cell via the Na+/ Ca2+ exchanger (5) and a small amount is taken
up by the mitochondria via the mitochondrial Ca2+ uniporter (MCU) (6). (7) The Na+/K+
ATPase transports Na+ out of the cell in order to maintain resting membrane potential.
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Figure 1.2 - Mechanisms regulating calcium-induced calcium release and excitationcontraction coupling.
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is the main intracellular store for Ca2+ in myocytes and is responsible for the majority of
cytosolic Ca2+ that induces contraction [164-166]. All of these structures work together to
deliver calcium to the contractile proteins of the sarcomeres during systole.

1.6.2

Calcium transport in cardiomyocytes

Calcium entry into the cardiomyocyte upon initiation of contraction is dependent on the
activation of L-type calcium channels in the T-tubules and plasma membrane, which
allow for the passive diffusion of calcium into the cytosol down its electrochemical
gradient [155-157]. Importantly, although extracellular calcium is the major source for
contractility in embryonic hearts, where the contractions are weak and develop slowly
[167, 168], the extracellular calcium in an adult cardiomyocyte is only sufficient to
activate contraction in a small population of sarcomeres. As such, calcium release from
intracellular stores, a process dependent on calcium influx from the extracellular
environment, is necessary for the development of proper tension and contractility.
Calcium-induced calcium release (CICR) involves release of Ca2+ from SR stores into the
cytosol through cardiac ryanodine receptors (RyR) on the SR membrane, downstream of
Ca2+ influx via the L-type Ca2+ channels on the T-tubules [166]. Notably, calcium release
channels in the cardiomyocytes are highly regulated and phosphorylation by
calcium/calmodulin-dependent protein kinase II (CaMKII) can inhibit channel opening
and play a protective role under conditions of calcium overload [169]. RyR on the SR can
be phosphorylated by PKA following sympathetic activation, an event observed during
heart failure, which results in increased calcium release from the SR and a positive
inotropic response [170-172]. This leads to myocyte damage due to calcium overload in
cardiomyocytes and may contribute to the adverse effects on cardiac function observed in
HF following long-term activation of neurohumoral signaling [171].
In addition to RyR, IP3-gated receptors are also present on the SR membrane [173, 174]
and can trigger Ca2+ release from intracellular stores [175, 176]. They are thought to
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regulate development of arrhythmias by increasing diastolic Ca2+ levels as well as
pathological signaling downstream of neurohumoral activation [177-180].

1.6.3

Regulation of cardiomyocyte contractility

Cardiomyocyte contraction occurs through movement of two sets of filaments, which
slide against each other and shorten during systolic contraction. This theory, known as
the sliding filament theory, utilizes calcium secreted from intracellular SR stores to
induce contraction in cardiomyocytes [181]. The thin and thick myofilaments that
compose the sarcomeres partially overlap under resting conditions and slide by one
another during contraction to generate tension and shorten the muscle [182]. Sarcomere
length is regulated by the amount of overlap between the thin and thick filaments and
appears to play a critical role in determining the intensity of excitation-contraction
coupling and, hence, the efficiency of contraction [183]. The contractile process is
dependent on the interaction between myosin on the thick filaments and actin on the thin
filaments, which form a cross-bridge during sarcomeric contraction [182]. The crossbridge formation that regulates contractility of the sarcomeres requires the presence of
cytosolic calcium, with the SR serving as the major source of intracellular calcium for
this process [184, 185]. Once released into the cytosol, calcium binds to the troponin
complex on the thin filament, which consists of three proteins including troponin I
(inhibitory subunit), troponin T (tropomyosin-binding subunit), and troponin C (calciumbinding subunit) [186-189]. This complex regulates the interaction between the thick and
thin filaments of filamentous actin (F-actin) which comprise the myofilaments in the
sarcomeres [186]. Upon binding to calcium, troponin C causes a rearrangement of
regulatory proteins and binds to the inhibitory troponin subunit (TnI) more strongly thus
causing it to dissociate from actin [190, 191]. This allows cross-bridge formation between
actin and myosin, the motor protein responsible for contraction of the sarcomeres and
cardiomyocyte shortening [192, 193]. Importantly, the amount of calcium entering the
cytosol during systole under basal conditions is only sufficient to bind approximately half
the troponin C molecules present in the cardiomyocyte. This allows the intensity of the
contractile response to be modulated by interventions that alter the amount of calcium
released from the SR during CICR. Furthermore, it also implies that the activity of both
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tropomyosin and the troponin complex play an important role in modulating tension
development during contraction.
During systole, the energy for contraction of the sarcomeres, and hence the
cardiomyocytes, is provided by ATP hydrolysis at the catalytic site of the myosin head, a
process mediated by an actin-activated ATPase found on the myosin head [194]. In order
for the sarcomeres to return to the relaxed state during diastole, interdigitation of actin
and myosin must be inhibited, a process dependent on ATP binding to the catalytic site of
myosin [195]. This sarcomeric relaxation is dependent on the export of Ca2+ from the
cytosol in order for troponin C to return to its resting state and inhibit actin-myosin
interaction. In order for the cell to maintain steady state calcium levels following systole,
cytosolic calcium must be effluxed across the plasma membrane or into the SR, a process
that occurs against the concentration gradient for this ion.
In order to pump calcium into the extracellular environment, the myocyte utilizes both
the plasma membrane calcium pump ATPase (PMCA) as well as the sodium/calcium
(Na+/Ca2+) exchanger (NCX), which is responsible for the majority of calcium efflux due
to its greater capacity for calcium than PMCA [196, 197]. The actions of PMCA are
dependent on ATP hydrolysis which provides the energy to power calcium transport
across the plasma membrane [198, 199]. Although PMCA does not play a major role in
regulating calcium efflux during diastole, it may play a role in cardiac remodeling as it
has been shown to regulate cardiomyocyte hypertrophy following hyperadrenergic
stimulation, in vitro [200].
The NCX is an antiporter, which utilizes the sodium gradient to translocate three sodium
ions into the cell in order to expel one calcium ion across the plasma membrane against
its electrochemical gradient [201, 202]. The NCX maintains normal steady state
intracellular calcium levels by effluxing a similar concentration of calcium as that which
enters the cell via the L-type calcium channels. However, in NCX knockout mice, normal
excitation-contraction coupling is maintained through a compensatory decrease in Ca2+
influx [203]. Importantly, NCX is activated via phosphorylation by PKA and PKC, a
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characteristic that is critical in preventing calcium overload in the cell [204, 205].
Interestingly, in the event of calcium overload, which often occurs in failing hearts, the
increase in calcium efflux through the NCX can lead to production of afterdepolarizations and ventricular fibrillation due to the increased influx of sodium, which
has electrogenic properties [206, 207]. In fact, the most important cause of sudden
cardiac death in heart failure is this ionic current generated by increased intracellular
sodium concentrations [208, 209].
In addition to calcium efflux into the extracellular space via plasma membrane
transporters, the SR also plays a crucial role in removing the majority of cytosolic
calcium in order to relax the sarcomeres [210]. The sarcoplasmic reticulum calcium
pump (SERCA2a) transports calcium into the SR following systole, a process dependent
on ATP hydrolysis. In order to maintain low concentrations of calcium in the SR lumen,
calcium is bound to calsequestrin in the SR [211]. The sequestration of calcium by the
calsequestrin protein is crucial in maintaining normal calcium stores and thus
cardiomyocyte function as altered intracellular calcium stores leads to pathological
responses [212, 213]. Importantly, movement of calcium across the SR membrane does
not generate an electrical current due to the presence of anion channels on the SR
membrane that allow anion transport along with calcium.
It is important to note that the energetic imbalance observed in the failing heart, where
there is a deficiency in reserve ATP levels, leads to defective function of the SERCA2a
pump. Furthermore, there is a decrease in the expression of SERCA2a in hypertrophied
cardiomyocytes, which can inhibit calcium uptake into the SR and thereby impair
relaxation during diastole, a process that further exacerbates cardiac dysfunction [214,
215]. The decrease in calcium movement into the SR via SERCA2a is of even greater
importance in heart failure because there is significant activation of other processes that
contribute to calcium overload and development of both atrial and ventricular
arrhythmias in the failing myocardium.
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In an attempt to reduce cytosolic calcium levels, mitochondria in failing cardiomyocytes
begin to accumulate excess calcium and have been shown to sequester very large
amounts of calcium [216, 217]. Calcium enters the mitochondria through the
mitochondrial Ca2+ uniporter (MCU) and activates enzymes that play key roles in the
tricarboxylic acid (TCA) cycle [218-220], which leads to an increase in NADH
production, and consequently ATP levels [221]. Normally, calcium uptake and release
from mitochondria play a very minor role in excitation-contraction coupling due to the
slow turnover of mitochondrial calcium transport [222, 223]. The mitochondria can
sequester significant amounts of Ca2+; however, beyond a certain threshold, the
mitochondria are unable to regulate [Ca2+] in the matrix and this leads to further
mitochondrial overload [224]. This increase in mitochondrial [Ca2+] leads to opening of
the mitochondrial permeability transition pore (mPTP) and cell death [225, 226]. mPTP
opening further abrogates the energetic deficits because it leads to uncoupling of
oxidative phosphorylation [227]. In fact, the negative effect of this process is two-fold as
mPTP opening leads to an increase in the production of reactive oxygen species (ROS),
which can further perpetuate the molecular changes observed in ischemia/reperfusion
injury and heart failure [228-230]. Together, these changes may serve as the molecular
basis for the progressive decline in cardiac contractility observed following activation of
neurohumoral mechanisms in heart failure.

1.6.4

Cardiac energetics

Under normal conditions, the heart maintains a large pool of reserve energy in the form
of phosphocreatine (PCr), which can then be used by the creatine kinase (CK) enzyme to
generate ATP and drive energy-requiring reactions in the heart [231]. In addition to PCr,
glycogen also serves as an energy store in the heart and can generate ATP via glycolytic
and oxidative metabolism [232].
Creatine (Cr) is not produced in excitable tissues like the heart but rather, it is transported
into cardiomyocytes through the actions of a facilitated creatine transporter against its
concentration gradient [233]. Importantly, Cr transporter levels in the failing myocardium
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are significantly decreased, and may explain the observed decrease in [Cr][234-236]. The
decrease in Cr levels in the failing heart leads to a decrease in cardiac energetic reserves
and likely contributes to the decreased [ATP] observed in heart failure because it occurs
earlier in cardiac disease than the decrease in ATP levels [237, 238]. In patients with
heart failure, the phosphocreatine-to-ATP (PCr/ATP) ratio is significantly reduced and
can serve as a predictor of mortality [239, 240]. Furthermore, absolute levels of both ATP
and phosphocreatine levels are significantly reduced [241-243]. This decrease in
PCr/ATP ratio is especially profound in the subendocardial region of the left ventricle
postinfarction due to marked effects of high shear wall stress in this region, which leads
to decreased ATP production and abnormal energy metabolism [244].
Importantly, the decrease in cardiac ATP levels leads to a greater impairment in
relaxation, rather than contraction, since many of the transport mechanisms that remove
cytosolic calcium following systole are ATP-dependent [245-247]. Therefore, the
decrease in ATP and increase in ADP seen in overloaded and failing hearts leads to
impaired cardiac diastole as the transport of calcium becomes significantly slower and
actin-myosin cross-bridge turnover is impaired [53, 248]. It is important to note that the
decrease in cardiac energy levels observed during heart failure are not drastic enough to
completely inhibit normal, energy-requiring reactions in the myocytes. This is
exemplified by the fact that mice that cannot synthesize Cr still display normal
contractility under baseline conditions; however, they display greater susceptibility to I/R
injury following treatment with an inotropic agent [249]. As such, though the rate of
these reactions is reduced, they can still occur in the failing myocardium, a characteristic
that has further detrimental effects due to increased energy consumption by inefficient
processes regulating myocardial work, especially those involving the contractile
machinery.
In addition, as mentioned previously, the increase in mitochondrial calcium levels
contributes to impairments in mitochondrial function. This leads to a decrease in ATP
regeneration via uncoupled oxidative phosphorylation, which leads to decreased
oxidative capacity and function of the myocardium [250-252]. Compromised
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mitochondrial function has further damaging effects because, in addition to reduced
glucose oxidation to produce ATP, fatty acid oxidation is also reduced [253, 254]. The
latter serves as the main source for ATP in a normal, healthy heart [255] and supplies
nearly 70% of total ATP under physiological conditions [256]. Fatty acids utilized for
energy by the myocardium are supplied from circulating triglyceride-rich lipoproteins
and nonesterified fatty acids, which are metabolized in the mitochondrial matrix to
generate acetyl-CoA, the substrate for ATP production via the tricarboxylic acid (TCA)
cycle [255].
In heart failure, there is a decrease in fatty acid β-oxidation, which is coupled to an
increase in glucose utilization, due to upregulation of enzymes involved in glycolytic
pathways [253, 257, 258]. The shift towards glyocolytic metabolism is thought to be a
compensatory response in order to maintain myocardial contractility. This is because
glucose metabolism leads to a more efficient utilization of oxygen to generate ATP than
fatty acid metabolism, which involves mitochondrial ETC uncoupling and can have
adverse effects in heart failure [259, 260].
In conjunction with activation of mechanisms that reduce ATP production, energy
utilization in remodeled cardiac myocytes is also greatly increased. Cardiomyocyte
hypertrophy can further aggravate the imbalance between energy production and
utilization. This is especially true in familial hypertrophic cardiomyopathy, where
mutations in sarcomeric proteins lead to inefficient ATP utilization and further
progression of cardiac dysfunction [261-263].

1.6.5

Implications of ROS production

Decreased utilization of fatty acids as a fuel source in heart failure changes the
myocardial energetic state. In addition, it also leads to lipid accumulation, and thus
cardiac lipotoxicity, due to increased levels of toxic intermediates in the myocardium
[264, 265]. These intermediates can lead to impaired cardiac function due to myocardial
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atrophy, protein degradation and cell death [266-268]. Lipotoxicity can play a critical role
in impaired left ventricular filling and both systolic and diastolic dysfunction [269-271].
It is important to note that mitochondrial uncoupling associated with decreased fatty acid
oxidation in heart failure also leads to excessive production of reactive oxygen species
(ROS), which is detrimental to cardiac function and can effectively induce cell damage
and death [272-274]. In fact, many of the pathways that lead to cardiomyocyte
hypertrophy and remodeling following exposure to external stimuli are activated by ROS
[275]. In fact, ROS plays a key role in mediating the pathological responses observed
Ang II-induced hypertrophy due to its role in activating downstream signaling, including
MAPKs [276]. Moreover, ROS appears to be critical for Ang II-mediated hypertrophy as
treatment with antioxidants is able to abolish Ang II-induced cardiac remodeling [277].
In addition to its effects on cardiac hypertrophy, ROS can also alter myocardial
contractility through a number of different mechanisms. It is able to reduce Ca2+ influx
via the L-type calcium channels as well as reduce calcium efflux from the cytosol by
decreasing the activity of SERCA2a [278, 279]. Furthermore, ROS can reduce
myocardial contractility through downstream phosphorylation of troponin T, which
reduces calcium sensitivity of the myofilaments as well as through oxidative modification
of actin and tropomyosin, which also lead contractile dysfunction [280-283].
Importantly, nearly all of the molecular and cellular abnormalities observed during the
progression of cardiac remodeling and heart failure are due to the activation of
neurohumoral responses. As mentioned previously, increased sympathetic activity is one
of the main neurohumoral mechanisms activated in response to an initial pathological
stimulus and alters ventricular hemodynamics to maintain cardiac output at homeostatic
levels. Notably, the autonomic nervous system is not comprised solely of the sympathetic
nervous system. Rather, parasympathetic signaling in the periphery is able to oppose
many of the actions of adrenergic signaling, including the positive chronotropic and
inotropic effects observed in heart failure during a state of enhanced sympathetic
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signaling. As such, it is reasonable to expect changes in cholinergic signaling coupled
with altered sympathetic tone in the failing heart.

1.7 Regulation of cholinergic signaling

ACh is the major chemical neurotransmitter in the periphery and regulates sympathetic
tone through signaling at pre-ganglionic sites and parasympathetic tone via signaling at
both pre- and post-ganglionic nerve terminals. The mechanisms regulating ACh
production and secretion are well known. Genesis of ACh depends on the actions of the
enzyme choline acetyltransferase (ChAT) [284] which converts free choline and acetylCoA into ACh, a process first described by Nachmansohn and Machado [285]. ChAT is
in kinetic excess in nerve terminals; therefore, minor reductions in ChAT activity have
negligible impact on ACh content and release [286]. ACh synthesis is exquisitely coupled
to the high-affinity choline transporter (CHT1), which serves as the rate-limiting step for
ACh production [287]. This is due to the importance of CHT1 in regulating the transport
of sufficient amounts of free choline from the extracellular environment into the
presynaptic nerve terminal [288] where it can be utilized to synthesize ACh and maintain
its sustained release. No other choline transporter can replace CHT1, as its genetic
deletion leads to death shortly after birth due to respiratory failure [289]. The secretion of
ACh into the extracellular environment is dependent on its packaging into exocytic
vesicles via the vesicular acetylcholine transporter (VAChT)[290]. The secretory vesicle
requires two distinct components for the proper packaging of ACh into the exocytic
vesicles. Firstly, a vacuolar type H+-ATPase is required to transfer protons from the
cytoplasm into the vesicle. Secondly, the VAChT, a 12-transmembrane domain protein,
is essential as it utilizes the electrochemical gradient generated by the proton ATPase to
store ACh in synaptic vesicles [290].
As part of the same family of transporters as VMAT1 and VMAT2, which function to
transport monamines, including dopamine and norepinephrine, into synaptic vesicles,
VAChT acts in a similar manner as a proton/amine antiporter [291, 292]. This transporter
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is present in lower species, such as Caenorhabditis elegans, where the vesicular
acetylcholine transporter gene (unc-17) appears to have a functional role as mutations in
unc-17 protect against organophosphorous toxicity in nematodes [293]. Normally,
organophosphorous compounds induce toxicity by inhibiting ACh degradation in the
synaptic cleft and thereby maintaining high levels of extracellular ACh. Decreased
function of unc-17 decreases ACh secretion and thereby protects against toxicity, thus
indicating a role for this transporter in cholinergic signaling. In addition, mammalian
species, including rats and humans, also express VAChT [290, 294], suggesting a
conserved functional role for this transporter in mediating ACh packaging in secretory
vesicles across species.
Interestingly, the VAChT gene is part of the “cholinergic gene locus,” a unique
arrangement in the mammalian genome. This locus is comprised of both the ChAT and
VAChT genes as well as the regulatory elements modulating gene transcription in this
locus [295]. In both Drosophila as well as mammals, the entire VAChT coding sequence
is found within the first intron of the ChAT gene [290, 295, 296]. This genetic
arrangement allows for a precise and intricate regulation of cholinergic neurotransmission
and, therefore, complex downstream functions in both the central nervous system as well
as the parasympathetic system.
Cholinergic neurotransmission is critically dependent on the function of VAChT, as
inhibition of this transporter using vesamicol decreases ACh packaging into synaptic
vesicles and leads to inhibition of ACh secretion [297]. Furthermore, elimination of the
VAChT gene abolishes stimulated ACh release [298]. In addition, decreased expression
levels of VAChT lead to proportional decreases in ACh release [299]. Overexpression of
VAChT in immature Xenopus neurons leads to increased synaptic responses [300].
Furthermore, overexpression of VAChT in mice has been shown to increase ACh release
[301, 302], improve physical fitness and cause abnormalities in cognitive behavior [301].
Hence, VAChT is unique in its ability to regulate ACh release.
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ACh can bind five different muscarinic receptor subtypes in the body; however, in the
cardiovascular system, the M2 and M3 subtypes play critical roles in regulating
cholinergic signaling. These actions are mediated by the binding of ACh to M2
muscarinic receptors in the atrial myocytes [303, 304]. M2 receptors are coupled to Gi
proteins, which mediate the decrease in inotropic and chronotropic responses following
muscarinic receptor activation through various downstream mechanisms. One involves
direct inhibition of adenylyl cyclase, which leads to decreased production of cAMP and
activation of protein kinase A (PKA) [305, 306]. Muscarinic receptor activation can also
lead to indirect inhibition of L-type Ca2+ channels through a decrease in cAMP
production [307]. Furthermore, the negative inotropic and chonotropic effects observed
following activation of M2 receptors is due to hyperpolarization of atrial cells following
the direct activation of inwardly rectifying ACh sensitive potassium channels (KACh) by
the Giβγ subunit of the M2 receptor [308]. In addition, the Giβγ subunit is also able to
activate NO production through PI3K-Akt mediated phosphorylation of eNOS.
Although the M2 receptor is the main muscarinic subtype in the heart, it has previously
been shown that M3 muscarinic receptors also play a role in mediating physiological
signaling in the heart. Previous work confirmed the importance of cholinergic signaling
via the M3 receptor subtype as pre-treatment with an M3-selective inhibitor could
attenuate the increase in IP3 formation observed following treatment with carbachol
[309]. This study suggests that cholinergic signaling via the M3 muscarinic receptor is
coupled to Gq-mediated activation of the PLC/IP3 pathway. Furthermore, M3 receptors
also mediate inotropic signaling in the atria as the biphasic inotropic response observed in
isolated atria can be attributed to both M2 and M3 receptor signaling, with the latter
mediating the positive inotropic response [310]. M3 muscarinic receptors also appear to
regulate pathophysiological responses. It has previously been reported that cholinergic
signaling via M3 receptors in the heart can lead to cardioprotection following myocardial
ischemia, a process thought to occur through inhibition of miR-376b-5p [311].
Furthermore, it was recently shown that upregulation of the M3 muscarinic receptor in
mice attenuates angiotensin II-induced cardiac hypertrophic response [312].
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ACh has also been shown to bind to M3 muscarinic receptors in the vascular smooth
muscles cells and thereby induce vasoconstriction via activation of phospholipase C and
IP3 production. However, these responses are typically ineffective under physiological
conditions as ACh can bind to endothelial cells in the vasculature and induce secretion of
nitric oxide (NO), which acts as a potent vasodilator in the cardiovascular system.
In addition to the direct effects of ACh on the heart via muscarinic receptors, it can also
regulate sympathetic signaling by binding to presynaptic receptors on sympathetic nerve
terminals innervating the heart. Binding of ACh to M1 muscarinic receptors at
presynaptic sympathetic nerves can increase NE release [313], while M2 muscarinic
receptors appear to mediate ACh-induced inhibition of NE release at the atria [314, 315].
GPCR signaling via downstream G proteins is partially modulated by the actions of the
Regulator of G Protein Signaling (RGS) proteins, which can terminate G protein
signaling by increasing hydrolysis of bound GTP [316]. RGS2, in particular, has been
shown to decrease both Gq and Gi protein signaling [317-319], though it shows Gqselectivity and acts on the latter with a lower potency [320]. In addition, RGS2 has
previously been shown to reduce adenylyl cyclase activity downstream of Gs signaling
[321]. Importantly, RGS2 can inhibit hypertrophy in response to β-adrenergic stimulation
[322], an effect that may partially be due to its role in inhibiting eIF2B-mediated protein
synthesis [323]. Furthermore, RGS2 KO mice display hypertension under basal
conditions [324] and increased ventricular dysfunction and dilation following transverse
aortic constriction (TAC) [325]. These data suggest that RGS2 signaling plays a role in
regulating signaling through both muscarinic and adrenergic receptors and modulating
the cardiovascular response to pathological stimuli by altering autonomic regulation of
the heart.

1.8 Parasympathetic hypoactivity in heart failure
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Hyperactivity of the sympathetic nervous system in heart failure is coupled with
decreased activation of the parasympathetic nervous system leading to decreased
signaling through ACh [326]. A decrease in parasympathetic signaling is observed early
following induction of cardiac remodeling even prior to the onset of heart failure, and this
cholinergic hypoactivity appears to contribute to the cardiac dysfunction observed in HF
[326]. The importance of cholinergic signaling in cardiac remodeling is further
highlighted by previous data suggesting a strong association between decreased vagal
reflex, as measured through baroreceptor signaling, and ventricular arrhythmias
following myocardial infarction [327, 328]. This decrease in cholinergic signaling may
partially be due to the production of autoantibodies against M2-muscarinic receptors,
which significantly reduce ligand binding in patients with idiopathic dilated
cardiomyopathy and effectively inhibit downstream signaling [329].
Importantly, it was previously reported that pacing-induced LV dysfunction and heart
failure in dogs leads to changes in both sympathetic as well as vagal control of the heart
[330]. Furthermore, changes in vagus nerve-mediated regulation of heart rate have been
observed during the early stages of LV dysfunction, suggesting that alterations in
cholinergic signaling in the heart may contribute to the HF phenotype [330]. These
changes in vagal control of heart rate appear to occur to both cardiac post-ganglionic
signaling, as well as alterations in parasympathetic pre-ganglionic signaling [331].
In agreement with the notion of a causal relationship between lower cholinergic signaling
and cardiac dysfunction, M2 muscarinic receptor knockout mice exhibit a greater
impairment in ventricular function following an acute dose of phenylephrine, which
increases cardiac afterload [332]. Although these mice exhibited no difference in
ventricular function under baseline conditions, chronic treatment with isoproterenol to
induce cardiac remodeling led to a significant increase in matrix metalloproteinase
(MMP) activity in M2 receptor KO mice, as compared to WT mice [332]. This suggests
that cholinergic tone may play a role in regulating MMP activity and, therefore, the
progression of cardiac dysfunction as increased MMP activity has been associated with
ventricular dysfunction in patients with heart failure [35, 333]. In addition, we have
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previously reported that mice with reduced cholinergic neurotransmission due to
decreased expression of VAChT exhibit cardiac remodeling and dysfunction [334]. It has
also been reported that mice with a decrease in the expression of the presynaptic, high
affinity choline transporter (CHT1; CHT1 heterozygous), a protein necessary for the
uptake of choline and thus crucial for ACh synthesis, leads to age-dependent ventricular
remodeling and dysfunction [335].
There are several possible mechanisms that may lead to decreased cholinergic signaling
in the heart. One such mechanism may involve the activation of mechanoreceptors in
dilated hearts, due to greater mechanical stretch of the cardiac muscle. This mechanical
stretch activates sympathetic afferent fibres which, in turn, leads to a reflex inhibition of
intracardiac cholinergic signaling [336]. Due to the decrease in parasympathetic signaling
observed in heart failure, increasing cholinergic tone may serve to improve outcomes in
HF patients.

1.9 Parasympathetic system as a target in the failing heart

Both

acetylcholinesterase

(AChE)

and

butyrylcholinesterase

(BChE)

modulate

extracellular levels of ACh by regulating its hydrolysis. In fact, it has been shown that
AChE KO mice are able to utilize BChE to break down acetylcholine, suggesting a role
for this enzyme in the regulation of cholinergic neurotransmission [337]. Although the
heart contains both AChE and BChE, the levels of BChE are much higher than those of
AChE [338, 339]. Furthermore, both AChE and BChE are found in blood; however, the
levels of circulating BChE are significantly greater than those of AChE [338] and likely
serve to regulate ACh metabolism throughout the body. A previous report has suggested
an inverse association between serum levels of butyrylcholinesterase (BuChE) and
overall mortality in middle-aged and elderly individuals [340]. Furthermore, BuChE
levels have been associated with several cardiovascular risk factors including albumin,
cholesterol and triglycerides [340]. An additional study suggested that increasing levels
of BuChE were associated with negative long-term outcomes, including mortality, in
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patients with stable coronary artery disease (CAD) [341]. In fact, the same group of
researchers utilized cholinesterase activity as a biomarker to predict mortality in CAD
patients and found a very strong inverse relationship between cholinesterase activity and
prediction of mortality [342].
Although the aforementioned studies suggest the need for at least a minimal level of
cholinesterase activity to reduce mortality in patients with cardiovascular disease,
accumulating evidence suggests that restoring cholinergic activity after experimental
heart failure can improve functional outcomes. In fact, in an animal model of heart
failure, the addition of vagal nerve stimulation to β-blockade therapy led to
improvements in cardiac contractility, as measured through LV systolic and end-diastolic
pressure, as well as animal survival [343, 344]. Additionally, chronic treatment with the
cholinesterase inhibitor, donepezil, reduces cardiac remodeling and increases survival
rates in animal models of heart failure [345, 346]. Furthermore, increasing ACh levels
through administration of a peripheral cholinesterase inhibitor, pyridostigmine, led to
greater vagal control of the heart and a reduction in ventricular dysfunction associated
with heart failure in rats [347]. Importantly, the positive effect of enhancing cholinergic
tone is not limited to animal models of heart failure. A clinical trial in which a small
group of patients were subjected to vagal stimulation via an implantable system and
followed for up to 6 months showed an increase in both their NYHA class score as well
as LV end-systolic volume [348]. Furthermore, it has been shown that vagal nerve
stimulation is tolerated well and improves quality of life and LV function in chronic heart
failure patients [349]. Additionally, it was recently reported that the use of cholinesterase
inhibitors in patients with Alzheimer’s disease led to a 34% reduction in risk of
myocardial infarction and death [350]. Furthermore, a Phase II clinical trial is currently
underway to study the safety of the cholinesterase inhibitor, pyridostigmine, when
administered alone in HF patients (Clinicaltrials.gov Identifier: NCT01415921). This
study may serve as a precursor for additional clinical trials aimed at developing a novel
therapeutic approach for the treatment of HF.
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The mechanisms of action leading to the protective effects of cholinesterase inhibition
have yet to be completely understood. One possibility is that cholinesterase inhibitors can
reduce remodeling and cardiac dysfunction by directly enhancing the levels of ACh.
However, it is also possible that quarternary cholinesterase inhibitors, such as
pyridostigmine, can impact the progression of cardiac dysfunction through an indirect
pathway via their ability to alter gene expression, as previously shown in the brain [351,
352]. Although this phenomenon has not yet been reported in the heart, it is possible that
a similar mechanism of action as that observed in the brain also exists in cardiac tissue
and contributes to reduced remodeling and dysfunction in heart failure.
Increasing systemic ACh levels through the use of cholinesterase inhibitors appears to
decrease dysfunction following induction of cardiac disease. Additionally, oral
administration of choline also appears to decrease the hypertrophic response in mice
subjected to transverse aortic constriction (TAC), an effect that may be dependent on the
actions of a specific miRNA, miR-133a, as well as calcineurin [353]. Importantly, the
anti-hypertrophic effects of orally administered choline are due to its direct actions on
cardiomyocytes, as choline treatment is able to prevent cellular hypertrophy in cultured
cardiomyocytes treated with isoproterenol in order to induce remodeling [353].
The effect of choline is not limited to protection against afterload-induced hypertrophy. It
was previously reported that choline pre-treatment also leads to a reduction in Ang IIinduced remodeling through inhibition of cellular signaling via the ROS-mediated p38
MAPK pathway as well as the Ca2+-calcineurin signaling pathway, both of which are
associated with Ang II-mediated cardiac dysfunction [354]. The protective effect of
choline appears to be due to its direct actions on cardiomyocytes as pre-treatment was
also able to attenuate the Ang II-induced hypertrophic response in cultured neonatal
cardiomyocytes [354]. Although choline treatment appears to have a protective effect, it
is yet unclear whether this is due to its role in the production of ACh or due to the fact
that choline can act as a direct agonist of M3 muscarinic receptors, which have been
linked to cardioprotection.
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In agreement with the notion that cholinergic tone in the heart plays a role in HF, cardiac
sympathetic nerves switch neurotransmitters and undergo cholinergic transdifferentiation
during heart failure in both animal models and humans [355]. Genetic inhibition of this
transdifferentiation increases mortality of animal models suggesting that this
transdifferential switch is protective [355]. This observation agrees with previous
findings from our laboratory that genetic disturbance of cholinergic machinery in mice
leads to cardiac dysfunction, a phenotype that can be reversed by treatment with
peripheral cholinesterase inhibitors [334].

1.10 Non-neuronal cholinergic system

For many years, ACh has been classified as the major neurotransmitter for
parasympathetic signaling. The importance of ACh in the nervous system is indisputable;
however, ACh can also play a significant role in cells other than neurons as the nonneuronal cholinergic system (NNCS) appears to be linked to proper function of various
organ systems in both health and disease. ACh is a phylogenetically ancient molecule that
can be produced and secreted by both prokaryotes (bacteria) and lower order eukaryotes
including fungi and protozoa [284]. Furthermore, several different cell types in higher
order eukaryotes, including humans, utilize ACh as a signaling molecule. These include
keratinocytes, which have been shown to produce ACh at very high levels [356], as well
as both oesophageal and upper respiratory tract epithelial cells [357, 358]. Furthermore,
prototypical markers of the cholinergic system have also been detected in the kidney
[359], as well as pancreatic α-cells where non-neuronal ACh plays a crucial role in
priming β-cells to secrete insulin in humans [360]. Finally, the NNCS is active in
regulating immune function as T-cells secrete ACh, which can then act in an
autocrine/paracrine fashion to inhibit inflammatory cytokine production [361, 362].
Increasing systemic cholinergic tone leads to positive outcomes with regards to left
ventricular remodeling and function in various HF models. A universally accepted
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principle in autonomic regulation of cardiac function is that parasympathetic innervation
of the ventricles is very sparse [363, 364]. However, vagal stimulation has been shown to
reduce ventricular contractility in the absence of sympathetic drive [365-367]. These
direct negative inotropic effects in response to vagal stimulation have led to further
analysis of parasympathetic innervation in the ventricles. Some studies suggest that,
contrary to previous work, cholinergic nerve fibers are abundantly present in the
ventricles. Immunostaining for AChE has revealed a dense innervation of both the
endocardial and epicardial surfaces of the ventricles in several species, including human
[368-370]. Additionally, immunostaining using the cholinergic marker, CHT1, has
revealed that the presence of parasympathetic nerve fibers in the ventricles is mainly
restricted to the cardiac conduction system, although some staining was observed in the
ventricular free wall [363]. In addition to vagal innervation of the ventricles, it has
recently been proposed that cardiomyocytes are also able to synthesize and release ACh
at the cellular level. Cardiomyocytes possess the machinery (ChAT, VAChT and CHT1)
for de novo production and storage of ACh [371, 372]. It has been suggested that
ventricular cardiomyocytes may synthesize ACh. This non-neuronal ACh may then act in
an autocrine/paracrine fashion to amplify neuronal cholinergic signaling and thereby
protect the heart under stressful conditions, including heart failure [372]. VAChT, which
is an important component of the cholinergic machinery, was shown to be present in
vesicles in cardiomyocytes [371] suggesting a quantal release of ACh from these cells.
Other studies have also recently highlighted the importance of this non-neuronal
cholinergic system. Previous work has shown that ChAT KO HL-1 cells, derived from
murine atrial cardiac tissue, display lower levels of cellular ATP, which leads to
decreased viability following induction of chemical hypoxia [375]. In addition, ChAT
KO HL-1 cells appear to generate greater levels of ROS than control cells following an
acute challenge with norepinephrine, as measured using the ROS indicator APF [375].
This increase in ROS production in ChAT KO cells may contribute to the increased
caspase-3 activation and apoptotic response that was observed following norepinephrine
treatment [375]. Conversely, cardiac-specific overexpression of choline acetyltransferase
(ChAT-Tg), the enzyme responsible for the synthesis of ACh, appears to decrease
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remodeling and enhance survival following myocardial infarction [376]. These ChAT-Tg
mice also appear to be less susceptible to ex vivo ischemia-reperfusion injury, which was
induced using a Langerdorff apparatus [376]. The infarcted region was significantly
decreased in the ChAT-Tg mice and the time from onset of ischemia to beating arrest was
significantly increased in the mutant mice [376]. These data further highlight the
importance of the cardiac non-neuronal cholinergic system following induction of stress,
including ischemia. Together, these data provide for an unanticipated mechanism by
which non-neuronal ACh may play an important role in cardiac function.

1.11 Cholinergic anti-inflammatory pathway

ACh secretion from non-neuronal cells is not unique to cardiomyocytes. In fact,
lymphocytes can also release ACh, which plays a crucial role in regulating the immune
response by activating an inflammatory reflex, the cholinergic anti-inflammatory
pathway [361]. This reflex is dependent on the peripheral actions of ACh released from
the Vagus [377, 378]; however, nerve fibers innervating the splenic nerve from the celiac
ganglion are adrenergic, rather than cholinergic [379]. As such, the presence of ACh in
the spleen is not due to neuronal cholinergic innervation but, rather, activation of the
efferent arc of the Vagus nerve and downstream activation of splenic T cells, which then
secrete ACh [361]. This T cell-derived ACh can then activate α7 nAChRs on
macrophages and thereby inhibiting pro-inflammatory cytokine secretion including
TNFα, IL-1β and IL-6 [377, 378]. The anti-inflammatory effects of ACh appear to be
mediated specifically by its interaction with the α7 receptors on macrophages as this
effect can be blunted using selective nicotinic antagonists or α7 receptor knockout mice
[378, 380-382].
This pathway appears to play a crucial role in the progression of several cardiovascular
diseases. In fact, in a two-kidney, one-clip animal model of hypertension, a significant
downregulation of α7 receptors, coupled with an increase in serum levels of TNFα, was
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previously observed [383]. This occurred downstream of reduced vagal tone thus
suggesting that the cholinergic anti-inflammatory pathway plays a role in the induction of
secondary hypertension.
Increased expression of inflammatory cytokines, which may serve as an indicator of
reduced activity of the cholinergic anti-inflammatory reflex, has been observed in both
systemic circulation during chronic heart failure as well as in the failing myocardium
[384, 385]. Activation of the cholinergic anti-inflammatory pathway, which is dependent
on both vagal as well as non-neuronal ACh, has been shown to be beneficial in heart
failure [386], and may contribute to the cardioprotective effects of increased cholinergic
tone observed in several animal models of heart failure, including volume overload,
tachycardia and myocardial infarction [343-346]. This cholinergic anti-inflammatory
pathway serves as an important determinant of the extent of cardiac remodeling following
induction of cardiac disease. Notably, it appears to be altered in heart failure due to the
decrease in parasympathetic tone, and thus peripheral ACh secretion. In fact, it was
recently shown that, following LPS-induced endotoxemia in rats, vagal nerve stimulation
is able to partially attenuate myocardial inflammation and hemodynamic alterations
[387]. Furthermore, the inflammatory response in these rats was enhanced following
vagotomy, thus suggesting that parasympathetic signaling via the Vagus plays a critical
role in reducing the local inflammatory response and decreasing cardiac dysfunction
[387].
Although it is still unclear whether there is a direct correlation between the levels of
circulating inflammatory cytokines and cardiac dysfunction, recent observations suggest
a possible relationship between inflammation and progression of heart failure. In a canine
high-rate pacing model of heart failure, chronic vagal nerve stimulation led to significant
inhibition of heart failure development, which was associated with attenuated systemic
inflammation [344], thus suggesting a possible beneficial effect of reduced inflammatory
cytokines in heart failure. Additionally, spontaneously hypertensive rats (SHRs), as well
as those with abdominal aorta coarctation-induced hypertension, exhibited greater end
organ damage (EOD) coupled with decreased levels of the α7nAChR [388]. Furthermore,
chronic treatment of SHRs with an α7nAChR agonist led to decreased tissue levels of
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pro-inflammatory cytokines which was associated with decreased EOD [388]. Increased
levels of inflammatory cytokines have been shown to be directly related to decreased left
ventricular ejection fraction [389]. Moreover, increased levels of the pro-inflammatory
cytokine TNFα can induce cardiac hypertrophy and promote cardiomyocyte apoptosis,
thus contributing to the onset and progression of ventricular dysfunction and remodeling
[384, 390]. These data suggest an important role for the cholinergic inflammatory reflex
in regulating cardiac function and attenuating the progression of heart failure, perhaps by
regulating circulating cytokines such as TNFα.
Despite the overwhelming evidence for immune regulation through peripheral
cholinergic signaling, it was recently reported that the reflex activation of the
inflammatory system by the autonomic nervous system following LPS treatment is due to
the actions of the sympathetic system, and not the Vagus nerve [391]. However, contrary
to this recently published report, it is well established that the parasympathetic nervous
system is very important in regulating the innate immune response and can inhibit
cytokine release and systemic inflammation [392]. In fact, several studies have provided
novel insight into the specific mechanisms through which neuronal ACh can act
peripherally to control the immune response and regulate the extent of cardiac
dysfunction.

1.12 Rationale and Hypothesis

Heart failure is a very prominent progressive clinical syndrome and is exemplified by a
number of structural and molecular changes, which take place following activation of
neurohumoral mechanisms to maintain cardiac homeostasis. Enhanced sympathetic
signaling is a critical modulator of neurohumoral signaling, but it can have severe adverse
effects due to long-term activation. Conversely, it is abundantly clear that increased
sympathetic activation is often coupled with reduced parasympathetic signaling in heart
failure. However, the role of the parasympathetic system in cardiac dysfunction has not
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been thoroughly studied, despite its importance in regulating various physiological
pathways (Fig. 1.3). As such, enhanced cholinergic signaling has yet to be utilized
clinically as a pharmacological target, partly due to the lack of information available with
regards to the specific changes that take place solely due to reduced cholinergic signaling
in heart failure. Therefore, it is important to further our understanding of the mechanisms
through which cholinergic signaling can modulate cardiac function. In addition, the role
of parasympathetic signaling in cardiac disease must be elucidated to determine its
contribution to abnormal signaling in the remodeled myocardium.
Therefore, the overall objective of this thesis is to determine whether altered cholinergic
signaling plays a role in regulating cardiac function under physiological conditions as
well as whether altered cholinergic signaling can influence the progression of cardiac
dysfunction. Specifically, the aim of this thesis is to:
1. Examine the molecular alterations that contribute to cardiac dysfunction in a
mouse model with deficient cholinergic signaling.
2. Determine whether the non-neuronal cholinergic system plays a role in regulating
cardiac function and ventricular contractility, under both physiological and
pathological conditions.
3. Determine whether enhanced cholinergic signaling influences cardiac function
under physiological conditions.
Previously, several lines of research have begun to highlight the importance of
cholinergic signaling in maintaining cardiovascular homeostasis in both health and
disease. As such, we hypothesized that alterations in both neuronal and non-neuronal
cholinergic signaling can regulate cardiac function under baseline conditions as well as
modify the progression of cardiac remodeling, a precursor to the onset of heart failure.

44

Figure 1.3 - Autonomic regulation of cardiac function. (1) Baroreceptors in the carotid
arteries and aortic arch monitor arterial pressure. Increased arterial pressure activates
signaling to the Nucleus of the Tractus Solitarius (NTS) and reduces sympathetic output
and simultaneously activates the parasympathetic nervous system. A decrease in arterial
pressure has the opposite effect. (2) Activation of sympathetic nerves leads to positive
chronotropic and inotropic responses as well as arteriolar constriction. (3) Activation of
the parasympathetic system via the vagus nerve leads to negative chronotropy and
lusitropy. (4) The cardiac non-neuronal cholinergic system amplifies parasympathetic
cholinergic signaling and regulates heart rate recovery following activity. In addition, the
cardiomyocyte-derived ACh prevents cardiac remodeling and hypertrophy under
physiological conditions. (5) Vagus and/or sympathetic splanchnic nerve stimulation
leads to activation of the anti-inflammatory pathway, which involves secretion of nonneuronal ACh from splenic T cells. This T cell-derived ACh activates α7 nicotinic
acetylcholine receptors (α7nAChRs) on macrophages and inhibits the release of proinflammatory cytokines.
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Figure 1.3 - Autonomic regulation of cardiac function.
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2

Chapter 2

2.1 Chapter Summary

Autonomic dysfunction is observed in many cardiovascular diseases and contributes to
cardiac remodeling and heart disease. We previously reported that a decrease in the
expression levels of the vesicular acetylcholine transporter (VAChT) in geneticallymodified homozygous mice (VAChT KDHOM) leads to decreased cholinergic tone,
autonomic imbalance and a phenotype resembling heart failure. In order to further
understand the molecular changes resulting from chronic long-term decrease in
parasympathetic tone, we undertook a transcriptome-based, microarray-driven approach
to analyze gene expression changes in ventricular tissue from VAChT KDHOM mice. We
demonstrate that a decrease in cholinergic tone is associated with alterations in gene
expression in mutant hearts, which might contribute to increased ROS levels observed in
these cardiomyocytes. In contrast, in another model of cardiac remodeling and autonomic
imbalance, induced through chronic isoproterenol treatment to increase sympathetic
drive, these genes did not appear to be altered in a pattern similar to that observed in
VAChT KDHOM hearts. These data suggest the importance of maintaining a fine balance
between the two branches of the autonomic nervous system and the significance of
absolute levels of cholinergic tone in proper cardiac function.

92

2.2 Introduction
In many cardiovascular diseases an over-activation of sympathetic tone coupled with a
decrease in parasympathetic tone is observed [1-3]. This leads to an imbalance between
the two branches of the autonomic nervous system (ANS) that seems to contribute to
cardiac remodeling. The ANS is the main regulator of cardiac output and, as such, plays a
vital role in maintaining proper heart function. Recently, we reported that a systemic
reduction in the vesicular acetylcholine transporter (VAChT; [4]), the protein responsible
for packaging ACh into synaptic vesicles at parasympathetic nerve terminals, leads to a
phenotype resembling heart failure in mice [5]. Importantly, clinical presentation of heart
failure is often associated with increased activation of various neurohumoral processes,
including enhanced sympathetic activity and RAAS activation. However, due to the lack
of induction of these processes in VAChT KDHOM mice, they do not present with all the
molecular changes observed in the failing heart. The mutant hearts have altered calcium
handling and show changes in myocyte contractility, causing decreased left ventricular
fractional shortening in the VAChT mutant mice [5]. Furthermore, these pathological
changes can be reversed through treatment with pyridostigmine, a peripheral
cholinesterase inhibitor, thus suggesting that cardiac dysfunction in these mice results
from a reduction in cholinergic tone [5].
These results are in agreement with a number of recent publications which indicate that
increased levels of ACh can be protective and increase survival in experimental models
of heart failure. For example, vagal stimulation improves outcome in experimental
models of heart failure in rats [6]. It has also been reported that chronic treatment with
the cholinesterase inhibitor donepezil, an anti-Alzheimer’s drug, can reduce both cardiac
hypertrophy and remodeling and increase survival rates in rat and mouse models of heart
failure [7, 8]. Acetylcholine, released from vagal nerve terminals, has also been shown to
have cardioprotective effects through its ability to activate the phosphatidylinositol-3kinase (PI3K)-Akt pathway [6]. Moreover, a switch to a cholinergic phenotype occurs in
sympathetic terminals in mice as well as humans in heart failure and genetic inhibition of
this transdifferentiation in mice worsens outcomes in experimental heart failure [9].
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Hence, whereas higher levels of acetylcholine seem to be cardioprotective, lower levels
are usually related to increased heart dysfunction.
In order to gain insight into potential molecular changes that may occur in the heart under
conditions of chronically decreased cholinergic neurotransmission, we undertook a
microarray-driven, transcriptome-based analysis of hearts from VAChT KDHOM and
wild-type (WT) mice. Our goal was to determine whether a long-term decrease in ACh
levels leads to alterations in gene expression profiles that could contribute to heart
dysfunction.
We demonstrate here that chronic reduction in cholinergic neurotransmission in VAChT
mutant mice is associated with altered gene expression in the heart. Of the changes
observed, increased levels of the enzyme purine nucleoside phosphorylase could
contribute to increased reactive oxygen species (ROS) levels. Indeed, we found that
cardiomyocytes of mutant mice present an increase in ROS. Interestingly, we
demonstrate that the alterations in gene expression observed in ventricles from VAChT
mutant mice are distinct from those observed in a model of cardiac dysfunction with
increased sympathetic drive, indicating the importance of absolute levels of cholinergic
tone in regulating cardiac function.
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2.3 Materials and Methods

2.3.1

Animal models and drug administration

VAChT KDHOM mice were generated as previously described [4]. Three-month old male
wild-type (WT) and VAChT mutant littermates in a mixed C57BL6/j background
(backcrossed for 3 generations only, as further backcrossing onto the C57BL6/j
background causes infertility in this genotype) were used for all of the experiments. Mice
were housed in groups of 4 per cage in a temperature-controlled room with a 12/12
light/dark cycle. Food and water were provided ad libitum.
For the isoproterenol infusion experiments, 3-month-old male wild-type mice from the
colony were treated with isoproterenol (Sigma-Aldrich, Mississauga, Canada) at a dose
of 60 mg/kg/day or saline for two weeks using the Alzet Osmotic Pumps (Model 2002,
Durect Corporation, USA) and maintained in the Animal Care Facility for an additional
two weeks. All animals used in these studies were maintained at the University of
Western Ontario (UWO, London, Canada) and experiments were performed following
the guidelines and protocols approved by the University Council on Animal Care
(UCAC) for animal research.

2.3.2

RNA microarray analysis

All sample labelling and GeneChip processing was performed at the London Regional
Genomics

Centre

(Robarts

Research

Institute,

London,

Ontario,

Canada;

http://www.lrgc.ca). RNA quality was assessed using the Agilent 2100 Bioanalyzer
(Agilent Technologies Inc., Palo Alto, CA) and the RNA 6000 Nano kit (Caliper Life
Sciences, Mountain View, CA). Single stranded complimentary DNA (cDNA) was
prepared from 2.0 µg (ventricle extracts) of total RNA as per the Affymetrix GeneChip
Whole Transcript (WT) Sense Target Labeling Assay Manual (Affymetrix, Santa Clara,
CA). 5.5 µg of single stranded DNA was synthesized, end labeled and hybridized, for 16
hours at 45°C, to Mouse Gene 1.0 ST arrays to probe a set of 33,000 genes. All liquid
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handling steps were performed by a GeneChip Fluidics Station 450 and GeneChips were
scanned with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using
Command Console v1.1. Probes were summarized to gene level data in Partek Genomics
Suite v6.5 (Partek, St. Louis, MO) using the RMA algorithm [10]. Partek was used to
determine gene level ANOVA p-values, fold changes and GO (Gene Ontology)
enrichment, using a Fisher’s exact test. Differentially expressed genes were selected
based on an ANOVA p-value of less than 0.05 and 1.3 fold increase or decrease between
WT and knockdown samples. The data discussed in this publication have been deposited
in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession
number GSE37458 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37458).

2.3.3

Quantitative RT-PCR

Total RNA was extracted using the Fatty and Fibrous Tissue RNA Extraction Kit (BioRad Laboratories, Mississauga, Canada) according to the manufacturer’s protocol. Total
RNA from whole hearts was eluted in 80 µl of Elution Solution. Quantification and
quality analysis of RNA in the extracted samples was done by microfluidic analysis using
the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA). All RNA
samples used for the reverse transcription reaction had an RNA integrity number of ≥8.0.
20 µl of cDNA was synthesized from 500 ng of total RNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Streetsville, Canada) following
the manufacturer’s instructions. cDNA was subsequently subjected to qPCR on a CFX-96
Real Time System (Biorad) using the iQ SYBR GREEN SUPERMIX (Biorad). The
PCRs were cycled 40 times after initial denaturation (95oC, 3 min) with the following
parameters: 95oC for 10 s, annealing and extension at 60oC for 30s. For each experiment,
a non-template reaction was used as a negative control. Relative quantification of gene
expression was done with the DDCT method using β-actin gene expression to normalize
the data. All primers used for qPCR were validated before use to confirm that efficiency
was within the required range. Sequences of primers used are available upon request.
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2.3.4

Immunoblotting

Whole hearts were placed in modified ice-cold RIPA buffer and homogenized using a
motorized Dounce homogenizer. 40-80 µg of protein lysates were separated using SDSPAGE and transferred onto PVDF membranes. Antibodies, dilutions and their sources are
as follows: anti-acetyl-CoA carboxyase (1:1000; Cell Signaling), anti-ATP citrate lyase
(1:1000; Cell Signaling), anti-fatty acid synthase (1:1000; Cell Signaling), anti-purine
nucleoside phosphorylase (1:200; Santa Cruz Biotechnology), anti-α-tubulin (1:3000;
Sigma-Aldrich), and anti-α-actinin (1:2000; Sigma-Aldrich). α-tubulin or α-actinin was
used as a loading control for all samples and the protein was quantified using
densitometry analysis.

2.3.5

Cardiomyocyte isolation

Adult ventricular myocytes were isolated as previously described [11]. Briefly, hearts
were rapidly removed and perfused via the Langendorff method with Ca2+-free modified
Tyrode solution until the blood was cleared. Hearts were then perfused with Tyrode
solution containing 100 µM CaCl2 along with 1.4 mg/ml collagenase (type 2;
Worthington, Lakewood, NJ) and 0.04 mg/ml protease (type XIV; Sigma, St. Louis, MO)
until they were soft (~10 min). The hearts were removed from the perfusion apparatus,
minced into ~1-mm chunks, and stirred for 4 min in Tyrode solution containing 0.1 mM
CaCl2, 0.7 mg/ml collagenase, and 0.02 mg/ml protease. Cells were filtered through a
200-µm mesh to remove tissue chunks, and extracellular Ca2+ concentration was raised to
0.5 mM over 10 min through three centrifuge cycles.

2.3.6

ROS measurement

MitoSOX Red (Invitrogen) was used to measure mitochondrial reactive oxygen species
(ROS) production. Isolated cardiomyocytes were loaded with MitoSOX Red (3 µmol/l) in
DMEM for 20 min at room temperature, followed by washout. Confocal images were
obtained by excitation at 514 nm and measuring the emitted light at 585 nm in
cardiomyocytes bathed in normal Tyrode’s solution. The confocal imaging was
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performed with a Zeiss LSM 510 META confocal microscope (CEMEL-Confocal
Microscopy Facility, ICB/UFMG).

2.3.7

Statistical analyses

Results of qPCR, immunoblotting and MitoSOX experiments are provided as mean ±
SEM. The student’s t-test was used to assess statistical differences between two
experimental groups using SigmaStat software. p<0.05 was considered statistically
significant.
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2.4 Results

2.4.1

Analysis of transcriptional alterations in VAChT KDHOM
hearts

We have previously demonstrated that VAChT KDHOM mice with reduced cholinergic
neurotransmission develop cardiac dysfunction [5]. To determine the transcriptional
alterations in VAChT mutant mice, we performed a microarray analysis using total RNA
isolated from ventricles obtained from VAChT KDHOM and age-matched WT mice.
Ventricular tissue was used for the microarray analysis since previous experiments with
these mice revealed major alterations related to cardiac dysfunction in isolated ventricular
cardiomyocytes [5]. Therefore, we wanted to determine whether there were any changes
in gene expression in ventricular tissue that may contribute to this dysfunction. A list of
differentially expressed genes was generated by limiting the fold change to at least 1.3
with a significance of p≤0.05 (Table 2.1). The gene ontology (GO) analysis did not reveal
robust alterations in any specific pathway in the mutant ventricles. However, a total of 71
genes showed differential expression between VAChT KDHOM and WT mice, of which
52 genes were significantly up-regulated and 19 down-regulated.
To examine the robustness of our microarray results, we performed quantitative real-time
PCR (qPCR) on four randomly chosen genes which demonstrated a significant increase
(Tsen15, Gas5, Kpna2, Socs4) and two genes which demonstrated a significant decrease
(Rnase4, Ogdhl) in the microarray analysis. The qPCR results confirmed that the
expression of Tsen15, Gas5, Kpna2 and Socs4 were significantly increased and that of
Rnase4 and Ogdhl were significantly decreased in the ventricles obtained from VAChT
KDHOM mice (Fig. 2.1), a result which confirms our microarray data. Further analysis of
the ventricular microarray suggested a significant upregulation in the expression of two
purine nucleoside phosphorylases, Pnp and Pnp2. Both Pnp and Pnp2 are involved in
generating hypoxanthine, a metabolite of adenosine [12]. Hypoxanthine, produced in
endothelial cells, has been shown to translocate into cardiomyocytes and contribute to
production of oxygen free radicals [13, 14]. Several studies have previously shown that
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Table 2.1 – Genes which show transcriptional alterations in ventricles from VAChT KDHOM mutants.
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Figure 2.1 - qPCR analysis confirms the expression pattern of several genes detected
in the microarray analysis. mRNA expression of tRNA splicing endonuclease 3
(Tsen15; panel a), Growth arrest specific 5 (Gas5; panel b), karyopherin alpha 2 (Kpna2;
panel c) and suppressor of cytokine signaling 4 (Socs4; panel d) was increased in mutant
mice. mRNA analysis of ribonuclease, RNase A family 4 (Rnase4; panel e) and
oxoglutarate-dehydrogenase

like

(Ogdhl;

panel

f)

confirmed

transcriptional

downregulation in whole heart RNA from the mutant animals. Data represent the mean ±
SEM,

with

n

indicated

within

bars.

*p<0.05

versus

wild-type

mice.
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Figure 2.1 - qPCR analysis confirms the expression pattern of several genes detected
in the microarray analysis.
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increased ROS levels can play a major role in cardiac dysfunction in different
cardiomyopathies [15-18]. Therefore, due to the potential role of these enzymes in
contributing to cardiac malfunction in VAChT KDHOM mice, the increased expression of
these enzymes was further confirmed via qPCR (Fig. 2.2a,b). Importantly, this
transcriptional upregulation in Pnp/Pnp2 led to a significant increase in the protein
content of Pnp/Pnp2 in ventricular tissues obtained from VAChT mutant mice (Fig. 2.2c).

2.4.2

Mitochondrial superoxide levels are increased in VAChT
KDHOM animals

The increased expression of Pnp/Pnp2 in the hearts of mutant mice might predict a
greater production of ROS (as determined via superoxide formation) in these mice.
Interestingly, cardiomyocytes from VAChT KDHOM hearts showed a significant increase
in superoxide levels as compared to wild-type control cells (Fig. 2.3), suggesting greater
levels of ROS production in VAChT KD cardiomyocytes as compared to WT mice.

2.4.3

Lipid biosynthesis appears to be unaltered in VAChT KDHOM
mice

In addition to changes in ROS, which may contribute to phenotypic changes in these
mice, previous work has suggested a decrease in fatty acid oxidation during heart failure
can also contribute to further decline in cardiac function [19-22]. In order to examine
other potential changes in transcripts that could affect cardiac energetics in the VAChT
mutant mice, we used a candidate gene approach and analyzed specific genes involved in
the lipid biosynthetic process. In particular, we studied the expression of ATP citrate
lyase (ACLY), acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). These
genes, related to cardiac metabolism, are known to be altered in severe heart failure [23].
ACLY is responsible for converting citrate into oxaloacetate in the cytoplasm and, in the
process, generates a molecule of Acetyl-CoA which is utilized by ACC to produce
Malonyl-CoA, the substrate used for the generation of long chain fatty acids by FAS.
Real-time PCR revealed a significant upregulation in the expression of all three of these
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Figure 2.2 - Purine nucleoside phosphorylases are upregulated in the hearts of
VAChT KDHOM mice. mRNA expression of purine nucleoside phosphorylase (Pnp;
panel a) and purine nucleoside phosphorylase 2 (Pnp2, panel b) were upregulated.
Pnp/Pnp2 protein content appears to upregulated in VAChT KDHOM animals as compared
to wild-type mice (panel c). Data represent the mean ± SEM, with n indicated within
bars. *p<0.05 versus wild-type mice.
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Figure 2.2 - Purine nucleoside phosphorylases are upregulated in the hearts of
VAChT KDHOM mice.
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Figure 2.3 - VAChT KDHOM cardiomyocytes show increased levels of ROS. Isolated
cardiomyocytes loaded with a MitoSOX superoxide indicator reveal greater ROS levels
in mutant myocytes (sample image; panel a). A robust, significant increase in
fluorescence was observed in the KD cardiomyocytes as compared to wild-type control
cells (panel b). Data represent the mean ± SEM, with n indicated within bars. *p<0.05
versus wild-type mice. Scale bar=10µm.
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Figure 2.3 - VAChT KDHOM cardiomyocytes show increased levels of ROS.

109

Figure 2.4 - The transcription of genes related to fatty acid biosynthesis is
upregulated. mRNA expression of ATP citrate lyase (ACLY, panel a), Acetyl-CoA
carboxylase (ACC; panel b) and fatty acid synthase (FAS; panel c) was increased
expression in VAChT KDHOM mice. Data represent the mean ± SEM, with n indicated
within bars. *p<0.05 versus wild-type mice.
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Figure 2.4 - The transcription of genes related to fatty acid biosynthesis is
upregulated.
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genes in VAChT-mutant mice (Fig. 2.4). However, assessment of protein expression
levels using immunoblotting revealed no significant differences in the protein levels of
these enzymes between WT and VAChT mutant mice (Fig. 2.5).

2.4.4

Analysis of transcriptional alterations in isoproterenol-treated
hearts

It is unclear whether autonomic imbalance due to reduced cholinergic tone has similar
consequences to imbalance due to increased sympathetic tone. To examine whether the
alterations in gene expression observed in the ventricles of VAChT KDHOM mice were
observed in a different model of cardiac dysfunction, we chronically treated wild-type
mice with isoproterenol to induce cardiac remodeling. Isoproterenol-treated mice
demonstrated a significant increase in heart weight to tibia length ratio as compared to
saline-treated mice (Fig. 2.6a). Furthermore, isoproterenol-treated mice demonstrated a
significant increase in the expression of two markers of cardiac stress; namely, β-myosin
heavy chain (β-MHC: Fig. 2.6b) and atrial natriuretic peptide (ANP; Fig. 2.6c). Next we
examined potential changes in the expression pattern of genes that displayed altered
expression in the VAChT KDHOM mice. Interestingly, most of the genes which were
altered in VAChT KDHOM mice were not significantly altered in hearts obtained from
isoproterenol-treated mice (Fig. 2.7a-e). However, the expression of Ogdhl (Fig. 2.7f)
was significantly decreased following chronic treatment with isoproterenol, similar to the
transcriptional alterations observed in the VAChT mutant mice. The expression of PnP
and Pnp2 were not significantly different between isoproterenol-treated and saline-treated
mice (Fig. 2.8a,b), suggesting that alterations in these genes are specifically related to a
decrease in cholinergic tone.
In contrast to the transcriptional changes found in the microarray experiments, the
expression of genes related to the lipid biosynthetic pathway did, in fact, appear to be
similarly altered in isoproterenol-treated mice and VAChT KDHOM mice (Fig. 2.8c,d,e).
Furthermore, the relative change in the expression of these genes was much larger in
isoproterenol-treated mice than that observed in VAChT KDHOM hearts. Hence, some, but
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not all transcriptional alterations are reproduced between isoproterenol-treated mice and
VAChT KDHOM mice.
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Figure 2.5 - There are no alterations in the protein levels of enzymes involved in
lipid biosynthesis. Immunoblotting analysis of ATP citrate lyase (ACLY, panel a),
Acetyl-CoA carboxylase (ACC; panel b) and fatty acid synthase (FAS; panel c) revealed
no differences in the protein levels of these enzymes in VAChT KDHOM mice. Data
represent the mean ± SEM, with n indicated within bars. *p<0.05 versus wild-type mice.
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Figure 2.5 - There are no alterations in the protein levels of enzymes involved in
lipid biosynthesis.
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Figure 2.6 - Chronic treatment with isoproterenol (ISO)-induces cardiac remodeling
in wild-type mice. Two week ISO treatment led to a significant increase in heart
weight/tibia length ratio as compared to saline-treated control mice (panel a). The
expression of β-myosin heavy chain (β-MHC, panel b) and atrial natriuretic factor (ANF,
panel c) were significantly upregulated in ISO-treated mice. Data represent the mean ±
SEM, with n indicated within bars. *p<0.05 versus wild-type mice.
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Figure 2.6 - Chronic treatment with isoproterenol (ISO)-induces cardiac remodeling
in wild-type mice.
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Figure 2.7 - ISO treatment does not lead to the same transcriptional alterations
observed in VAChT KDHOM mice. mRNA expression of tRNA splicing endonuclease 3
(Tsen15; panel a), Growth arrest specific 5 (Gas5; panel b), karyopherin alpha 2
(Kpna2; panel c), suppressor of cytokine signaling 4 (Socs4; panel d), ribonuclease,
RNase A family 4 (Rnase4; panel e) and oxoglutarate-dehydrogenase like (Ogdhl; panel
f) were not significantly altered in the ISO-treated mice as compared to saline-treated
controls. Data represent the mean ± SEM, with n indicated within bars. *p<0.05 versus
wild-type mice.
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Figure 2.7 - ISO treatment does not lead to the same transcriptional alterations
observed in VAChT KDHOM mice.
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Figure 2.8 - Expression of genes related to fatty acid synthesis is increased following
isoproterenol (ISO) treatment. mRNA expression of purine nucleoside phosphrylases
(Pnp and Pnp2; panels a and panel b) were not altered following ISO treatment. ATP
citrate lyase (ACLY; panel c), acetyl-CoA carboxylase (ACC; panel d) and fatty acid
synthase (FAS; panel e) expression were all significantly increased in ISO-treated mice
as compared to saline-treated controls. Data represent the mean ± SEM, with n indicated
within bars. *p<0.05 versus wild-type mice.
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Figure 2.8 - Expression of genes related to fatty acid synthesis is increased following
isoproterenol (ISO) treatment.
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2.5 Discussion

Recent reports have implicated the parasympathetic nervous system in the development
and progression of heart failure as well as being a potential therapeutic target in heart
disease [24]. Vagal stimulation can improve outcome in experimental heart failure [6]
and this can be mimicked by treatment with cholinesterase inhibitors [8]. Our previous
studies have demonstrated that mice with a systemic decrease in cholinergic tone develop
cardiac dysfunction and exhibit many of the characteristics present in cardiac remodeling
[5]. Importantly, in VAChT KDHOM mice, these cardiac defects are ameliorated by
cholinesterase

inhibitor

treatment,

implicating

release

of

ACh

rather

than

developmentally-induced changes in the control of heart function. Interestingly, in heart
failure, transdifferentiation of sympathetic neurons into a cholinergic phenotype has
recently been demonstrated, and this appears to play a protective role [9]. However, the
role of acetylcholine in controlling long-term cardiac function is still poorly understood.
The present study examined whether the decrease in parasympathetic tone in VAChT
KDHOM mice leads to alterations in cardiac gene expression, which may contribute to the
observed cardiac dysfunction. Our microarray analysis revealed a number of
transcriptional changes with a total of 71 genes being significantly different between WT
and KD mice. Interestingly, transcript and protein levels of two purine nucleoside
phosphorylases (Pnp and Pnp2) were significantly increased in the VAChT mutant mice.
Both Pnp and Pnp2 are important enzymes responsible for the conversion of inosine to
hypoxanthine and have also been shown to metabolize adenosine into adenine, especially
under conditions of cardiac stress [12, 25, 26].
The increased levels of Pnp and Pnp2 in VAChT KDHOM mice may lead to the increased
production of hypoxanthine in mutant hearts [12]. Interestingly, endothelial cells in the
heart appear to be responsible for the majority of adenosine uptake [27]. In addition, they
are responsible for the metabolism of adenosine into several compounds, including
hypoxanthine [28]. Increased levels of this adenosine metabolite may serve a key role in
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the cardiac dysfunction observed in mutant mice. Hypoxanthine, for example, is
produced in endothelial cells and taken up by the ENT and ENBT1 transporters into
myocytes, where it is further metabolized into xanthine and urate [13, 14]. These
metabolites contribute to the production of ROS, which have been shown to play a role in
cardiac and vascular dysfunction in both ischemic and non-ischemic cardiomyopathies
[15-18]. Interestingly, we observed an increase in the levels of ROS in ventricular
cardiomyocytes isolated from VAChT KDHOM mice. Oxygen free radicals contribute to
declining cardiac function during heart failure via many different mechanisms and result
in damage to the myocardium [29, 30]. They can also have detrimental effects
specifically in cardiomyocytes as they can activate cell death through both necrotic and
apoptotic pathways [31, 32]. Future studies will be necessary to further characterize the
mechanisms which lead to increased ROS production in the mutant mice as well as
determine the physiological importance of these oxygen free radicals and their role in the
observed cardiac dysfunction. However, it is tempting to speculate that these alterations
may play a role in the dysfunction found in VAChT mutant mice.
It is important to note that ADP levels are increased in heart failure suggesting that
failing cardiac tissue utilizes greater amounts of ATP [33]. Under normal conditions, the
vasodilatory actions of adenosine may be able to compensate for this increased utilization
of ATP by myocardial tissue. However, VAChT KDHOM mice show increased levels of
Pnp which has previously been shown to metabolize adenosine into adenine [25, 26].
This may contribute to the inability of the mutant hearts to maintain normal contractile
function, an idea which is in accordance with previous research suggesting that the failing
heart is energy-starved [34, 35]. It should be noted that these alterations seems to be
selectively related to decreased cholinergic function, as the changes observed in the
microarray experiments were not observed in isoproterenol-treated mice.
Significant alterations in substrate metabolism have been observed during the progression
of heart failure and it is suggested that these changes contribute to cardiac remodeling
and dysfunction observed during disease progression [36]. Previous studies have shown
that, in end stage heart failure, there is an increase in glucose oxidation coupled with a
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decrease in fatty acid oxidation and these changes in substrate utilization lead to adverse
effects during late stage heart failure [19-22].
To further examine transcriptional alterations in VAChT mutant hearts that may not have
been identified in the microarray, we chose genes related to the lipid biosynthetic
pathway (ACLY, ACC and FAS). These pathways have been previously found to be
altered in heart failure [23]. In agreement with the notion that these pathways may be
altered in cardiac dysfunction, chronic treatment with the β-agonist isoproterenol, which
mimics the sympathetic overactivation observed in several cardiac diseases, increased
mRNA levels for ACLY, ACC and FAS several fold. We also found an increase in
mRNA expression of ACLY, ACC and FAS in VAChT mutant mice, suggesting at least
some similarities between autonomic imbalance due to decreased cholinergic tone and
sympathetic overactivation. Although gene expression changes were confirmed for
several genes involved in the generation of long-chain fatty acids in VAChT-mutant
mice, the protein levels for these enzymes appeared to be unaltered, although we cannot
discard the possibility that their turnover might be increased.
It is important to recognize that the transcriptional differences observed in ISO-treated
hearts is distinct from those observed in VAChT KDHOM mice. It is possible that at least
some of these differences are due to the genetic mouse strain utilized for the ISO
treatment experiment. It has long been recognized that the genetic divergence between
common laboratory mouse strains leads to changes in their response to cardiac stress. As
such, a more detailed study will be required to elucidate the basis of the transcriptional
differences observed in VAChT KDHOM and ISO-treated mice to determine which
alterations are due to a difference in mouse strains, as opposed to changes in autonomic
signaling.
An additional caveat must be taken into consideration when comparing the ISO model of
cardiac dysfunction with VAChT KDHOM animals. The extent of cardiac remodeling in
both of these models has not been thorough analyzed and, as such, there is no evidence
that the extent of cardiac remodeling is similar in both animal models. It is likely that a
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difference in the extent of molecular remodeling may contribute to the altered
transcriptional response observed when the two models are compared.
Importantly, VAChT KDHOM animals exhibit a global decrease in VAChT levels and,
therefore, decreased cholinergic tone. This is significant because it has recently been
proposed that cardiomyocytes possess the machinery (VAChT, ChAT and CHT1) for de
novo production of ACh [37, 38] and are able to synthesize and release this
neurotransmitter. This non-neuronal ACh may then act in an autocrine/paracrine fashion
to amplify neuronal cholinergic signaling [38]. We have found that this non-neuronal
cardiomyocyte release of ACh plays an important role in the protection of myocytes
against isoproterenol-induced hypertrophy and that VAChT mutant mice are deficient in
non-neuronal ACh secretion as well [39]. We cannot discard the possibility that the gene
alterations we uncovered here may, at least in part, be due to deficient ACh release from
cardiomyocytes. Future studies will be necessary to specifically analyze the importance
of this non-neuronal cholinergic system in myocytes and its contribution to the cardiac
dysfunction observed after reduced cholinergic tone. This may provide an unanticipated
mechanism by which non-neuronal ACh can play an important role in cardiac function.
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Chapter 3

3.1 Copyright Permission
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3.2 Chapter Summary

Recent work has provided compelling evidence that increased levels of acetylcholine
(ACh) can be protective in heart failure, whereas reduced levels of ACh secretion can
cause heart malfunction. Previous data show that cardiomyocytes themselves can actively
secrete ACh, raising the question of whether this cardiomyocyte derived ACh may
contribute to the protective effects of ACh in the heart. To address the functionality of
this non-neuronal ACh machinery, we used cholinesterase inhibitors and a siRNA
targeted to AChE (acetylcholinesterase) as a way to increase the availability of ACh
secreted by cardiac cells. By using nitric oxide (NO) formation as a biological sensor for
released ACh, we showed that cholinesterase inhibition increased NO levels in freshly
isolated ventricular myocytes and that this effect was prevented by atropine, a muscarinic
receptor antagonist, and by inhibition of ACh synthesis or vesicular storage. Functionally,
cholinesterase inhibition prevented the hypertrophic effect as well as molecular changes
and

calcium

transient

alterations

induced

by

adrenergic

overstimulation

in

cardiomyocytes. Moreover, inhibition of ACh storage or atropine blunted the antihypertrophic action of cholinesterase inhibition. Altogether, our results show that
cardiomyocytes possess functional cholinergic machinery that offsets deleterious effects
of hyperadrenergic stimulation. In addition, we show that adrenergic stimulation
upregulates expression levels of cholinergic components. We propose that this
cardiomyocyte cholinergic signaling could amplify the protective effects of the
parasympathetic nervous system in the heart and may counteract or partially neutralize
hypertrophic adrenergic effects.
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3.3 Introduction

Extrinsic control of heart function is primarily regulated by the autonomic nervous
system. The parasympathetic branch, which releases the neurotransmitter acetylcholine
(ACh), is well known to control heart rate [1] by predominantly regulating atrial function
[2]. Rich cholinergic innervations are found in the sinoatrial node, atrial myocardium,
atrioventricular node and in the ventricular conducting system of many species [3].
Although less abundant, parasympathetic fibers are also found throughout the ventricles,
where stimulation of type 2 muscarinic acetylcholine receptor (M2-AChR) by ACh leads
to L-type calcium channel inhibition and, consequently, reduced cardiomyocyte
contractility [4]. Recently, novel physiological functions of ACh in the heart have
emerged and new data suggest that this neurotransmitter plays unanticipated long-term
roles in cardiac protection that may not be necessarily linked to its role in regulating the
electrical properties of the heart [5].
ACh is synthesized in the cytoplasm of nerve terminals through the action of choline
acetyltransferase (ChAT) and stored within acidic synaptic vesicles for release. Activity
coupled transport of ACh into synaptic vesicles in nerve endings is mediated by the
vesicular acetylcholine transporter (VAChT) [6-8]. Released ACh, which activates
muscarinic receptors on cardiac cells, is rapidly degraded by the enzyme
acetylcholinesterase (AChE) to form acetate and choline. Choline is then recycled
through the action of the high-affinity choline transporter (CHT1), and reused as a
substrate for the synthesis of new ACh molecules [9].
Previously, we have shown that VAChT knockdown homozygous mice (VAChT
KDHOM mice), which express only 30% of normal VAChT levels, present a number of
cholinergic deficits due to reduced ACh release [8], including a remarkable dysfunction
in ventricular myocytes [10]. This is characterized by depressed ventricular contractile
function, calcium (Ca2+) signaling dysfunction and altered gene expression in ventricular
myocytes [10]. Confirming these findings, another model of cholinergic dysfunction with
reduced CHT1 expression showed age-dependent ventricular dysfunction [11]. Along
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these lines, M2-AChR knockout (KO) mice presented increased susceptibility to cardiac
stress [12]. Taken together, these results suggest that decreased cholinergic function can
affect outcomes for proper heart activity. Complementary to these findings, increased
availability of ACh can be protective in heart disease. For example, in vivo stimulation of
the vagus nerve [13] or treatment with a cholinesterase inhibitor [14] led to improved
outcome in experimental heart failure in rats. Recent data from Kanazawa et al. [15] have
provided further evidence for cholinergic mediated cardioprotection. These authors found
that cholinergic transdifferentiation of sympathetic neurons takes place during heart
failure in rats, mice and humans. Moreover, inhibition of transdifferentiation in mice
increased mortality in a mouse model of heart failure.
Multiple mechanisms may contribute to this protective effect of ACh on ventricular
myocyte function. For example, increased parasympathetic tone can directly modulate
heart function and also increase anti-inflammatory activity [16], which would be highly
beneficial in heart failure. Furthermore, previous works have shown that ventricular
cardiomyocytes express all the required components involved in ACh synthesis and
release, and actively secrete ACh [17,18]. Yet, the relevance of this non-neuronal
cardiomyocyte-derived cholinergic system in ventricular function is poorly understood.
Here, we address the functional significance of this machinery in cardiac cells and show
that cardiomyocyte released ACh can act in an autocrine/paracrine manner to mitigate the
effects of adrenergic overstimulation. Together, our results point to another level of
cholinergic control of cardiac function, which goes beyond the cardiac parasympathetic
system, and is intrinsic to ventricular myocytes.
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3.4 Materials and Methods

3.4.1

Animal models

In this study we used adult and neonatal C57BL/6 mice and Wistar rats. Rat and mouse
neonatal cardiomyocytes were isolated from 2-4 and 2-day old animals, respectively.
Adult ventricular myocytes were isolated from 10-12 week old male mice and from male
Wistar rats weighing 220-250g. The VAChT knockdown homozygous mouse line
(VAChT KDHOM mice) [8] was previously described. Animals were maintained at
UFMG, Brazil, and at the University of Western Ontario in accordance with NIH
guidelines and the Canadian Council for Animal Care for the care and use of animals.
Experiments were performed according to approved animal protocols from the
Institutional Animal Care and Use Committee at UFMG (protocol# 016/11) and at the
University of Western Ontario (2008-089).

3.4.2

Neonatal cardiomyocyte culture

Rat and mouse neonatal cardiomyocytes were cultured as previously described [19,20].
Briefly, cardiac cells were plated in dishes containing M199 medium supplemented with
100 units/ml penicillin, 100µg/ml streptomycin, 10% Fetal Bovine Serum and 2 mmol/L
L-glutamine. To prevent growth of fibroblasts, medium was supplemented with 20
µg/mL cytosine-D-arabinofuranoside (ARA-c). After 48 hours, neonatal cardiomyocytes
were exposed to isoproterenol (10 µmol/L) and/or pyridostigmine or neostigmine (10
µmol/L or 1 mmol/L) for 48 hours at the indicated concentrations. The cells were then
used for immunofluorescence, Western blotting or qPCR analyses. When necessary, cells
were incubated with atropine (10 µmol/L), vesamicol (5 µmol/L) or Nω-Nitro-L-Arginine
Methyl Ester Hydrochloride (L-NAME, 10 µmol/L) for 48 hours. ACh (10 µmol/L) and
phenylephrine (50 µmol/L) were also used in these experiments.
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3.4.3

Preparation of siRNA

Potential target sites within the acetylcholinesterase gene were selected and then searched
with NCBI Blast to confirm specificity for the enzyme. The siRNA for AChE was
prepared as previously described by our group [21]. The sense and antisense
oligonucleotides

of

siRNA

were

respectively,

as

AAAAGGTGGTAGCATCCAATACCTGTCTC-3′

follows:

and

5′5′-

AATATTGGATGCTACCACCTTCCTGTCTC-3′. In some studies we designed and
tested

a

second

siRNA

targeting

AACGTATTGGTAGCAGACATTCCTGTCTC-3′
AAAATGTCTGCTACCAATACGCCTGTCTC-3′.

AChE
and

For

(sense)
(antisense)

siRNA

studies,

5′5′neonatal

cardiomyocyte cultures at day 4 were transfected with 100nM of siRNA. The cells were
incubated at 37°C in an atmosphere of 5% CO2 for 30 hours and then exposed to
isoproterenol (10 µmol/L) for another 24 hours prior to use.

3.4.4

NO measurement

For these experiments we used freshly isolated adult ventricular myocytes from wild-type
and VAChT KDHOM mice aged 10-12 weeks. Measurement of NO production in living
ventricular myocytes was done using the membrane permeable fluorescent indicator 4amino-5-methylamino-

2′,7′-difluorofluorescein

diacetate

(DAF-FM

diacetate,

Invitrogen). To detect cytosolic NO, cardiomyocytes were loaded at 37°C with 5 µmol/ L
DAF-FM diacetate for 30 min and then washed for 30 min with Tyrode solution.
Cardiomyocytes were then incubated with ACh (10 µmol/L) or pyridostigmine (1
mmol/L) for 30 min. After this time, the fluorescence generated by NO production was
recorded using a confocal microscope (CEMEL, UFMG). Analyses were performed with
ImageJ software (NIH). In a separate group of experiments, cardiomyocytes were preincubated with atropine (10 µmol/L) or hemicholinium-3 (10 µmol/L) for 30 min before
the addition of acetylcholine or pyridostigmine to the cells. In another set of experiments,
we incubated mouse ventricular myocytes with different concentrations of ACh (0.1 to 10
µmol/L) or PYR (0.1 to 1000 µmol/L).
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3.4.5

FM1-43 FX

Freshly isolated adult ventricular myocytes were loaded with FM1-43 FX dye (4 µM,
Invitrogen) for 1 hour at 37°C in order to establish the localization of recycling vesicles.
Before being fixed in a 4% paraformaldehyde (PFA) solution, the cells were
ressuspended in Tyrode solution and washed for approximately 20 min to remove excess
dye. Cells were then submitted to our immunofluorescence protocol.

3.4.6

Statistical analysis

All data are expressed as mean ± SEM, and the number of cells or experiments is shown
as n. Significant differences between groups were determined with a Student's t-test or
ANOVA followed by the Bonferroni post hoc test. Values of p < 0.05 were considered to
be statistically significant.
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3.5 Results

3.5.1

Cardiomyocytes present functional ACh synthesis and
release machinery

Previous work has shown that adult and neonatal rat cardiomyocytes express the three
proteins involved in ACh synthesis and storage (ChAT, VAChT and CHT1) [17]. To
further assess how ubiquitous this phenomenon is, we extended these findings and
compared the expression of these three cholinergic markers in freshly isolated ventricular
myocytes from adult and neonatal mice. As shown in Fig. 3.1A, both neonatal and adult
cardiomyocytes express VAChT, observed as a 75 kDa band. For these experiments we
used an anti-VAChT antibody that has previously been validated by using striatal specific
VAChT knockout mice [23]. Our data show that the major band identified by this
antibody is highly expressed in brain, and shows lower levels of expression in
cardiomyocytes, as expected (Fig. 3.1A). ChAT, the enzyme responsible for ACh
synthesis, was also detected in both neonatal cardiomyocytes and in adult ventricular
cells (Fig. 3.1B). Interestingly, in cardiomyocytes, ChAT was observed mainly as a 52
kDa protein, in contrast with the more abundant 80 kDa protein found in the brain. The
52 kDa protein was also found in the brain, albeit in lower levels. It is possible that the 52
kDa protein is the result of alternative splicing of ChAT in cardiomyocytes. We also
detected CHT1 in both adult and neonatal cardiomyocytes (Fig. 3.1C). We further
analysed these cholinergic markers by using immunofluorescence and confocal
microscopy to ascertain their localization in isolated adult mouse ventricular myocytes.
Importantly, in cardiomyocytes, VAChT staining was found mainly in a perinuclear
compartment, although VAChT punctate staining was also found in the cytoplasm (Fig.
3.1D). Because VAChT is a transmembrane protein usually located in endosomal,
synaptic and recycling vesicles, we also tested whether this transporter would co-localize
with the vital dye FM1-43 FX, a fixable analogue of FM1-43 which can be used to
visualize recycling vesicles [24]. FM1-43 FX staining was observed all over the cardiac
cell, but was enriched at the perinuclear region, where it extensively co-localized with
VAChT (Fig. 3.1E). This finding is in agreement with previous data showing the
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Figure 3.1 - Mouse cardiomyocytes express prototypical cholinergic markers. A–C.
Representative Western blots of immunoreactivity for VAChT, ChAT, and CHT1 in
neonatal and adult mouse ventricular myocytes. Brain samples were used as a positive
control. α-tubulin was used as a loading control. D–G. VAChT, FM1-43 FX, ChAT and
CHT1 staining in adult mouse ventricular myocytes. Cardiomyocytes were also labeled
with antibody against the sarcomeric protein α-actinin to show cellular organization.
Scale bar = 10 µm.
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Figure 3.1 - Mouse cardiomyocytes express prototypical cholinergic markers.

142

presence of vesicle-associated membrane proteins (VAMP) in a punctate perinuclear
pattern in cardiomyocytes [25]. In addition, we observed ChAT immunostaining in the
nuclear region in close proximity to where VAChT is localized (Fig. 3.1F). The nuclear
localization of ChAT matches previous findings in neurons [26]. In agreement with the
Western blot data, CHT1 was also found in isolated cardiomyocytes. However, in
contrast with the localization of VAChT and ChAT, CHT1 was mostly localized to the
plasma membrane (Fig. 3.1G), where it presumably plays an active role in the reuptake of
choline.
A critical issue in identifying ACh secretion in non-neuronal cell culture is its rapid
degradation by AChE, an enzyme that has very high catalytic activity and is abundantly
expressed in cardiomyocytes [17]. Furthermore, detection of very low levels of ACh is
usually a challenge. One of the many responses of cardiomyocytes to ACh is an increase
in NO levels [27]. Therefore, we next sought to determine whether we could use the
generation of NO as a biological sensor for the effects of cardiomyocyte-derived ACh.
Thus, freshly isolated ventricular myocytes from adult wild-type mice were loaded with
the fluorescent indicator DAF-FM to assess NO generation in response to ACh (Fig.
3.2A-F). Fig. 3.2A shows representative images of DAF fluorescence in mouse
ventricular myocytes. Average values (Fig. 3.2B) show that exogenously added ACh (10
µmol/L) induced a significant increase in NO generation in ventricular myocytes, which
was blocked by atropine, a muscarinic antagonist. As shown in Fig. 3.2B, atropine alone
had no effect on NO generation. In order to test if ACh released by cardiomyocytes could
act in these cells in an autocrine/paracrine manner, we used a reversible cholinesterase
inhibitor (pyridostigmine) as a way to increase the availability of cardiomyocyte derived
ACh, by preventing its degradation by AChE. Wild-type cardiomyocytes were incubated
with pyridostigmine (1 mmol/L; 30 minutes), and DAF fluorescence was assessed. As
shown in Fig. 3.2C-D, adult mouse ventricular myocytes treated with pyridostigmine
alone presented increased NO generation to levels similar to that found in cells exposed
to exogenous ACh. This effect was completely blocked by atropine. To investigate if the
effect of pyridostigmine on NO generation was dependent on CHT1 activity, we treated
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Figure 3.2 - NO levels can be used as a biosensor to detect ACh release in
cardiomyocytes. A–F. DAF fluorescence measurements performed in wild-type (WT)
cardiomyocytes. A. Sample confocal images show cellular increase in DAF fluorescence
in cardiomyocytes from WT mice treated with ACh. B. Averaged DAF fluorescence
increase in adult ventricular myocytes following acute treatment with exogenously added
ACh for 30 min. The pre-incubation of muscarinic receptor antagonist, atropine (AT),
inhibits the increase in DAF fluorescence in ACh treated cardiomyocytes. C. Sample
images

of

DAF

fluorescence

of

cardiomyocytes

incubated

with

ACh, pyridostigmine (PYR) or PYR/AT. D. Effect of cholinesterase inhibition on DAF
fluorescence in the presence or absence of atropine (AT) pre-treatment. Cardiomyocytes
exposed to pyridostigmine presented an increase in DAF fluorescence, which was blunted
by atropine. E. Sample images of DAF loaded cardiac myocytes treated with
hemicholinium-3 (HC-3) and/or PYR for 30 min. F. HC-3 blunted PYR induced increase
in DAF fluorescence in ventricular myocytes. G. Sample images of DAF fluorescence in
ventricular myocytes of VAChT KDHOM mice incubated with ACh or PYR.
H. Cholinesterase inhibition in cardiomyocytes with reduced VAChT expression levels
does not lead to a significant increase in NO generation. n = number of cells analyzed.
*p < 0.05 when compared to the other groups. #p < 0.05 when compared to CT and
PYR/AT groups. All cells were loaded with fluorescent dye following the same protocol,
and imaging was done preserving the same parameters in both control and drug treated
cardiomyocytes. Scale bar = 10 µm.
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Figure 3.2 - NO levels can be used as a biosensor to detect ACh release in
cardiomyocytes.
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the cells with hemicholinium-3 (HC-3, 10 µmol/L), a CHT1 inhibitor that abolishes ACh
synthesis. Fig. 3.2E-F shows that pre-incubation of cardiomyocytes with HC-3 also
prevented the effects of pyridostigmine on DAF fluorescence. Similar to atropine, HC-3
alone had no effect on DAF fluorescence.
To assess the specificity of pyridostigmine effect on NO production we compared the
concentration dependency of ACh and pyridostigmine on DAF loaded ventricular
myocytes. Cardiac cells were exposed to increased concentrations of ACh and
pyridostigmine and DAF fluorescence was assessed. As shown in Fig. 3.3A-B, both ACh
and pyridostigmine produced a concentration dependent increase in NO levels, thus
eliminating the possibility that pyridostigmine exerts off target effects.
We then examined the effects of pyridostigmine on DAF fluorescence in cardiomyocytes
from VAChT KDHOM mice, an animal model that presents 70% reduction in VAChT
levels and concomitant decrease in ACh release [8]. Fig. 3.2G-H shows that
cardiomyocytes obtained from VAChT KDHOM mice fail to respond to pyridostigmine.
This finding contrasted with the significant response to pyridostigmine found in wildtype myocytes (Fig. 3.2C-F). Moreover, exogenously added ACh elicited a significant
increase in DAF fluorescence in cardiomyocytes from VAChT KDHOM mice. The
response to ACh found in these cells was similar to the one observed in wild-type
cardiomyocytes (Fig. 3.2B,D). Therefore, by using a cholinesterase inhibitor, it is
possible to increase the availability of cardiomyocyte derived ACh, which in turn
activates muscarinic receptors to increase NO levels. Taken together, these data show that
cardiomyocytes are capable of synthesizing and releasing ACh confirming the
functionality of cholinergic machinery in these cells. Moreover, it seems that both choline
reuptake and ACh storage in VAChT positive organelles are required for ACh secretion
from adult cardiomyocytes.
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Figure 3.3 - Concentration-dependent effects of ACh and PYR on NO generation in
mouse ventricular myocytes. A-B. Averaged DAF fluorescence increase in adult
ventricular myocytes following acute treatment with exogenously added ACh for 20
minutes. Bar graph shows a progressive increase in cardiomyocyte induced NO
production upon ACh (0.1 to 10 µmol/L) or pyridostigmine (PYR) stimulation. PYR
doses ranged from 0.1 to 1000 µmol/L. n= number of cardiomyocytes analysed. † p<0.05
when compared to control and ACh 0.1 µmol/L. * p<0.05 when compared to control. #
p<0.05 when compared to PYR 1000 µmol/L.
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Figure 3.3 - Concentration-dependent effects of ACh and PYR on NO generation in
mouse ventricular myocytes.
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3.5.2

Cholinesterase inhibition prevents adrenergic hypertrophic
signaling

Our data indicate that cholinesterase inhibition increases the availability of ACh secreted
by cardiomyocytes. Therefore, we investigated the possibility that this cardiomyocyte
cholinergic signaling can exert protective effects. Thus, the next group of experiments
was conducted in mouse neonatal cardiomyocytes as these cells are easier to maintain in
culture than isolated adult cells and their phenotype is highly stable [28,29]. In order to
simulate disease conditions, neonatal cardiomyocytes were treated with isoproterenol
(ISO, 10 µmol/L) for 48 hours and cellular hypertrophy was assessed by direct
measurement

of

myocyte

surface

area. Fig.

3.4A

shows

representative

immunofluorescence images from α-actinin stained cardiomyocytes. Cardiomyocytes
treated with isoproterenol demonstrated increased cell surface area by 40% (Fig. 3.4B),
whereas concomitant treatment with vesamicol (5 µmol/L), a specific VAChT inhibitor,
caused an even greater increase in cell surface area (80%), thus implicating released ACh
in the endogenous protection against cellular hypertrophy. Importantly, pyridostigmine
(10 µmol/L) prevented the hypertrophic effect of isoproterenol. Similar effects were
observed in cells treated with 1 mmol/L pyridostigmine (data not shown). The action of
pyridostigmine was dependent on VAChT activity, and ACh secretion, as isoproterenol
was again able to effectively induce hypertrophy when vesamicol was present in the
media. We further confirmed these data in a second cohort of cells that were treated with
isoproterenol and another cholinesterase inhibitor, neostigmine (10 µmol/L). Fig. 3.4CD shows that neostigmine was as effective as pyridostigmine in preventing the
hypertrophic actions of isoproterenol. We again found that vesamicol was able to block
the protective effect of neostigmine. Together, these data suggest that ACh released by
cardiomyocytes can offset hypertrophic effects of isoproterenol on mouse neonatal
cardiac cells.

3.5.3

Mechanisms involved in mitigation of isoproterenol-induced
hypertrophy

In order to further understand the mechanisms involved in this protective response to
endogenously secreted ACh, we used rat cardiomyocytes, which also have an intrinsic
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Figure 3.4 - Cholinesterase inhibition in mouse neonatal cardiomyocytes prevents
isoproterenol induced hypertrophy. A. Sample immunofluorescence images of αactinin/DAPI stained neonatal cardiac cells. Isoproterenol (ISO) induced a significant
increase in cardiomyocyte surface area, an effect that was more pronounced in the
presence of vesamicol (VES), and abolished by pyridostigmine (PYR). Pyridostigmine
effects on isoproterenol treated cells were eliminated by vesamicol. B. Bar graph of
cardiomyocyte surface area measurements. *p<0.05 when compared to control and
ISO/PYR. #p<0.05 when compared to ISO and ISO/PYR/VES. C-D. Isoproterenol
induced hypertrophy was blunted by neostigmine (NEO). Neostigmine effects were
prevented in the presence of vesamicol. *p<0.05 when compared to control and
ISO/NEO. # p<0.05 when compared to ISO. n= number of cells analysed in each
experimental group. Scale Bar=25µm.
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Figure 3.4 - Cholinesterase inhibition in mouse neonatal cardiomyocytes prevents
isoproterenol induced hypertrophy.
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cholinergic system, as previously demonstrated by others [17,18], and are easier to
culture than mouse cells [30]. Initially, we assessed expression levels of cholinergic
markers in rat cardiomyocytes (Fig. 3.5). Overall these data match previous findings in
the literature [17,18], and also confirm our data obtained from mouse cardiomyocytes, as
we show that rat cardiomyocytes express VAChT, ChAT, M2-AChR and AChE. In adult
rat ventricular cells, VAChT is detected as a 75 kDa and a 47 kDa band (Fig. 3.5A).
VAChT expression was also observed in neonatal rat cardiomyocytes isolated from 2-4
day old rats, although in these cells VAChT was observed at an intermediate size band, as
previously reported [17]. These differences in molecular mass are probably due to
different glycosylation patterns of VAChT molecules [31,32]. ChAT was also detected in
both cellular systems (Fig. 3.5B). In addition, we show that adult and neonatal
cardiomyocytes express AChE (Fig. 3.5C), as shown by others [33].
Our finding that VAChT is presented at the perinuclear region is potentially important
since it suggests that cardiomyocytes segregate the exocytotic machinery at the nuclear
region, as observed for other granules in these cells [25,34]. In order to confirm this
finding, we stained isolated rat adult ventricular myocytes and imaged them by confocal
microscopy. As previously observed, VAChT is mainly found at the perinuclear region
where it colocalized with recycling vesicles stained with FM1-43 FX (Fig. 3.5D, arrow).
Some sparse VAChT positive vesicles were also observed along the T-tubular system
(Fig. 3.5D, arrowhead). In addition, we observed ChAT immunostaining in the nuclear
and intercalated disk regions, as well as in T-tubules, with some presence in the
perinuclear area (Fig. 3.5E). M2-AChR receptor immunostaining was also enriched at the
perinuclear region, with some staining found at the T-tubules (Fig. 3.5F). Corroborating
the data obtained from adult ventricular myocytes, neonatal rat cardiomyocytes also
showed intense staining and similar subcellular localization for both VAChT (Fig. 3.5G)
and ChAT (Fig. 3.5H). Taken together, our data from mice and rats confirm the presence
of prototypical cholinergic markers in adult and neonatal cardiomyocytes and show for
the first time that VAChT positive vesicles segregate to the nuclear periphery along with
other cholinergic markers.
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Figure 3.5 - Rat cardiomyocytes express neuronal cholinergic markers. A-C.
Western blots of VAChT, ChAT and AChE in neonatal and adult rat ventricular
myocytes. D. VAChT distribution in adult ventricular myocytes. FM1-43 FX-loaded
vesicles exhibited a punctuate fluorescence mainly at the perinuclear region of ventricular
myocytes, which colocalizes with VAChT. VAChT vesicles at perinuclear hotspots are
indicated by the yellow arrow. Some sparse VAChT staining was also found at T-tubules
(arrowhead). E. ChAT immunolocalization was found at the nuclear region, T-tubular
system and intercalated disks. F. M2-AChR staining is localized to the perinuclear area
and T-tubular system. G-H. VAChT and ChAT staining are also detected in neonatal rat
cardiomyocytes. Similar staining patterns were observed between neonatal and adult
cardiomyocytes. Arrows show VAChT presence at the perinuclear and cytosolic regions.
Cardiomyocytes were also labeled with an antibody against the sarcomeric protein αactinin to show cellular organization. Scale Bar=10µm.
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Figure 3.5 - Rat cardiomyocytes express neuronal cholinergic markers.
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hypertrophy
A.

induced

Representative

immunofluorescence images from α-actinin/DAPI stained neonatal cardiomyocytes in
control (CT), isoproterenol (ISO) and isoproterenol/pyridostigmine (ISO/PYR) treated
groups. B. Quantification of cardiomyocyte surface area from experiments shown in A.
C–D. Representative immunofluorescence images and quantification of cellular surface
area from α-actinin/DAPI stained neonatal cardiomyocytes from CT, ACh and PYR
treated groups. *p < 0.05 when compared to control and ISO/PYR groups. n = number of
cells analyzed in each group. Scale bar = 10 µm.

155

Figure

3.6

-

Cholinesterase

inhibition

suppresses

by isoproterenol in rat neonatal cardiomyocytes.

hypertrophy

induced

156

In order to gain mechanistic insight into the functionality of this system, and to verify
whether its anti-hypertrophic action is conserved between mice and rats, we exposed
neonatal rat cardiomyocytes to isoproterenol and pyridostigmine. As shown in Fig. 3.6,
pyridostigmine was again effective in preventing the hypertrophic effects of
isoproterenol. Importantly, neither pyridostigmine nor ACh (10 µmol/L) alone altered the
cell surface area of neonatal rat cardiomyocytes (Fig. 3.6C-D). To further confirm these
findings, we depleted endogenous acetylcholinesterase in rat neonatal cardiomyocytes
using specific siRNA targeting AChE. Real-time PCR shows the efficiency of siRNA
induced reduction of AChE mRNA (by approximately 80%, Fig. 3.7A). Treatment of
cardiomyocytes with isoproterenol is well known to increase expression levels of atrial
natriuretic peptide (ANP) [35] and β-myosin heavy chain (β-MHC) transcripts [36].
Therefore, the expression levels of these transcripts was analysed by qPCR. As expected,
we observed a significant upregulation of ANP and β-MHC levels upon isoproterenol
stimulation of neonatal rat cardiomyocytes. Importantly, AChE silencing partially
abolished the effect of isoproterenol on ANP and β-MHC expression (Fig. 3.7B-C).
Similar findings were observed with a distinct siRNA targeted to AChE (data not shown).
Thus these data further support the hypothesis that preservation of endogenously secreted
ACh prevents the activation of the hypertrophic signaling cascade induced by
isoproterenol in cardiomyocytes.
Similarly, the effect of isoproterenol on β-MHC mRNA was also abolished in
cardiomyocytes treated with the pharmacological cholinesterase inhibitor, pyridostigmine
(Fig. 3.8A). In order to gain mechanistic insight into how cardiomyocyte derived ACh
exerts its anti-hypertrophic effects, we investigated whether nitric oxide was involved in
this process. Thus, we assessed the effect of L-NAME on β-MHC mRNA levels in
neonatal rat cardiomyocytes treated with isoproterenol and pyridostigmine. Inhibition of
nitric oxide production with L-NAME significantly blunted pyridostigmine induced βMHC transcript downregulation in isoproterenol treated cardiomyocytes, indicating a role
for NO in the anti-hypertrophic response elicited by intrinsic ACh (Fig. 3.8A). Moreover,
isoproterenol induced ANP upregulation was also abolished in neonatal cardiomyocytes
incubated with pyridostigmine (Fig. 3.8B), supporting our findings obtained with AChE-
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Figure 3.7 - AChE silencing attenuates isoproterenol induced fetal gene expression
in neonatal cardiomyocytes. A. siRNA targeting AChE significantly reduces mRNA
expression levels of this enzyme. B–C. Isoproterenol treatment significantly increases
ANP and β‐MHC mRNA levels in neonatal cardiomyocytes, an effect that is partially
abolished in cells transfected with siRNA targeting AChE. n = 4 to 8 samples from each
group. *p < 0.05 when compared to the other groups.
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Figure 3.7 - AChE silencing attenuates isoproterenol induced fetal gene expression
in neonatal cardiomyocytes.
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Figure 3.8 - Cholinesterase inhibition prevents isoproterenol induced remodeling in
neonatal rat cardiomyocytes. A. Cholinesterase inhibition in neonatal cardiomyocytes
prevents isoproterenol (ISO) induced upregulation of β‐MHC mRNA, an effect that is
lost in the presence of L-NAME. n = 4 to 5 samples from each group. B. qPCR
experiments revealed a significant upregulation in ANP transcript levels in ISO treated
cells. Pyridostigmine prevented ANP upregulation induced by ISO treatment. The effect
of ISO on ANP transcription in pyridostigmine (PYR) treated cells was restored upon
exposure to atropine (AT). n = 3 to 5 samples from each group. C. ISO stimulation
increased perinuclear ANP staining with levels of staining in ISO/PYR treated
cardiomyocytes comparable to that in control cells. The ability of PYR to prevent ANP
increase under ISO stimulation was blunted by atropine. D. In control cells, NFAT is
found mainly in the cytosol, and upon ISO stimulation this pro-hypertrophic transcription
factor translocates to the nucleus. ISO induced NFAT translocation was completely
suppressed by PYR. Addition of either vesamicol or atropine significantly inhibited PYR
effects on NFAT localization in ISO treated cells. E. Bar graph showing the relative
amount of nuclear/cytosolic NFAT. n = number of cells analyzed. *p < 0.05 when
compared to control and ISO/PYR groups. Scale bar = 10 µm.
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Figure 3.8 - Cholinesterase inhibition prevents isoproterenol induced remodeling in
neonatal rat cardiomyocytes.
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siRNA. Interestingly, the effect of pyridostigmine in preventing ANP transcript
upregulation was inhibited by atropine (Fig. 3.8B), confirming the finding that available
ACh after pyridostigmine treatment uses muscarinic receptors. ANP protein localization
was also analysed in the presence of isoproterenol by immunostaining (Fig. 3.8C).
Isoproterenol stimulation resulted in significantly increased perinuclear ANP staining, an
effect that was prevented by pyridostigmine. Similar results were observed when
isoproterenol treated cells were exposed to neostigmine (Fig. 3.9). The ability of
pyridostigmine to prevent ANP increase under isoproterenol stimulation was lost when
cardiomyocytes were exposed to atropine (Fig. 3.8C).
A prominent signaling cascade stimulated by isoproterenol, and whose overactivation is
associated with hypertrophic remodeling in cardiomyocytes, is the nuclear factor of
activated T cells (NFAT) pathway. In neonatal cardiomyocytes, isoproterenol treatment
leads to NFAT translocation to the nucleus, as previously described by others [37]. Fig.
3.8D-E shows the localization of NFAT in non-treated neonatal rat cardiomyocytes and
demonstrates that isoproterenol stimulation leads to increased immunoreactivity for
NFAT in the nucleus. The isoproterenol induced nuclear translocation of NFAT was
completely prevented by pyridostigmine. Similar finding was observed in isoproterenol
treated neonatal cardiomyocytes that were exposed to ACh (Fig. 3.10). Addition of
vesamicol, a specific inhibitor of the VAChT, or atropine, significantly blunted the
effects of pyridostigmine on NFAT translocation in isoproterenol treated cells (Fig. 3.8DE).
To further assess the possible mechanism through which ACh released by
cardiomyocytes

prevents

isoproterenol-induced

hypertrophy,

we

examined

Ca2+ transients in isolated adult rat cardiomyocytes kept in culture for 20 hours.
Activation of β-adrenergic receptors by isoproterenol in ventricular myocytes is known to
enhance the magnitude of the intracellular Ca2+ transient, [Ca2+]i, which contributes to the
alterations in intracellular signaling. It is also known that ACh binds to M2-AChR which
couple to Gi/0 family of G proteins [38] and inhibits adenylyl cyclase. In many ways,
therefore, the effects of ACh are opposed to those of sympathetic activation. Freshly
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Figure 3.9 - Neostigmine exerts anti-hypertrophic effects. Representative images of
neonatal cardiomyocytes stained with anti-ANP (green) are displayed. The nucleus was
stained with DAPI (blue). Neostigmine (NEO) treatment abolished isoproterenol (ISO)
induced changes in ANP localization. Scale Bar= 10µm.
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Figure 3.9 - Neostigmine exerts anti-hypertrophic effects.
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Figure 3.10 - ACh blunts isoproterenol induced NFAT translocation. Neonatal rat
cardiomyocytes were labeled with antibody against NFAT (green). The nucleus was
stained with DAPI (blue). ACh blunts hypertrophic signaling induced by isoproterenol by
inhibiting NFAT nuclear translocation in rat neonatal cardiomyocytes. Scale Bar=10µm.
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Figure 3.10 - ACh blunts isoproterenol induced NFAT translocation.
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Figure 3.11 - Cardiomyocyte cholinergic signaling prevents isoproterenol effects on
Ca2+ transients. A. (Top) Sample Ca2+ transient images recorded in Fluo-4/AM loadedventricular myocytes kept in culture for 20 h. (Bottom) Ca2+ transient profile. B.
Averaged bar graph showing the increase in Ca2+ transient following isoproterenol
stimulation. Cholinesterase inhibition by pyridostigmine prevented isoproterenol effects
on Ca2+ transient amplitude. n = number of cells analyzed. * = p < 0.05 when compared
to the other groups.
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Figure 3.11 - Cardiomyocyte cholinergic signaling prevents isoproterenol effects on
Ca2+ transients.
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isolated rat ventricular myocytes were plated in laminin-coated dishes and treated with
isoproterenol (1 µmol/L). After a 20 hour treatment, cells were loaded with Fluo-4/AM
for 30 min, and Ca2+ transient parameters were examined in a confocal microscope. (Fig.
3.11A) displays typical line scan fluorescence images recorded from electrically
stimulated ventricular myocytes. Chronic activation of β-adrenergic receptor by
isoproterenol increases Ca2+ transient amplitude, and this, in part, is responsible for the
adrenergic regulation of myocytes (Fig. 3.11B). Concomitant addition of pyridostigmine
(500 µmol/L) to isoproterenol-treated myocytes significantly attenuated the increase in
Ca2+ transient amplitude induced by isoproterenol thus suggesting an opposing effect of
pyridostigmine. Collectively, these data support the functionality of ACh synthesis and
release machinery in ventricular myocytes, and indicate that non-neuronal ACh can
activate muscarinic receptors to counteract the effect of isoproterenol at the calcium
signaling level.
We next investigated whether pyridostigmine could also inhibit the hypertrophic response
induced by another adrenergic stimulus, phenylephrine, which is known to activate a Gq
signaling pathway through α-adrenergic receptors stimulation [39]. Neonatal rat
cardiomyocytes treated with 50 µmol/L phenylephrine for 48 hours presented a 39%
increase in cell surface area when compared to control cardiomyocytes (Fig. 3.12A-B).
This hypertrophic effect was partially prevented by pyridostigmine. Moreover,
pyridostigmine significantly attenuated phenylephrine-induced upregulation of ANP
transcript levels (Fig. 3.12C). Once again, atropine and L-NAME were effective in
preventing pyridostigmine effects on phenylephrine treated neonatal cardiomyocytes.
Collectively, our data show that increased availability of released ACh prevents
phenylephrine-induced pathological remodeling in cardiomyocytes.

3.5.4

Cardiomyocyte cholinergic machinery is upregulated by
adrenergic stimulation

Previous studies using neuronal cells [40] have implicated protein kinase A as an
important modulator of VAChT and ChAT mRNA levels, which indicates that adrenergic
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Figure 3.12 - Phenylephrine-induced hypertrophy is partially abolished by
cholinesterase inhibition in neonatal cardiac myocytes. A. Sample images of αactinin/DAPI stained neonatal rat cardiomyocytes treated for 48 h with phenylephrine
(PHE) or PHE/PYR. Scale bar = 10 µm. B. Bar graph showing partial inhibition of PHE
induced hypertrophy in PYR-treated neonatal cardiomyocytes. n = number of cells
analyzed. C. PYR treatment of PHE exposed cardiomyocytes significantly prevents ANP
mRNA upregulation. Addition of either atropine or L-NAME blunted PYR effects on
ANP mRNA in PHE-exposed cells. n = 3–7 samples from each group. *p < 0.05 when
compared to control and PHE/PYR group. #p < 0.05 when compared to control group.
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Figure 3.12 - Phenylephrine-induced hypertrophy is partially abolished by
cholinesterase inhibition in neonatal cardiac myocytes.
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stimulus could regulate expression of cholinergic components. In order to better
understand how this intrinsic cholinergic system is modulated and to explore at the
mechanistic level how cholinergic signaling counteracts the adrenergic effects, we next
assessed the expression levels of cholinergic machinery components in response to
isoproterenol and phenylephrine. In neonatal rat cardiomyocytes, ChAT, VAChT and
M2-AChR mRNA were upregulated by isoproterenol (Fig. 3.13A) and phenylephrine
(Fig. 3.13B). Similar effect was seen at the protein level for ChAT, VAChT and M2AChR on isoproterenol treated cardiomyocytes (Fig. 3.13C-E). We then investigated the
effect of isoproterenol on ChAT, VAChT and M2-AChR localization in neonatal
cardiomyocytes by performing immunofluorescence experiments. As shown in Fig.
3.13F, isoproterenol treatment significantly increased ChAT levels at both cytoplasm and
nuclei of neonatal cardiomyocytes. Moreover, neonatal cardiomyocytes treated with
isoproterenol presented increased VAChT and M2-AChR cytoplasmic staining (Fig.
3.13G-H). In conclusion, these data show that adrenergic stimulation upregulates the
expression levels of cholinergic components in cardiac myocytes.
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Figure

3.13

-

Adrenergic

stimulation

upregulates

expression

of

cholinergic machinery in cardiomyocytes. A–B. Either isoproterenol (ISO) or
phenyleprine (PHE) upregulates mRNA levels of ChAT, VAChT and M2-AChR in
neonatal cardiac cells. n = 2 to 5 samples from each group. C–E. Top, representative
Western blot. Bottom, bar graph showing the effect of isoproterenol on ChAT, VAChT
and M2-AChR protein levels. n = number of cardiomyocyte samples analyzed from each
group. F–H. Immunofluorescence images showing ChAT, VAChT and M2-AChR
changes upon isoproterenol stimulation. The nucleus was stained with DAPI (blue).
*p < 0.05 when compared to control. Scale bar = 10 µm.
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Figure 3.13 - Adrenergic stimulation upregulates expression of
cholinergic machinery in cardiomyocytes.
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3.6 Discussion

An intrinsic cardiomyocyte cholinergic system has recently been described [17,18].
However, the physiological role of this cardiomyocyte cholinergic machinery and its
significance for cardiac function during normal and disease conditions is unknown. Here,
we present for the first time evidence that activation of this novel and unexpected
machinery has an important role in cardiomyocyte protection, in vitro. These data bring
into perspective another level of cholinergic control of cardiac function, which goes
beyond the cardiac parasympathetic system, and it is intrinsic to ventricular myocytes.

3.6.1

Localization of cholinergic proteins in cardiomyocytes

We have extended the observations of two previous reports [17,18], and provide evidence
that neonatal and adult cardiomyocytes express prototypical cholinergic markers
responsible for ACh synthesis and release. Particularly intriguing is the localization of
VAChT to the perinuclear region. Our experiments with vital dye FM1-43 show that this
region accumulates recycling vesicles that would be required for the release of ACh.
Importantly, cardiomyocytes present all the necessary components required for the
exocytosis endocytosis cycle, including SNARE molecules such as SNAP-23, Syntaxin4, VAMP-1, VAMP-2 and VAMP-3, as well as NSF and its co-factor α-SNAP, the
calcium sensor synaptotagmin, and the GTPases Rab8 and Rab4 [25]. Interestingly,
SNARE proteins, VAMP-1, VAMP-2, VAMP-3 and syntaxin-4 are found at the
perinuclear region of cardiomyocytes [25], supporting our findings. ANP granules are
also present in the perinuclear region of cardiomyocytes, suggesting that secretory
granules and vesicles are sequestered away from the cellular periphery in these cells. This
may represent a way to segregate the exocytosis machinery required to secrete proteins
and small molecules from the constant changes in Ca2+ levels that occur in
cardiomyocytes. It is worth mentioning that Inositol 1,4,5-trisphosphate (InsP3) receptors
are found in the perinuclear region [41] where they could provide specific Ca2+ signals to
activate exocytosis in these cells. However, we cannot discard at the moment the
possibility that at least part of the ACh in vesicles is secreted constitutively. The
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mechanisms involved in triggering and regulating ACh secretion in cardiomyocytes
remain to be identified.
Interestingly, in nerve terminals CHT1 is found mainly in synaptic vesicles and
endosomal organelles [42] and only a fraction of the protein is present at the plasma
membrane [9]. This does not seem to be the case in cardiomyocytes where the protein is
found mainly at the sarcolemma. We note that others have also described similar
localization of CHT1 in cardiomyocytes [18].
We have also identified M2-AChR at the perinuclear region of cardiac cells in addition to
its localization at the T-tubular system. This finding is in agreement with previous data
showing the presence of the Gi subunit at the nuclear periphery of ventricular myocytes
[43]. In addition, β-adrenergic receptors have also been found at these nuclear structures
[43]. Whether this intracellular pool of receptors represents newly-synthesized and
recycling receptors or represents functional receptors is still unknown. The possibility
that ACh may play unanticipated roles in regulating gene transcription in the cardiac cells
by activating nuclear M2 receptors is intriguing. The functional consequences of this
nuclear receptor activation, however, have yet to be elucidated.

3.6.2

ACh release by cardiomyocytes depends on VAChT activity

Although others have shown that ACh is released by cardiomyocytes [17,18], our data
extend these findings by demonstrating the functionality of this phenomenon. By using
the production of NO as a biosensor for released ACh, and by using the cardiomyocytes
themselves as a detection sensor, we showed that inhibition of cholinesterase
significantly increases DAF fluorescence i.e. increases NO levels. This effect is similar to
that observed when exogenous ACh is added to freshly isolated ventricular myocytes and
it is completely abolished by a muscarinic antagonist and by a specific inhibitor of the
CHT1. CHT1 is required in nerve terminals for the synthesis of ACh [44], and our data
suggest it has similar roles in cardiomyocytes. It is particularly interesting that HC-3 can
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block the effects of pyridostigmine as it suggests that no other sources of choline can be
utilized in order to generate ACh in cardiac cells.
Our data indicate that ACh secretion by cardiomyocytes requires vesicular mechanisms
since ventricular myocytes obtained from mice that express substantially less VAChT
(VAChT knockdown mice) showed decreased availability of ACh for activation of DAF
fluorescence. This result is consistent with our finding that some of the effects of
pyridostigmine or neostigmine are inhibited by vesamicol, a selective VAChT inhibitor.
VAChT is part of an ancient transport machinery [45] and, as long as it is present in
acidic vesicles, it will be able to transport ACh [46]. Hence, taken together, these
experiments provide strong evidence that ACh release by cardiomyocytes depends on
VAChT activity. Moreover, our data show that observed effects of pyridostigmine occur
via preservation of ACh. It is unlikely that pyridostigmine would have off target effects
as similar results were also observed with a second cholinesterase inhibitor, neostigmine,
and in cells transfected with a siRNA targeted to AChE. Moreover anti-hypertrophic
effects of pyridostigmine were not observed in the absence of ACh transport to vesicles.

3.6.3

ACh secreted by cardiomyocytes prevents adrenergic
hypertrophic effects

Since proteins involved in the synthesis and release of ACh are found in cardiomyocytes,
this raises the question as to whether this intrinsic cholinergic system has any direct
functional role in regulating cardiomyocyte activity. Considering that we used a
cholinesterase inhibitor to observe the effect of cardiomyocyte-derived ACh, it could be
argued that this local cholinergic machinery is not essential to cardiac function. However,
it should be noted that although parasympathetic innervations in the ventricle are scarce
[47], muscarinic receptors are expressed in ventricular myocytes [48]. Therefore, we
speculate that this intrinsic cardiomyocyte cholinergic signaling is part of an adaptive
defense mechanism against cardiomyocyte insults. This is further supported by our
finding that ventricular myocytes from VAChT knockdown mice present a Ca2+ signaling
dysfunction that is restored upon pyridostigmine administration, in vivo [10], indicating
that lack of ACh release has profound effects on ventricular myocytes.
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While our data indicates that basal ACh release by cardiomyocytes is low, it is plausible
that under certain circumstances ACh release can increase, and exerts protective effects.
Modulation of ChAT, VAChT and CHT1 expression levels has already been
demonstrated in neuronal cells [49,50]. Accordingly, cAMP leads to a significant
increase in ChAT and VAChT mRNA levels in SN56 cells. Here, we show for the first
time that chronic adrenergic stimulation upregulates expression levels of cholinergic
components VAChT, ChAT and M2-AChR in rat cardiac cells, suggesting that ACh
release is increased under these conditions. Supporting this assumption, we show that
isoproterenol-induced increase in cell surface area is exacerbated when VAChT activity,
and consequently ACh release, is inhibited. Together, these findings unravel a role for
intrinsic ACh as an in situ negative feedback signal that counteracts adrenergic effects.
At the mechanistic level, the ability of pyridostigmine to prevent the increase in
Ca2+ transient induced by prolonged treatment with isoproterenol is of major importance
since alterations in Ca2+ may act as a trigger for cardiac remodeling. Accordingly, ACh
secreted locally by cardiomyocytes can act in a paracrine/autocrine manner to antagonize
the effects of hyperadrenergic stimulation. Taking this into consideration, we speculate
that under certain circumstances local cardiac cholinergic system could contribute to the
protective effects of the parasympathetic nervous system in the heart. This possibility
must be considered in future studies of cardiovascular pathology in which treatment with
cholinesterase inhibitor is being evaluated, in vivo.
The role of non-neuronal ACh synthesis and release machinery in other cell types has
also begun to be elucidated. For example, in the immune system, ACh synthesized by a
population of T lymphocytes has been recently shown to be required for the function of
the cholinergic anti-inflammatory system [51]. In humans, non-neuronal ACh in α cells
in the pancreas is important for the secretion of insulin [52]. Here we also show a
putative role for cholinergic signaling present in cardiomyocytes by opposing the
hypertrophic effects of adrenergic stimulation. It is worth mentioning that the only source
of ACh in our experiments is the cardiac cell, as evidenced by the absence of neuronal
cells in our culture conditions. Moreover, the use of a broad range of pharmacological
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agents that interfere with the synthesis and storage of ACh in vesicles support the notion
that cardiomyocytes have adapted mechanisms used by neurons to secrete ACh. Given
that ACh is an ancient and widespread chemical used for cell-cell communication, it
should not come as a surprise to find so many distinct non-neuronal roles for ACh. Future
experiments, using conditional knockout mice [23,53] will be necessary to further define
the role of this non-neuronal cholinergic system in cardiomyocytes in physiological and
pathological alterations in the heart in vivo.

3.6.4

Conclusion

Taken together, our results show that cardiomyocytes express neuronal proteins required
for ACh synthesis and release and are capable of secreting ACh. In these cells, VAChT is
found mainly at the perinuclear region, where it extensively colocalizes with recycling
vesicles that are required for ACh release. ACh secretion by cardiomyocytes depends on
both VAChT activity and choline reuptake by CHT1, as observed in neurons. In addition,
we show that cardiomyocyte secreted ACh impairs adrenergic hypertrophic signaling,
indicating that ACh acting autocrinally has a protective role.

179

3.7 Acknowledgments

This work was supported by grants from NIH R03TW008425 from the Fogarty
International Center (SG), Conselho Nacional de Desenvolvimento Científico e
Tecnológico (SG, CG, RRR), Fundação de Amparo à Pesquisa do Estado de Minas
Gerais (SG, CG and RRR), PRONEX APQ-00746-09 (SG), the Heart and Stroke
Foundation of Ontario (MAMP and VFP) and CIHR (RG, VFP and MAMP). C. RochaResende is a recipient of the CNPq PhD fellowship at the Post-graduation Program in
Biological Science: Physiology and Pharmacology at UFMG. Ashbeel Roy is a recipient
of the Queen Elizabeth II Scholarship in Science and Technology (QEIISST). Robert
Gros is supported by a New Investigator Award from the Heart and Stroke Foundation of
Canada.

180

3.8 References
[1] Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart.
Pharmacol Res 2001;44:161–82.
[2] Loffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart.
Pharmacol Rev 1985;37:1–24.
[3] Kent KM, Epstein SE, Cooper T, Jacobowitz DM. Cholinergic innervation of the
canine and human ventricular conducting system. Anatomic and electrophysiologic
correlations. Circulation 1974;50:948–55.
[4] Nagata K, Ye C, Jain M, Milstone DS, Liao R, Mortensen RM. Galpha(i2) but not
Galpha(i3) is required for muscarinic inhibition of contractility and calcium currents in
adult cardiomyocytes. Circ Res 2000;87:903–9.
[5] Katare RG, Ando M, Kakinuma Y, Arikawa M, Yamasaki F, Sato T. Differential
regulation of TNF receptors by vagal nerve stimulation protects heart against acute
ischemic injury. J Mol Cell Cardiol 2010;49:234–44.
[6] de Castro BM, Pereira GS, Magalhaes V, Rossato JI, De JX, Martins-Silva C.
Reduced expression of the vesicular acetylcholine transporter causes learning deficits in
mice. Genes Brain Behav 2009;8:23–35.
[7] de Castro BM, De JX, Martins-Silva C, Lima RD, Amaral E, Menezes C, et al. The
vesicular acetylcholine transporter is required for neuromuscular development and
function. Mol Cell Biol 2009;29:5238–50.
[8] Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM, Amaral E, et al.
Mice deficient for the vesicular acetylcholine transporter are myasthenic and have
deficits in object and social recognition. Neuron 2006;51:601–12.
[9] Ribeiro FM, Black SA, Prado VF, Rylett RJ, Ferguson SS, Prado MA. The “ins” and
“outs” of the high-affinity choline transporter CHT1. J Neurochem 2006;97:1–12.

181

[10] Lara A, Damasceno DD, Pires R, Gros R, Gomes ER, Gavioli M, et al.
Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling
and heart failure. Mol Cell Biol 2010;30:1746–56.
[11] English BA, Appalsamy M, Diedrich A, Ruggiero AM, Lund D, Wright J, et al.
Tachycardia, reduced vagal capacity, and age-dependent ventricular dysfunction arising
from diminished expression of the presynaptic choline transporter. Am J Physiol Heart
Circ Physiol 2010;299:H799–810.
[12] LaCroix C, Freeling J, Giles A, Wess J, Li YF. Deficiency of M2 muscarinic
acetylcholine receptors increases susceptibility of ventricular function to chronic
adrenergic stress. Am J Physiol Heart Circ Physiol 2008;294:H810–20.
[13] Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve
stimulation markedly improves long-term survival after chronic heart failure in rats.
Circulation 2004;109:120–4.
[14] Freeling J, Wattier K, LaCroix C, Li YF. Neostigmine and pilocarpine attenuated
tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with
pressure overload. Exp Physiol 2008;93:75–82.
[15] Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, et
al. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via
gp130-signaling cytokines in rodents. J Clin Invest 2010;120:408–21.
[16] Huston JM, Tracey KJ. The pulse of inflammation: heart rate variability, the
cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med
2011;269:45–53.
[17] Kakinuma Y, Akiyama T, Sato T. Cholinoceptive and cholinergic properties of
cardiomyocytes involving an amplification mechanism for vagal efferent effects in
sparsely innervated ventricular myocardium. FEBS J 2009;276:5111–25.
[18] Rana OR, Schauerte P, Kluttig R, Schroder JW, Koenen RR, Weber C, et al.
Acetylcholine as an age-dependent non-neuronal source in the heart. Auton Neurosci

182

2010;156:82–9.
[19] Guatimosim S, Amaya MJ, Guerra MT, Aguiar CJ, Goes AM, Gomez-Viquez NL,
et al. Nuclear Ca2+ regulates cardiomyocyte function. Cell Calcium 2008;44:230–42.
[20] Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, et al.
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.
Nature 2003;421:634–9.
[21] Aguiar CJ, Andrade VL, Gomes ER, Alves MN, Ladeira MS, Pinheiro AC, et al.
Succinate

modulates

Ca(2+)

transient

and

cardiomyocyte

viability

through

PKAdependent pathway. Cell Calcium 2010;47:37–46.
[22] Guatimosim S, Sobie EA, dos Santos CJ, Martin LA, Lederer WJ. Molecular
identification of a TTX-sensitive Ca(2+) current. Am J Physiol Cell Physiol 2001;280:
C1327–39.
[23] Guzman MS, De JX, Raulic S, Souza IA, Li AX, Schmid S, et al. Elimination of the
vesicular acetylcholine transporter in the striatum reveals regulation of behavior by
cholinergic-glutamatergic co-transmission. PLoS Biol 2011;9:e1001194.
[24] Guatimosim C, Romano-Silva MA, Gomez MV, Prado MA. Use of fluorescent
probes to follow membrane traffic in nerve terminals. Braz J Med Biol Res 1998;31:
1491–500.
[25] FerlitoM, FultonWB, Zauher MA,Marban E, Steenbergen C, Lowenstein CJ.
VAMP-1, VAMP-2, and syntaxin-4 regulate ANP release from cardiac myocytes. J Mol
Cell Cardiol 2010;49:791–800.
[26] Gill SK, Bhattacharya M, Ferguson SS, Rylett RJ. Identification of a novel nuclear
localization signal common to 69- and 82-kDa human choline acetyltransferase. J Biol
Chem 2003;278:20217–24.
[27] Kitakaze M, Node K, Komamura K, Minamino T, Inoue M, Hori M, et al. Evidence
for nitric oxide generation in the cardiomyocytes: its augmentation by hypoxia. J Mol

183

Cell Cardiol 1995;27:2149–54.
[28] Louch WE, Sheehan KA, Wolska BM. Methods in cardiomyocyte isolation, culture,
and gene transfer. J Mol Cell Cardiol 2011;51:288–98.
[29] Volz A, Piper HM, Siegmund B, Schwartz P. Longevity of adult ventricular rat heart
muscle cells in serum-free primary culture. J Mol Cell Cardiol 1991;23:161–73.
[30] Zaruba MM, Field LJ. The mouse as a model system to study cardiac regeneration.
Drug Discov Today Dis Models 2008;5:165–71.
[31] Liu Y, Edwards RH. Differential localization of vesicular acetylcholine and
monoamine transporters in PC12 cells but not CHO cells. J Cell Biol 1997;139:907–16.
[32] Varoqui H, Meunier FM, Meunier FA, Molgo J, Berrard S, Cervini R, et al.
Expression of the vesicular acetylcholine transporter in mammalian cells. Prog Brain Res
1996;109:83–95.
[33] Nyquist-Battie C, Hagler KE, Love S. Reduced levels of globular and asymmetric
forms of acetylcholinesterase in rat left ventricle with pressure overload hypertrophy.
Life Sci 1994;55:653–9.
[34] Peters CG, Miller DF, Giovannucci DR. Identification, localization and interaction
of SNARE proteins in atrial cardiac myocytes. J Mol Cell Cardiol 2006;40: 361–74.
[35] Morisco C, Zebrowski DC, Vatner DE, Vatner SF, Sadoshima J. Beta-adrenergic
cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol
Cell Cardiol 2001;33:561–73.
[36] Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal
gene induction. Am J Physiol Heart Circ Physiol 2006;291:H1299–308.
[37] Zou Y, Yao A, Zhu W, Kudoh S, Hiroi Y, Shimoyama M, et al. Isoproterenol
activates extracellular signal-regulated protein kinases in cardiomyocytes through

184

calcineurin. Circulation 2001;104:102–8.
[38] Lanzafame AA, Christopoulos A, Mitchelson F. Cellular signaling mechanisms for
muscarinic acetylcholine receptors. Receptors Channels 2003;9:241–60.
[39] Fleming JW, Wisler PL, Watanabe AM. Signal transduction by G proteins in cardiac
tissues. Circulation 1992;85:420–33.
[40] Castell X, Cheviron N, Barnier JV, Diebler MF. Exploring the regulation of the
expression of ChAT and VAChT genes in NG108-15 cells: implication of PKA and PI3K
signaling pathways. Neurochem Res 2003;28:557–64.
[41] Luo D, Yang D, Lan X, Li K, Li X, Chen J, et al. Nuclear Ca2+ sparks and waves
mediated by inositol 1,4,5-trisphosphate receptors in neonatal rat cardiomyocytes. Cell
Calcium 2008;43:165–74.
[42] Ribeiro FM, ves-Silva J, Volknandt W, Martins-Silva C, Mahmud H, Wilhelm A, et
al. The hemicholinium-3 sensitive high affinity choline transporter is internalized by
clathrin-mediated endocytosis and is present in endosomes and synaptic vesicles. J
Neurochem 2003;87:136–46.
[43] Boivin B, Lavoie C, Vaniotis G, Baragli A, Villeneuve LR, Ethier N, et al.
Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and
mouse ventricular cardiomyocytes. Cardiovasc Res 2006;71:69–78.
[44] Ferguson SM, Bazalakova M, Savchenko V, Tapia JC, Wright J, Blakely RD. Lethal
impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline
transporter knockout mice. Proc Natl Acad Sci U S A 2004;101:8762–7.
[45] Bravo DT, Kolmakova NG, Parsons SM. New transport assay demonstrates
vesicular acetylcholine transporter has many alternative substrates. Neurochem Int
2005;47:243–7.
[46] Prado MA, Reis RA, Prado VF, de Mello MC, Gomez MV, de Mello FG.
Regulation of acetylcholine synthesis and storage. Neurochem Int 2002;41:291–9.

185

[47] Hancock JC, Hoover DB, Hougland MW. Distribution of muscarinic receptors and
acetylcholinesterase in the rat heart. J Auton Nerv Syst 1987;19:59–66.
[48] Wei JW, Sulakhe PV. Regional and subcellular distribution of myocardial
muscarinic cholinergic receptors. Eur J Pharmacol 1978;52:235–8.
[49] Berse B, Blusztajn JK. Coordinated up-regulation of choline acetyltransferase and
vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha,
cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a
murine septal cell line. J Biol Chem 1995;270:22101–4.
[50] Brock M, Nickel AC, Madziar B, Blusztajn JK, Berse B. Differential regulation of
the high affinity choline transporter and the cholinergic locus by cAMP signaling
pathways. Brain Res 2007;1145:1–10.
[51] Rosas-BallinaM, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C,
et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit.
Science 2011;334:98–101.
[52] Rodriguez-Diaz R, Dando R, Jacques-Silva MC, Fachado A, Molina J, Abdulreda
MH, et al. Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming
beta cell function in humans. Nat Med 2011;17:888–92.
[53] Martins-Silva C, De JX, Guzman MS, Lima RD, Santos MS, Kushmerick C, et al.
Novel strains of mice deficient for the vesicular acetylcholine transporter: insights on
transcriptional regulation and control of locomotor behavior. PLoS One 2011;6:e17611.

186

Chapter 4
CARDIOMYOCYTE-SECRETED ACETYLCHOLINE IS
REQUIRED FOR MAINTENANCE OF HOMEOSTASIS
IN THE HEART

A version of this chapter has previously been published: Roy A, Fields WC, RochaResende C, Resende RR, Guatimosim S, Prado VF, Gros R, Prado MA. (2013).
Cardiomyocyte-secreted acetylcholine is required for maintenance of homeostasis in the
heart. FASEB J. 2013 Dec;27(12):5072-82.
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4.2 Chapter Summary

Heart activity and long-term function are regulated by the sympathetic and
parasympathetic branches of the nervous system. Parasympathetic neurons have received
increased attention recently because acetylcholine (ACh) has been shown to play
protective roles in heart disease. However, parasympathetic innervation is sparse in the
heart, raising the question of how cholinergic signalling regulates cardiomyocytes. We
hypothesized that non-neuronal secretion of ACh from cardiomyocytes plays a role in
cholinergic regulation of cardiac activity. To test this possibility, we eliminated secretion
of ACh exclusively from cardiomyocytes by targeting the vesicular acetylcholine
transporter (VAChT). We find that lack of cardiomyocyte-secreted ACh disturbs the
regulation of cardiac activity and causes cardiomyocyte remodelling. Mutant mice
present normal hemodynamic parameters under non-stressful conditions; however,
following exercise, their heart rate response is increased. Moreover, hearts from mutant
mice present increased oxidative stress, altered calcium signalling, remodelling and
hypertrophy. Hence, without cardiomyocyte-derived ACh secretion, hearts from mutant
mice show signs of imbalanced autonomic activity consistent with decreased cholinergic
drive. These unexpected results suggest that cardiomyocyte-derived ACh is required for
maintenance of cardiac homeostasis and regulates critical signalling pathways necessary
to maintain normal heart activity. We propose that this non-neuronal source of ACh
boosts parasympathetic cholinergic signalling to counterbalance sympathetic activity
regulating multiple aspects of heart physiology.
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4.3 Introduction

Acetylcholine released by parasympathetic nerves regulates the minute to minute
changes in heart rate and contractility required for proper cardiovascular function via
muscarinic receptors, opposing the activity of the sympathetic nervous system [1]. In
addition to regulating atrial activity, ACh plays multiple roles in ventricular function [2,
3], notwithstanding limited parasympathetic innervation in ventricular regions [4, 5]. The
exact mechanisms by which ACh can have such widespread effects, despite somewhat
limited parasympathetic innervation in regions other than the atria, are not fully
understood. Interestingly, in the pancreas [6] as well as the immune system [7, 8], nonneuronal sources of ACh secretion have recently been shown to play a role in regulating
insulin secretion [6] and the cholinergic anti-inflammatory system [9, 10], respectively.
However, there is limited information regarding the contribution of non-neuronal ACh
for autonomic regulation of other bodily functions, in vivo.
Recent experiments have indicated that cultured cardiomyocytes, similar to pancreatic
alpha cells [6] and lymphocytes [7], can express the enzymatic machinery required for
ACh synthesis [11, 12]. Moreover, secretion of ACh from cultured cardiomyocytes
depends on the activity of the vesicular acetylcholine transporter (VAChT) [12].
However, whether this non-neuronal source of ACh plays a physiological role in the
regulation of heart activity or function is unknown. Here, we used the Cre-loxP system to
eliminate VAChT exclusively in cardiomyocytes and test for potential roles for
cardiomyocyte-secreted ACh in heart activity. We found that this novel form of cellular
communication is required for physiological regulation of heart size and stress levels,
likely by maintaining high levels of ACh at synaptic junctions. We also discovered that
the recovery of heart rate following exercise or stress is disturbed in the absence of this
non-neuronal source of ACh, suggesting widespread effects of non-neuronal
cardiomyocyte-derived

ACh.

Our

study

provides

a

novel

mechanism

autocrine/paracrine regulation of cardiomyocytes by non-neuronal ACh secretion.

for
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4.4 Materials and Methods

4.4.1

Animals

Transgenic mice expressing Cre under the control of the cardiac-specific murine alpha
myosin-heavy chain promoter (Myh6-cre) were obtained from JAX Laboratories
(B6.FVB-Tg(Myh6-cre)2182Mds/J, stock #011038) and bred to VAChT-floxed (flanked
by lox P) mice (VAChTflox/flox) [13]. VAChTflox/flox mice have been backcrossed 5 times
to C57BL6/j mice as described [13]. VAChTflox/flox mice are not different from wild-type
mice [14]. Littermates (VAChTWT/flox,Myh6-cre+ X VAChTWT/flox,Myh6-cre-) were crossed to
generate VAChTflox/flox,Myh6-cre+ and VAChTflox/flox,Myh6-cre-. F2 littermates were then bred
to generate mice used for this study. VAChTflox/flox,Myh6-cre- littermates were used as
controls.
In order to generate the cardiomyocyte-specific ChAT knockout mice, Myh6-cre mice
were bred to ChAT-floxed mice [15] obtained from JAX Laboratories (B6.129Chattm1Jrs/J; Jackson Laboratory; ChATflox/flox) [13]. Littermates (ChATWT/flox,Myh6-cre+ X
ChATWT/flox,Myh6-cre-) were crossed to generate ChATflox/flox,Myh6-cre+ and ChATflox/flox,Myh6cre-

.

The Rosa-EYFP strain (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J; JAX Laboratories;
stock # 006148) was used as a Cre reporter. Animals were maintained and cared for
according to approved animal protocol at the University of Western Ontario (2008-127)
and following Canadian Council on Animal Care. Only male mice were used for adult
cardiomyocyte isolation and all in vivo experiments. Neonatal cardiomyocytes were
isolated and cultured from mice of both genders.

4.4.2

Neonatal cardiomyocyte culture

Neonatal cardiomyocytes were isolated as previously described [16]. Briefly, cardiac
cells were plated in dishes containing M199 medium supplemented with 100 units/mL
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penicillin, 100 µg/mL streptomycin, 10% FBS and 2 mmol/L L-glutamine. Cytosine-Darabinofuranoside (ARA-c) (20 µg/mL) was used to prevent growth of fibroblasts. For
hypertrophy studies, cardiac cells at day 4 in culture were incubated with vesamicol
(VES, 5 µM) or hemicholium-3 (HC-3, 10 µM) for 48 h and then used for
immunofluorescence or qPCR analyses.

4.4.3

qPCR/RT-PCR

RNA was extracted from isolated cardiomyocytes and cDNA was synthesized as
previously described [17]. A brain sample was used as a positive control for VAChT and
a non-template reaction was used as a negative control. qPCR for ANP and GRK5 was
performed as previously described [17].

4.4.4

Immunoblotting

Isolated adult cardiomyocytes were lysed using ice-cold modified RIPA buffer. 80 µg of
protein was separated using SDS-PAGE and PVDF membranes were probed with antiVAChT antibody (1:200; Synaptic Systems). α-actinin (1:2000; Sigma-Aldrich) was used
as a loading control.

4.4.5

Immunostaining

Adult cardiomyocytes were subjected to immunofluorescence protocol as previously
described [12]. Cells were incubated with one of the following antibodies: anti-VAChT
(1:50; Synaptic Systems), anti-ChAT (1:100; Abcam), anti-CHT1 (1:500; kindly supplied
by Dr. R. Jane Rylett) [18], anti-ANP (1:200; Abcam) or anti-GRK5 (1:100; Santa Cruz
Biotechnologies). The cells were co-labelled with α-actinin (1:200; Sigma-Aldrich). αactinin labeled cells were used to measure cardiomyocyte cell surface area. Images were
acquired using either the Leica SP5 II or Zeiss LSM 510 Meta confocal system (63x
objective, 488 nm Argon laser and 546 nm HeNe laser were used for excitation of
fluorophores).

193

4.4.6

Measurement of ACh secretion (Fluorometric Assay)

Transmitter release was measured using the Choline/ACh Quantification Kit (Biovision)
as previously described [19]. Briefly, cultured media was collected from VAChTflox/flox
and VAChTMyh6-Cre-flox/flox cardiomyocytes and incubated with either 100 µM
pyridostigmine bromide (Sigma-Aldrich; P9797) or 100 µM pyridostigmine bromide and
1 µM vesamicol hydrochloride (Sigma-Aldrich; V100) at 37ºC for 4 hours. Cultured
media was collected and centrifuged at 10,000 RPM for 5 minutes at 4ºC. The resulting
supernatant was collected and filtered using a 0.2 µm Acrodisc Syringe Filter (PALL Life
Sciences) and placed on ice. ACh concentration was determined using the fluorometric
Choline/ACh Quantification Kit (Ex=535, Em=590 nm). Each sample was assayed in
duplicate and experiments were conducted at least 4 times using separate cultures.

4.4.7

Measurement of ACh secretion (HPLC-electrochemical
detection)

Cultured neonatal cardiomyocytes from VAChTflox/flox and VAChTMyh6-Cre-flox/flox were
treated with 100 µM pyridostigmine bromide (Sigma Aldrich; P9797) and incubated for 4
hours at 37ºC. It has previously been reported that both subacute treatment with
pyridostigmine [20] as well as acute exposure to stress [21] can increase the transcription
of acetylcholinesterase (AChE) in the brain. However, in vitro studies have confirmed
that pyridostigmine is a very potent AChE inhibitor (IC50 = 0.33 µM for inhibition of
erythrocyte AChE activity) [22]. As such, 100 µM pyridostigmine was used in our
experiments to ensure the inhibition of virtually all AChE activity throughout the
experiment. Cultured medium was collected and centrifuged at 13,200 RPM for 5
minutes at 4ºC. The supernatant was filtered through a 0.2 µM Acrodisc Syringe Filter
(PALL Life Sciences; PN=4602) and injected into an ESA UltiMATE 3000 system with
a Choulochem electrochemical detector. The sequence was run using the following
components and parameters: Flow rate: 0.300 mL/min; Injection volume: 20 µL; Cell
potential: 275 mV; Column: MGII CAPCELL PAK C18 column (Shiseido; Cat. No.=
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92461); Column temperature: 40ºC; ACh post-column solid phase reactor (Thermo
Scientific; 70-0640A).

4.4.8

NO measurement

Neonatal cardiomyocytes from control and cVAChT mice were used to measure NO
production as previously described [12]. Cells were incubated with either carbachol (10
µM) or pyridostigmine (100 µM). Images were acquired using the Leica SP5 II confocal
system and analyzed using ImageJ software.

4.4.9

Immunohistochemistry

Hearts were excised and fixed using 4% PFA. IHC was performed on slices as previously
described [23]. Slices were incubated with either anti-VAChT (1:200; Synaptic Systems)
or anti-CHT1 (1:200) [18] to visualize intracardiac ganglia and terminals respectively.

4.4.10

Heart rate and BP recordings

Both heart rate and blood pressure were recorded from conscious animals using the
CODA tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) as
previously described [24].

4.4.11

Electrocardiography

ECGs were recorded using radio telemeters as previously described [3]. HR was recorded
continuously over 24h to obtain baseline recordings. Additionally, heart rates were
recorded in the home cages immediately following IP injection of saline or following an
acute exercise routine (ramp up from 5 m/min to 15 m/min over 60 s, followed by 180 s
at 15 m/min).
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4.4.12

Cardiomyocyte morphometry

In situ cardiomyocyte cell surface area was measured as previously described [3].

4.4.13

ROS measurement

ROS levels were measured using the MitoSOX Red superoxide indicator (Invitrogen) as
previously described [17].

4.4.14

Protein oxidation measurement

Protein was isolated from whole hearts using ice-cold modified RIPA buffer, separated
using SDS-PAGE and transferred onto PVDF membrane. The levels of oxidatively
modified proteins were analyzed in control and cVAChT hearts using the OxyBlot
Protein Oxidation Detection Kit (Millipore) following the manufacturer’s directions.

4.4.15

Indirect calorimetry, activity and inactivity

These experiments were performed using the CLAMS metabolic chamber system
(Columbus Instruments) as previously described [25, 26]. VO2, VCO2, food and water
intake, activity and inactivity were measured. Respiratory exchange ratio and energy
expenditure/heat were calculated within the Oxymax software. Periods of inactivity
(sleep) were obtained using the sleep detection algorithms available within the Oxymax
software.

4.4.16

Preparation of siRNA

Potential target sites within the VAChT gene were selected and then searched with NCBI
Blast to confirm specificity for the transporter. The siRNA for VAChT was prepared as
previously described by our group [27]. The sense and antisense oligonucleotides of
siRNA were respectively, as follows: 5'-GGAGCAGGGAGGCAGAAGAAGCTGT-3'
and 5'-ACAGCTTCTTCTGCCTCCCTGCTCCAT-3'. For siRNA studies, neonatal
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cardiomyocyte cultures were transfected at day 4 with 100 nM of siRNA 48 h prior to
measurements. The cells were then used for immunofluorescence, immunobloting or
qPCR analyses.

4.4.17

Cardiomyocyte isolation and Ca2+ recordings

Adult cardiomyocytes were isolated and calcium transients were recorded as previously
described [3, 17] using line-scan imaging on a Zeiss LSM 510 Meta confocal
microscope. Images were processed and Ca2+ recordings were analyzed using ImageJ
software.

4.4.18

Hemodynamic measurements

Invasive left ventricular (LV) hemodynamic measurements were obtained under baseline
as well as following administration of isoproterenol (0.5 µg intraperitoneally [i.p.]) using
a Millar Mikro-tip pressure transducer (Millar Instruments, Houston, TX, USA) as
previously described [3]. All the LV parameters were obtained using the PowerLab Chart
Analysis software (AD Instruments, Colorado Springs, CO, USA).

4.4.19

Statistical analyses

Results for experiments are provided as mean ± SEM. Student’s t-test, one-way ANOVA
with a Tukey’s post-hoc test or two-way ANOVA were used to assess statistical
differences between experimental groups using as required using Graphpad or SigmaStat.
p<0.05 was considered statistically significant.
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4.5 Results

4.5.1

Generation of cardiomyocyte-specific VAChT null mice

Previous experiments indicated that, in cultured neonatal cardiomyocytes, ACh secretion
is dependent on the activity of VAChT (12), a transporter that is critical for ACh storage
in nerve-endings [28, 29]. In order to selectively interfere with secretion of ACh from
cardiomyocytes in vivo we generated a cardiomyocyte-specific VAChT knockout mouse
line (VAChTMyh6-Cre-flox/flox; named cVAChT mice henceforth) by crossing the Myh6-Cre
mice (B6.FVB-Tg(Myh6-cre)2182Mds/J; Jackson Laboratory) with VAChT floxed mice
[13] (Fig. 4.1a,b). The α-MHC (Myh6) promoter drives Cre expression exclusively in
cardiomyocytes [30]. Although previous reports indicated that Cre is expressed mainly in
ventricles in Myh6-Cre mice, Cre expression in the atria has been observed during
development [31]. To confirm elimination of VAChT in cVAChT mice, we isolated adult
cardiomyocytes and performed RT-PCR to detect VAChT transcripts (Fig. 4.2a). A band
of 167 bp was detected in VAChTflox/flox, but not in cVAChT mice. Sequencing analysis
confirmed that this band represented the VAChT sequence. Moreover, immunoblot (Fig.
4.2b) and immunofluorescence analysis (Fig. 4.2c) confirmed elimination of VAChT in
isolated ventricular cardiomyocytes from cVAChT mice. Moreover, whole-mount
fluorescent IHC in the atria of control mice revealed that VAChT is also expressed in SA
nodal cells, as co-localization was observed between VAChT and HCN4, a marker for
the SA node (Fig. 4.2d). Importantly, VAChT staining in SA nodal cells was absent in
cVAChT tissue indicating that VAChT was also deleted in these cells in cVAChT mice
(Fig. 4.2d). Furthermore, VAChT expression in parasympathetic ganglia, recognized
through their characteristic morphology, and in nerve terminals was not altered in
cVAChT mice (Fig. 4.2d,e), indicating that we specifically eliminated non-neuronal
VAChT in the heart. In support of these data, we used a reporter mouse line to
demonstrate that Cre expression is absent in parasympathetic nerve terminals stained with
an antibody against the high affinity choline transporter (CHT1; Fig. 4.1c). Additionally,
expression of CHT1, the high affinity choline transporter was not affected in isolated
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Figure 4.1 - Generation of cardiomyocyte–specific VAChT KO mice. (a) Schematic
drawing of the VAChT alleles generated. Boxes represent the different exons of ChAT or
VAChT. The position of the initiation codon (ATG) for VAChT and ChAT and the stop
codon (Stop) of VAChT are indicated. P1, P2, and P3 indicate the primers used for PCR
genotyping and the fragment sizes generated. LoxP sequence and some restriction
enzymatic sites are represented. The VAChT gene is within the first intron of ChAT. (b)
Representative genotyping results for mutant cVAChT (VAChTflox/flox, Myh6‐cre+) mice
(lanes 1 and 2) and control (VAChTflox/flox‐) mice (lanes 3 and 4 respectively). (c) YFP
expression, which is regulated by Cre recombinase expression, in the ventricles (c; top
panel) and intracardiac ganglia, specifically labeled with CHT1, in the right atrium (c;
bottom panel) in Myh6-Cre+;Rosa+ mice. The nuclei are labeled in blue using the TOPRO 3 counterstain. The Myh6-Cre mice were used to generate cardiomyocyte-specific
VAChT knockout (cVAChT) mice. Assessment of CHT1 (d) and ChAT (e) expression
via immunofluorescence in isolated cardiomyocytes from cVAChT mice (scale bar=25
µm).
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Figure 4.1 - Generation of cardiomyocyte–specific VAChT KO mice.
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Supplementary Figure S1. Generation of cardiomyocyte–specific VAChT KO mice. (a) Schematic drawing
of the VAChT alleles generated. Boxes represent the different exons of ChAT or VAChT. The position of the
initiation codon (ATG) for VAChT and ChAT and the stop codon (Stop) of VAChT are indicated. P1, P2, and
P3 indicate the primers used for PCR genotyping and the fragment sizes generated. LoxP sequence and some
restriction enzymatic sites are represented. The VAChT gene is within the first intron of ChAT. (b)
Representative genotyping results for mutant cVAChT (VAChTflox/flox, Myh6‐cre+) mice (lanes 1 and 2) and
control (VAChTflox/flox‐) mice (lanes 3 and 4 respectively). (c) YFP expression in the ventricles (c; top panel)
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Figure 4.2 - Selective elimination of VAChT in cardiomyocytes of cVAChT mice.
VAChT expression was determined by (a) PCR (Br=Brain, NC=Negative control), (b)
immunoblotting and (c) immunofluorescence in adult cardiomyocytes. (d) Co-labeling
for VAChT and HCN4 in whole-mount atrial tissue from control and cVAChT mice. (e)
VAChT immunoreactivity in intracardiac parasympathetic ganglia from cVAChT mice
(arrows indicate positive staining for parasympathetic ganglia).
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Figure 4.2 - Selective elimination of VAChT in cardiomyocytes of cVAChT mice.
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cardiomyocytes from cVAChT mice (Fig. 4.1d). However, cVAChT cardiomyocytes
appeared to have greater levels of ChAT expression (Fig. 4.1e), an observation similar to
that previously reported in VAChT KO mice, which reflects, in part, a rearrangement of
the cholinergic gene locus following Cre-mediated recombination [23].

4.5.2

Genetic removal of VAChT from cardiomyocytes inhibits
ACh release

Secretion of ACh from cultured neonatal cardiomyocytes was analyzed using a
fluorometric assay to detect choline/ACh levels in culture media. The assay was
performed in neonatal cardiomyocytes after 4 days in culture, to avoid potential
contribution of parasympathetic neurons that could contaminate adult cardiomyocyte
preparations. Using this method, we were able to confidently detect as low as 10
pmols/well for ACh (Fig. 4.3a). ACh release from control myocytes could be easily
detected in the presence of pyridostigmine, a cholinesterase inhibitor used to preserve
secreted neurotransmitter (Fig. 4.3b). In the presence of vesamicol, a specific inhibitor of
the VAChT, ACh release from these cells was significantly diminished (Fig. 4.3b). In
agreement with the pharmacological data, cVAChT cardiomyocytes showed no
detectable ACh release (Fig. 4.4a).
We have confirmed these findings by performing HPLC with electrochemical detection
of ACh in media from cultured cardiomyocytes. We were able to confidently detect up to
125 fmol of ACh on the column (Fig. 4.3c). ACh secretion was detectable from wild-type
cardiomyocytes in the presence of pyridostigmine (Fig. 4.3d); however, ACh secretion
from cells treated with vesamicol was significantly reduced (Fig. 4.3d). Furthermore, no
ACh was detected in media from cVAChT cardiomyocytes using HPLC with
electrochemical detection, whereas ACh could be detected in media from WT
cardiomyocytes (Fig. 4.4b; Fig. 4.3e).
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Figure 4.3 - Measurement of ACh release from neonatal cardiomyocytes. (a)
Standard curve for measurement of ACh ranging from 10-50 pmols/well using a
fluorometric choline/acetylcholine assay. (b) Measurement of ACh release from cultured,
neonatal cardiomyocytes in the presence of pyridostigmine alone or pyridostigmine and
vesamicol together. n=number of separate cell isolations. ***p<0.001 vs. control. (c)
Standard curve for measurement of ACh ranging from 125-1000 pmols OTC using
HPLC-ED. (d) Measurement of ACh release from wild-type neonatal cardiomyocytes
using HPLC-ED in the presence of pyridostigmine alone or pyridostigmine and
vesamicol together. n=number of separate cell isolations. ***p<0.001 vs. control. (e)
Representative

chromatograms

of

ACh

release

from

control

and

cVAChT

cardiomyocytes (blank and 500 fmol standard OTC are shown for comparison). (f) NO
levels as an indirect measure of ACh release in cultured neonatal cardiomyocytes using
DAF fluorescence. Cells were treated with either carbachol (Carb.) to activate muscarinic
receptors and increase NO levels or pyridostigmine (PYR), which preserves secreted
ACh that can increase NO production12. Cardiomyocytes were also co-treated with PYR
and either vesamicol (VAChT inhibitor) or hemicholinium-3 (CHT1 inhibitor).
n=number of cells examined from five separate cell isolations. Scale bar=25 µm. *p<0.05
vs. control and doubled-treated groups.
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Figure 4.3 - Measurement of ACh release from neonatal cardiomyocytes.
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Figure 4.4 - Acetylcholine secretion is inhibited from cVAChT cardiomyocytes. (a)
Acetylcholine release from neonatal cardiomyocytes isolated and cultured from control
and cVAChT mice. n=number of separate cell isolations for each genotype. ***p<0.001
vs. control. (b) Acetylcholine release from control and cVAChT neonatal cardiomyocytes
as detected through HPLC-Electrochemical Detection. n=number of separate cell
isolations for each genotype. **p<0.01 vs. control. (c) Bioassay to measure ACh release
in cultured neonatal cardiomyocytes using DAF fluorescence. Cells were treated with
either carbachol (Carb.) to activate muscarinic receptors and increase NO levels or
pyridostigmine (PYR), which preserves secreted ACh that can then activate muscarinic
receptors and increase the production of NO(12). n=number of cells examined from five
separate cell isolations for each genotype. Scale bar=25 µm. *p<0.05 vs. control. Data are
represented as the mean ± SEM.
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Figure 4.4 - Acetylcholine secretion is inhibited from cVAChT cardiomyocytes.
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We further confirmed that secretion of ACh was inhibited in cVAChT neonatal myocyte
cultures through the use of a bioassay with the fluorescent dye DAF-FM, as previously
described [12]. DAF becomes fluorescent in the presence of nitric oxide (NO), which is
produced by activation of muscarinic receptors by secreted ACh from cardiomyocytes.
To validate this bioassay we used neonatal cardiomyocytes from C57BL/6 wild-type
(WT) mice. We showed that DAF fluorescence was significantly increased in WT
cardiomyocytes following treatment with carbachol (a muscarinic agonist; Fig. 4.3f).
Pyridostigmine also augmented the fluorescent signal (Fig. 4.3f). Conversely, no
fluorescence increase was observed in cardiomyocytes co-treated with pyridostigmine
and either hemicholinium-3 (to inhibit the production of ACh) or vesamicol (Fig. 4.3f).
These results indicate that this bioassay has enough sensitivity to detect changes in ACh
release from WT cardiomyocytes. When cardiomyocytes from cVAChT mice were
tested, DAF fluorescence was significantly increased in response to carbachol; however,
no response was observed following treatment with the cholinesterase inhibitor
pyridostigmine. In contrast, response for cardiomyocytes from littermate controls
presented a robust response to carbachol and cholinesterase inhibition (Fig. 4.4c).
Together, these results clearly establish using multiple methodologies that secretion of
ACh from cardiomyocytes is impaired in cVAChT mice.

4.5.3

Inhibition of ACh secretion from cardiomyocytes alters heart
activity

cVAChT mice did not present any gross abnormalities in appearance or body weight
(29.1±4.1g in control vs. 30.8±4.9 g in cVAChT mice). Furthermore, these mice did not
present alterations in several metabolic parameters, as measured using metabolic cages
(Table 4.1), suggesting that the cardiomyocyte changes observed were not deleterious to
mutant mice under control conditions. Accordingly, we did not observe changes in blood
pressure as determined by tail-cuff (Fig. 4.5a), nor in basal heart rate as measured by
radio telemetry (ECG, Fig. 4.5b). In contrast, cVAChT mice showed an increase in heart
rate when analysed using the non-invasive tail-cuff system (Fig. 4.5a). This increase in
heart rate was not due to the presence of Cre recombinase, as it was not observed in
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Table 4.1 – Metabolic activity and inactivity parameters for VAChTflox/flox (n=6) and
cVAChT
mice. activity and inactivity parameters for flox/flox (n=6) and
Table 4.1(n=6)
– Metabolic
cVAChT (n=6) mice.
Parameter

Light 12 h
VAChTflox/flox
cVAChT
0.91 ± 0.92
0.92 ± 0.11

Dark 12 h
VAChTflox/flox
cVAChT
2.54 ± 0.35
2.44 ± 0.23

Food intake
(g/12 h)
Water
0.73 ± 0.17
1.12 ± 0.21
2.44 ± 0.27
(ml/12 h)
VO2
2390.1 ±
2489.8 ±
3082.5 ±
(ml/kg/h)
120.3
177.1
180.2
VCO2
2239.3 ±
2378.1 ±
2948.7 ±
(ml/kg/h)
133.8
143.5
175.2
RER
0.94 ± 0.04
0.96 ± 0.02
0.96 ± 0.02
Energy expenditure
0.36 ± 0.01
0.38 ± 0.02
0.46 ± 0.02
(kcal/h)
Total activity
1229.8 ± 55.7
1408.8 ±
3791.3 ±
(counts/h)
86.3
443.4
Amb. activity
306.1 ± 32.4 428.3 ± 67.0
1531.2 ±
(counts/h)
305.9
Sleep time
422.7 ± 10.0
404.4 ± 9.3
187.7 ± 10.8
(min)
RER: Respiratory exchange rate; Amb. activity: Ambulatory activity
!

3.04 ± 0.22
3242.0 ±
194.1
3123.4 ±
153.8
0.97 ± 0.02
0.50 ± 0.03
4442.9 ±
597.1
2024.0
±342.5
199.0 ± 21.7
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Figure 4.5 - Analysis of heart rate in cVAChT mice. (a) Blood pressure and heart rate
analysis in VAChTflox/flox and cVAChT mice using the CODA tail cuff system. (b) Heart
rate over 24 hours in awake, free moving VAChTflox/flox and cVAChT mice in their home
cage (n≥4 mice/genotype). (c) Heart rate response following gentle restraint and IP saline
injection (n≥4 mice/genotype). (d) Heart rate recovery following acute, brief exercise in
VAChTflox/flox and cVAChT mice (n≥4 mice/genotype). Data are represented as the mean
± SEM. *p<0.05 vs. control mice.
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Figure 4.5 - Analysis of heart rate in cVAChT mice.
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Myh6-cre mice were compared to wild-type mice under the same conditions (Fig. 4.6a).
These results suggest a possible role for cardiomyocyte-derived ACh in the regulation of
heart rate.
In order to further confirm that the increased heart rate observed in cVAChT mice via
tail-cuff was due to inhibition of the non-neuronal cholinergic system in cardiomyocytes,
we generated cardiomyocyte-specific ChAT knockout mice (ChATMyh6-Cre-flox/flox). This
ChAT floxed line has been previously characterized and, when crossed to Cre lines,
ChAT expression is abolished in a manner that parallels elimination of ACh [15, 32].
Tail-cuff analysis in these mice also revealed increased heart rate in mice lacking ACh
production (Fig. 4.6b).
Tail-cuff measurements require physical restraint, which is stressful for mice, while ECG
measurements are obtained under conditions similar to the home cage environment.
Hence, we hypothesized that the difference in heart rate observed using these two
different techniques might reflect an imbalance in cardiac regulation in mutant mice.
Specifically, that cardiomyocyte-derived ACh could play a physiological role in boosting
the parasympathetic signalling required for recovery of heart rate in response to stress. To
test this hypothesis we used ECG telemetry to record heart rates immediately after mice
were stressed by an intraperitoneal injection of saline. We observed that heart rate
recovery of cVAChT mice to baseline levels was slower when compared to control
VAChTflox/flox mice (Fig. 4.5c). These data suggest that, following increased sympathetic
demand due to stress, regulation of heart function by the parasympathetic system relies,
at least in part, on ACh secreted from cardiomyocytes. To further test this possibility,
cVAChT and littermate controls implanted with ECG telemeters were submitted to an
acute, low intensity, treadmill exercise test. Immediately following this mild exercise
routine, heart rates in control and cVAChT mice were recorded in their home cage. The
results demonstrate that this exercise routine led to a significantly greater increase in
heart rate in cVAChT mice as compared to control mice (Fig. 4.5d). Moreover, heart rate
recovery to pre-exercise levels took significantly longer in cVAChT mice when
compared to control mice (Fig. 4.5d). These results suggest that cardiomyocyte-derived
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Figure 4.6 - Tail-cuff analysis using the non-invasive CODA system. (a) Blood
pressure and heart rate analysis in WT and Myh6-Cre+ mice (n≥5 mice/genotype). (b)
Blood pressure and heart rate analysis in ChATflox/flox and ChATMyh6-Cre-flox/flox mice using
the CODA tail cuff system, n≥8 mice/genotype. Data are represented as mean ± SEM.
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Figure 4.6 - Tail-cuff analysis using the non-invasive CODA system.
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ACh may normally offset sympathetic activity, helping the heart to respond to increased
sympathetic demand.

4.5.4

cVAChT mice display cardiac hypertrophy and molecular
remodeling

The results above suggest that control of heart rate, particularly under stress, is affected in
cVAChT mice potentially due to decreased cholinergic signalling. Previous experiments
indicated that in vitro inhibition of either VAChT activity or ACh synthesis increased
hypertrophy in cultured neonatal cardiomyocytes treated with sympathetic agonists [12].
In order to determine whether cardiomyocyte-secreted ACh plays a role in cardiac
remodelling in vivo, we analyzed heart weight in 3 month-old mutant mice. As shown in
Fig. 4.7a, cVAChT mice showed increased heart size. Cardiac hypertrophy was due to
remodelling of cVAChT myocytes, which exhibited a significant increase in surface area
when measured both in vitro (Fig. 4.7b) and in situ (Fig. 4.7c). Importantly, the presence
of Cre recombinase alone did not lead to either cardiac or cardiomyocyte hypertrophy
(Fig. 4.8a, b).
To further test whether the observed hypertrophic response was indeed dependent on
VAChT expression and activity, we cultured wild-type neonatal cardiomyocytes and
treated them with a pharmacological inhibitor of VAChT activity (vesamicol), or with
siRNA against VAChT (Fig. 4.8c). VAChT knockdown was confirmed through qPCR
and immunoblotting, which revealed an 80% and 60% decrease in VAChT mRNA and
protein levels, respectively. Both of these treatments led to a significant increase in
cardiomyocyte size after 48h in culture. Furthermore, cardiomyocytes treated with an
inhibitor of CHT1 (hemicholinium-3), which blocks ACh synthesis, presented similar
hypertrophy (Fig. 4.8c), thus confirming that the hypertrophic response was due to
inhibition of cholinergic signalling at the level of the myocytes.
Cardiac hypertrophy is associated with increased expression of fetal program genes,
which contribute to cardiac remodelling [33]. Expression of the markers of cardiac
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Figure 4.7 - Cardiac hypertrophy in cVAChT mice. (a) Heart weight normalized to
tibia length in VAChTflox/flox and cVAChT mice (n=number of mice). (b) Surface area of
isolated cardiomyocytes (scale bar = 25 µm, n=number of mice/genotype, at least 75 cells
were analyzed/genotype). (c) Surface area of cardiomyocytes in situ (scale bar = 25 µm,
n=number of mice/genotype, at least 70 cells were analyzed/genotype). Data are
represented as the mean ± SEM. *p<0.05 vs. control.
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Figure 4.7 - Cardiac hypertrophy in cVAChT mice.
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Figure 4.8 - Measurement of hypertrophy in mice expressing Cre recombinase or
following inhibition of VAChT in vitro. (a) Heart weight normalized to tibia length in
WT and Myh6-Cre+ mice (n=number of mice). (b) Surface area of isolated
cardiomyocytes in WT and Myh6-Cre+ mice (n=number of cells from 3 separate
isolations). Scale bar=25 µm. (c) Surface area of cultured neonatal cardiomyocytes
following treatment with the VAChT inhibitor vesamicol (VES), the CHT1 inhibitor
hemicholinium-3 (HC-3) or VAChT knockdown using siRNA (n=number of cells).
VAChT knockdown was confirmed through qPCR and immunoblotting, which revealed
an 80% and 60% decrease in VAChT levels, respectively. All images are representative
of, at least, three independent experiments in which multiple cells were examined.
*p<0.05 vs. control.
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Supplementary Figure S3. Tail-cuff analysis using the non-invasive CODA system. (a) Blood pressure a
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remodelling and stress, β-myosin heavy chain (β-MHC) and atrial natriuretic peptide
(ANP), was increased several fold in cardiomyocytes from cVAChT mice (Fig. 4.9a).
Immunostaining in isolated cardiomyocytes revealed also increased ANP protein levels
(Fig. 4.9b,c), compatible with cardiomyocyte remodelling. Cardiomyocyte remodelling
and reactivation of the fetal gene program are usually associated with increased cellular
stress [34]. Furthermore, hypertrophy induced through hyperadrenergic signalling has
been coupled to increased ROS levels [35]. If removal of VAChT from cardiomyocytes
leads to imbalanced autonomic control of the heart, it is possible that mutant
cardiomyocytes are under considerably more stress than control cardiomyocytes. We
tested this possibility and found that cardiomyocytes isolated from cVAChT mice
showed increased levels of ROS (as determined via mitochondrial superoxide levels; Fig.
4.9d), suggesting that myocytes lacking the intrinsic cholinergic system display increased
levels of stress. Furthermore, we determined that increased ROS levels in myocytes led to
an increase in overall protein oxidation in the whole heart in cVAChT mice (Fig. 4.9e), as
measured using the OxyBlot protein oxidation kit, which can detect the levels of oxidized
proteins.
Increased levels of mitochondrial ROS have previously been shown to increase [Ca2+]i in
arterial myocytes, especially following induction of hypoxic stress [36]. Therefore, we
sought to determine whether the increased levels of ROS observed in cVAChT myocytes
were accompanied with changes in calcium transients in ventricular cardiomyocytes. In
agreement with this possibility, we detected an alteration in calcium handling in
cardiomyocytes obtained from mutant mice with an increase in peak calcium (Ca2+)
transients (Fig. 4.9f,g). These results suggest that elimination of VAChT in
cardiomyocytes leads to remodelling of cardiomyocytes, with overactivation of Ca2+
transients potentially altering cardiac function.
It is likely that inhibition of the non-neuronal cholinergic system leads to imbalanced
regulation of cardiac activity. As such, we analyzed whether components involved in
sympathetic signalling and thus, regulation of cardiomyocyte function, were altered in
cVAChT mice. G-protein coupled receptor kinases (GRKs) have been shown to play
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Figure 4.9 - Cellular stress in cVAChT cardiomyocytes. (a) Expression of the cardiac
stress markers, β-MHC and ANP, in control and cVAChT cardiomyocytes (n=number of
mice). (b, c) Immunostaining for ANP in adult cardiomyocytes from control and
cVAChT mice (scale bar=25 µm). (d) Measurement of ROS levels in isolated
cardiomyocytes loaded with the MitoSOX superoxide indicator (scale bar=25 µm,
n=number of cells; at least 3 mice/genotype). (e) Measurement of oxidized protein levels
in whole hearts from control and cVAChT mice (n=number of mice). (f, g) Assessment
of calcium transients in isolated ventricular myocytes from VAChTflox/flox and cVAChT
mice. (f) Representative recordings of line-scan profile of Ca2+ transients in control and
cVAChT myocytes (g) Summary of peak Ca2+ (n=number of cardiomyocytes; cells
isolated from at least 3 mice/genotype). Data are represented as the mean ± SEM.
*p<0.05 vs. control.
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Figure 4.9 - Cellular stress in cVAChT cardiomyocytes.
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important roles in cardiac hypertrophy in response to increased sympathetic activation
[37, 38]. Therefore, we examined the expression of GRK2 and GRK5, the two most
predominantly expressed GRKs in cardiac tissue. Although GRK2 did not show any
changes in expression, mRNA expression of GRK5 was significantly increased in
cVAChT myocytes (Fig. 4.10a). Moreover, immunostaining analysis showed that
subcellular localization of GRK5 was altered in cVAChT cardiomyocytes, as mutated
cells showed increased nuclear localization for GRK5 as compared to control
cardiomyocytes (Fig. 4.10b,c).

4.5.5

Cardiomyocyte remodeling in cVAChT mice affects LV
function

Ventricular cardiomyocytes from cVAChT mice display remodelling and hypertrophy;
therefore, we tested whether these alterations affected left ventricular contractility.
Invasive hemodynamic assessments were performed on anesthetised control and
cVAChT mice. As shown in Table 4.2, the hemodynamic parameters were similar in both
genotypes under baseline conditions; however, the LV hemodynamics were altered in
cVAChT mice following a bolus dose of isoproterenol, used to increase cardiac
contractility. Interestingly, although heart rate was similar in both genotypes under
baseline, the cVAChT mice showed a significant decrease in heart rate following ISO
treatment. Furthermore, the maximum rate of LV pressure rise (peak +dP/dtmax) was
significantly decreased and the maximum rate of LV pressure fall (peak -dP/dtmin)
showed a tendency for decrease in cVAChT mice (p=0.0508). In addition, the
contractility index of cVAChT mice was not different from control counterparts under
baseline; however, there was a significant reduction in the contractility index following
ISO treatment in cVAChT mice. These results suggest compromised left ventricular
function in the mutant mice, especially under increased cardiac demand, as induced
through treatment with ISO.
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Figure 4.10 - Cardiac remodeling in cVAChT cardiomyocytes. (a) mRNA expression
of GRK5 in isolated cells from control and cVAChT mice (n=number of mice). (b, c)
Immunostaining for GRK5 in isolated myocytes (scale bar=25 µm). Data are represented
as the mean ± SEM. *p<0.05 vs. control.
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Figure 4.10 - Cardiac remodelling in cVAChT cardiomyocytes.
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Table
4.2 – Hemodynamic parameters for control (n=9) and cVAChT (n=9) mice
!
!
under
baseline and following isoproterenol stimulation.

Table 1. Hemodynamic parameters for control (n=9) and cVAChT (n=9) mice under baseline and
following isoproterenol stimulation.
Baseline
Isoproterenol
Parameter
VAChTflox/flox
VAChTMyh6-cre-flox/flox VAChTflox/flox VAChTMyh6-cre-flox/flox
HR (bpm)
289.9 ± 24.7
267.4 ± 16.7
629.2 ± 11.2
566.1 ± 15.7*
LVSP (mm Hg)
103.3 ± 6.5
101.8 ± 4.0
97.2 ± 7.4
92.1 ± 5.6
LVEDP (mm Hg)
7.0 ± 2.4
12.5 ± 3.3
-0.3 ± 1.5
2.3 ± 2.0
+dP/dTmax (mmHg/s)
7699 ± 809
6999 ± 720
16819 ± 1766
12432 ± 861*
-dP/dTmin (mmHg/s)
-7370 ± 395
-6752 ± 518
-9770 ± 1019
-7413 ± 212‡
-1
Contractility index (s )
154.8 ± 8.1
148.9 ± 13.9
347.5 ± 14.1
280.1 ± 15.6*
HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; +dP/dTmax,
maximum first derivative of the change in left ventricle pressure; -dP/dTmin, minimum first derivative of the change in
left ventricle pressure.
*
p<0.05, ‡p=0.0508. Values are mean ± SEM.

!
!
!
!
!
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4.6 Discussion

Our experiments reveal a novel and unexpected way by which cardiovascular function is
regulated. These data indicate that cardiomyocytes can secrete significant amounts of
ACh in vivo via a VAChT-dependent mechanism, similar to that observed in nerve
terminals [39]. cVAChT mice seem to lack the capacity to sustain normal levels of
cholinergic signalling, implicating non-neuronal ACh as part of a physiological system
that controls cardiac function.
Lack of cardiomyocyte-secreted ACh leads to altered heart rate regulation under stress.
The SA node controls heart rate; therefore, the alteration in heart rate we observed in
cVAChT mice is likely related to the altered expression of VAChT in SA node myocytes
observed in these mutants. Importantly, measurements of heart rate in the absence of
stress indicate that regulation of basal activity does not seem to depend on this
cardiomyocyte cholinergic system. Hence, contribution of cardiomyocyte-derived ACh is
revealed only when there is increased demand on the parasympathetic system, such as
following exercise. Importantly, an inverse relationship between decreased serum AChE
levels and delayed heart rate recovery following exercise has previously been reported in
healthy human subjects [40]. This previous work provides further support for the
importance of peripheral ACh levels, including cardiomyocyte-derived ACh, in
regulating cardiac function.
It is likely that non-neuronal ACh, secreted from cardiomyocytes, functions through
similar second messenger systems as those activated when neuronal ACh binds to
muscarinic receptors. Future electrophysiological studies will determine the mechanisms
leading to alterations in chronotropic responses observed following inhibition of nonneuronal cholinergic signalling in the specialized cardiomyocytes of the SA node.
It is well established that increased sympathetic signalling can lead to cardiac
remodelling and increased cardiomyocyte stress in the working myocardium [41]. Indeed,
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even though cVAChT mice presented normal regulation of heart rate under non-stressful
conditions, changes in heart rate, due to lack of cardiomyocyte-derived ACh, may cause
long-term changes in heart function. It appears that lack of the intrinsic cholinergic
system in cardiomyocytes leads to an increase in basal stress. This may play an important
role in the regulation of cardiac function because it has previously been reported that
increased stress can lead to an upregulation of AChE transcription in the brain [42]. It
will be important to determine whether cVAChT mice display altered AChE transcription
in the heart, which may then serve to further exacerbate the stress response by increasing
degradation of neuronal ACh released at the level of the heart.
Lack of cardiomyocyte-derived ACh was associated to ventricular cardiomyocyte
hypertrophy, molecular remodelling and increased oxidative stress, which argues for a
widespread effect of cardiomyocyte-secreted ACh. These molecular changes were
accompanied by alterations in left ventricular function and cardiac contractility under
increased demand due to treatment with ISO. The observed hypertrophy may be related
to the increased expression, as well as altered subcellular localization, of GRK5 observed
in cVAChT cardiomyocytes. It has been reported that GRK5 overexpression leads to
hypertrophy, which is dependent on its nuclear function [37]. Conversely, GRK5 null
mice display a delay in hypertrophy following transverse aortic restriction [43]. Further
studies will be required to elucidate potential GRK5-specific pathways affected in
cVAChT myocytes that can lead to remodelling and hypertrophy. In addition, it will be
important to determine whether the transcriptional activation of hypertrophic genes,
including GRK5, are regulated by miRNAs as it has previously been shown that
overexpression of the miR-212/132 family of miRNAs leads to pathological cardiac
hypertrophy [44]. It will be interesting to determine whether lack of cardiomyocytederived ACh leads to hypertrophy in a miRNA-dependent mechanism.
Interestingly, the increase in calcium transients observed in isolated cVAChT
cardiomyocytes would suggest a significant increase in inotropic response, in vivo.
However, the Millar catheter experiments suggest that LV hemodynamics, specifically
contractility and relaxation, are both significantly decreased following hyperadrenergic
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stimulation using a bolus dose of isoproterenol. These apparently contradictory results
might be due to a decrease in myofilament calcium sensitivity at the level of troponin. In
addition, it is also possible that the increase in mitochondria superoxide levels leads to a
deficiency in ATP production in cVAChT cardiomyocytes, which might result in
inhibition of calcium uptake into the SR.
Although the detailed mechanisms that trigger the release of ACh from cardiomyocytes
are not clear at the moment, a clear possibility might involve sympathetic signalling.
Previous experiments in vitro suggest that adrenergic stimulation can induce the
expression of cholinergic genes in cardiomyocytes [12]. Whether there are reciprocal
interactions between sympathetic activation and cardiomyocyte-derived ACh is
unknown. Interestingly, previous experiments have demonstrated that proteins involved
with exocytic release of neurotransmitters, or their homologues, are expressed in
vesicular compartments in cardiomyocytes [45]. Hence, secretory vesicle compartments
in cardiomyocytes are likely to be the source of ACh secretion (Fig. 4.11). It should be
noted we have previously established that VAChT is present in recycling vesicles in
cardiomyocytes [12]. Our observation that the cholinergic cardiomyocyte machinery
seems to control heart rate after stress and exercise suggests that cardiomyocyte-derived
ACh secretion may be regulated by sympathetic activity.
Interestingly, activation of the cholinergic anti-inflammatory pathway has been shown to
play an important role in preventing the release of pro-inflammatory cytokines from
circulating macrophages and thereby attenuating the effects of infection or injury [46].
Immune cells can serve as a non-neuronal source of ACh and its levels appear to be
altered in a miR-132 dependent mechanism involving targeting of AChE mRNA [47].
Although the activity of the cholinergic anti-inflammatory reflex has not been measured,
it is expected that its function will be unaltered due to the specificity of the Cre line used.
Recently, non-neuronal secretion of ACh in a VAChT-dependent manner was
demonstrated from pancreatic α cells, a process which regulates insulin secretion in
humans [6]. Here, we show that secretion of ACh from cardiomyocytes also has
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Figure 4.11 - Non-neuronal release of acetylcholine from cardiomyocytes. Wild-type
cardiomyocytes secrete acetylcholine in response to increased physiological stress (e.g.
exercise) in a VAChT-dependent manner to regulate heart rate. This response is blunted
in mice lacking VAChT specifically in cardiomyocytes due to the lack of non-neuronal
ACh release.

230

Figure 4.11 - Non-neuronal release of acetylcholine from cardiomyocytes.

FIGURE 7
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physiological relevance as this non-neuronal cholinergic system plays a previously
unsuspected role in regulating heart rate as well as remodelling. Based on these results, it
is necessary to re-evaluate how the sympathetic-parasympathetic systems control heart
activity to include this novel form of autocrine/paracrine communication from
cardiomyocytes. We propose that secretion of ACh from cardiomyocytes enhances
cholinergic signalling from parasympathetic neurons required to regulate cardiomyocyte
activity (Fig. 4.11). Cardiomyocyte-derived ACh augments extracellular levels of this
neurotransmitter in synaptic junctions between parasympathetic terminals and
cardiomyocytes during high demand; for example, in response to increased sympathetic
activation due to physiological stress. This novel mode of communication may serve to
offset constant sympathetic signalling avoiding increased cardiomyocyte stress and
hypertrophic responses.
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Chapter 5

5.1 Chapter Summary

Autonomic dysfunction is a characteristic of cardiac disease and decreased cholinergic
signaling is observed in the early stages of heart failure. We have previously shown that
rodent cardiomyocytes produce de novo ACh, which is critical in maintaining cardiac
homeostasis under physiological conditions. Here, we provide novel data indicating that
this non-neuronal cardiomyocyte system is also found in human ventricular
cardiomyocytes, which express ChAT and VAChT. Furthermore, VAChT expression is
significantly increased in ventricular tissue from heart failure patients, suggesting an
increase in cardiomyocyte-specific ACh secretion in disease. Mice with a genetic deletion
of cardiomyocyte-specific VAChT displayed enhanced ventricular dysfunction and
pathological remodeling in a pharmacological model of heart dysfunction, supporting the
importance of this intrinsic cholinergic system in the progression of cardiac remodeling.
Mice overexpressing VAChT did not display adverse phenotypes suggesting that the
increased VAChT expression observed in human HF may serve a protective role rather
than contribute to myocardial damage. The data presented here provide novel information
regarding the presence of a NNCS in human cardiomyocytes. It appears to be increased
in failing hearts and may play a compensatory role, given the known decrease in
parasympathetic activity in heart failure.
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5.2 Introduction

It is well established that chronic autonomic sympathetic/parasympathetic imbalance
plays a crucial role in the development of heart failure (HF) [1-4]. There appears to be a
significant increase in adrenergic signaling in heart failure, even in the initial stages of
cardiac remodeling prior to the onset of heart dysfunction [5]. The hyperadrenergic state
contributes to cardiac remodeling [5, 6] and this correlates with higher morbidity and
mortality [7], likely due to the fact that long-term activation of this process may result in
ventricular remodeling [3, 8].
The changes in autonomic control in heart failure also involve decreased parasympathetic
tone and are observed early [9-11]. Altered heart rate regulation due to changes in vagal
nerve activity has been observed shortly after induction of left ventricular dysfunction,
suggesting that alterations in cholinergic signaling in the heart may contribute to HF [12].
Previous work in mice has indicated that genetic disturbance of acetylcholine (ACh)
release, by targeting the vesicular acetylcholine transporter (VAChT), causes ventricular
dysfunction [13]. In agreement with these data, similar results are also observed in mice
with decreased levels of the high-affinity choline transporter [14].
It is surprising that cholinergic activity has such widespread consequences to ventricular
function, given the sparse levels of cholinergic innervation outside the atria [15]. In the
ventricles, cardiac innervation is mainly restricted to the cardiac conduction system [15,
16]. Recent experiments have provided evidence for one mechanism through which ACh
may regulate heart activity involves autocrine/paracrine secretion of non-neuronal ACh
by cardiac myocytes [17]. Indeed, ventricular cardiomyocytes possess the machinery for
de novo production, storage and secretion of ACh [18, 19]. The protein responsible for
packaging ACh into exocytic vesicles, the VAChT, is an important component of the
cholinergic machinery and is present in vesicles in cardiomyocytes [17], suggesting
quantal ACh release from myocytes.
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Cardiomyocyte overexpression of the enzyme responsible for the production of ACh,
choline acetyltransferase (ChAT), in transgenic mice suggests that increased levels of
cardiomyocyte ACh protects against myocardial infarction [20]. Moreover, our group has
recently reported that the cardiac non-neuronal cholinergic system (NNCS) plays a
critical role in regulating cardiac homeostasis in vivo [21]. Our data indicate that
inhibition of ACh secretion from cardiomyocytes delays heart rate recovery following
exercise and leads to significant ventricular remodeling characterized by molecular
alterations [21]. As such, these data suggested that cardiomyocyte-secreted ACh plays a
critical role in regulating cardiac function under physiological conditions.
Previous experiments have suggested that transdifferentiation of sympathetic to
cholinergic neurons takes place during progression of heart failure, a process that plays a
protective role [22]. This compensatory regulation may help to decrease the change
observed in parasympathetic activity in heart disease. Although neuronal and nonneuronal ACh may influence diseased states, it is unclear whether the non-neuronal
cholinergic machinery is present in human cardiomyocytes and whether it is of any
consequence for heart disease. We found that both healthy and diseased human
cardiomyocytes express markers of the cholinergic system. Furthermore, left ventricular
tissue from human patients with non-ischemic dilated cardiomyopathy (NICM) displayed
a significant increase in the expression of VAChT, including VAChT present in
cardiomyocytes, when compared to age-matched controls. Changes in VAChT levels
have significant impact on ACh secretion [23-26]. Therefore, to determine the
consequences of changes in ACh synthesis and secretion, we used genetically-modified
mice in which either ChAT or VAChT was selectively deleted in cardiomyocytes. The
data obtained with mouse models in this study suggest that compensatory changes in
VAChT levels in humans may play a role in mitigating the extent of cardiac remodeling
in heart failure.
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5.3 Materials and Methods

5.3.1

Animal models

Animals were maintained and cared for according to approved animal protocols at the
University of Western Ontario (2008-127) and following Canadian Council on Animal
Care guidelines. Only male mice were used for all in vivo experiments. Cardiomyocytespecific VAChT KO or ChAT knockout mice (VAChTMyh6-Cre-flox/flox; cVAChT;
ChATMyh6-Cre-flox/flox; cChAT) mice were generated as previously described in a previous
study [27]. ChAT-ChR2-EYFP mice overexpressing the VAChT [25, 28] (B6.CgTg(Chat-COP4*H134R/EYFP,Slc18a3)6Gfng/J) and have previously been characterized
[25, 29].

5.3.2

Human tissue samples

Left ventricular tissue samples were obtained from the Duke Human Heart Repository
(Durham, NC). LV myocardium was obtained from seven heart failure patients with nonischemic dilated cardiomyopathy (NICM) and age-matched non-failing individuals. LV
tissue was flash frozen for RNA and protein extraction and OCT embedded for
immunostaining. The use of these samples was approved by the Institutional Review
Board at Duke University Medical Center (Durham, NC).

5.3.3

Angiotensin II infusion

Angiotensin II (Sigma-Aldrich; A9525) was dissolved in sterile saline at a dose of 3
mg/kg/day in osmotic pumps (Model 1002, Alzet). The pumps were implanted
subcutaneously and Ang II was infused for 2 weeks following which the mice were
housed for an additional two weeks to allow remodeling prior to experimental use.
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5.3.4

Echocardiography

M-mode echocardiography was performed in both VAChTflox/flox and VAChTMyh6-Creflox/flox

mice following Ang II treatment. Left ventricular (LV) and right ventricular (RV)

ejection fraction and fractional shortening were measured using the Vevo 2100
ultrasound imaging system (Visual Sonics, Canada). Briefly, 2-dimensional images of the
heart were obtained in short-axis view using a dynamically focused 40 MHz probe. The
M-mode cursor was positioned perpendicular to the LV anterior and posterior walls. The
LV internal end-diastolic dimension (LVIDd) and LV internal systolic dimension
(LVIDs) were measured from M-mode recordings. LV ejection fraction was calculated
as: EF (%) = [(LVIDd)3 - (LVIDs)3]/(LVIDd)3×100. Fractional shortening was calculated
as: FS (%) = (LVIDd-LVIDs)/LVIDd×100. The M-mode measurements of the left
ventricular ejection fraction and fractional shortening were averaged from 3 cycles.

5.3.5

ROS measurement

ROS levels were measured using the MitoSOX Red superoxide indicator (Invitrogen) as
previously described [30].

5.3.6

Protein oxidation levels

Hearts from saline-treated or Ang II-treated mice were isolated, fixed and paraffinembedded. 5 µm tissue sections were obtained and oxidized protein levels were analyzed
using the OxyIHC Oxidative Stress Kit (Millipore) following the manufacturer’s
directions.

5.3.7

Histological analysis

5 µm sections were obtained from saline-treated and Ang II-treated VAChTflox/flox and
VAChTMyh6-Cre-flox/flox mice. The tissue sections were stained with hematoxylin and eosin
(H&E) using standard procedures. Light microscopic images were acquired at 20x
magnification at distinct locations within the left ventricular free wall.
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Cardiomyocyte cell surface area was measured using H&E stained sections where the
cardiomyocyte edges were distinctly observable. Cell surface was measured in sections
obtained from at least 4 mice/genotype.

5.3.8

Cardiac fibrosis

5 µm sections obtained from VAChTflox/flox and VAChTMyh6-Cre-flox/flox mice following
Ang II treatment were stained with Trichrome C using standard procedures to analyze
extent of cardiac fibrosis. Light microscopic images were acquired at 20x magnification
at separate locations within the left ventricular wall to analyze both interstitial and
perivascular collagen deposition was analyzed.

5.3.9

qPCR/RT-PCR

RNA was extracted from human left ventricular tissue or whole hearts and cDNA was
synthesized as previously described [30]. qPCR for VAChT, β-MHC, and ANP was
performed as previously described [30]. Actin and GAPDH were used to normalize
qPCR results for mice and humans, respectively. Primer sequences are available upon
request.

5.3.10

Immunoblotting

Protein was extracted from human left ventricular tissue using ice-cold modified RIPA
buffer. 50 µg of protein was separated using SDS-PAGE and transferred to PVDF
membranes, which were probed with anti-VAChT antibody (1:500; Synaptic Systems).
α-actinin (1:2000; Sigma-Aldrich) was used as a loading control.
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5.3.11

Immunostaining

Adult cardiomyocytes were subjected to an immunostaining protocol as previously
described [31]. Cells were co-stained with anti-ChAT (1:100; Abcam) and anti-α-actinin
(1:200; Sigma-Aldrich) antibodies. α-actinin labeled cells were used to measure
cardiomyocyte cell surface area. Images were acquired using the Zeiss LSM 510 Meta
confocal system.
For human LV tissue, 5 µm sections were subjected to the immunofluorescence protocol
as previously described [31]. The tissue was incubated with anti-VAChT (1:50; Synaptic
Systems) and anti-α-actinin (1:500; Sigma-Aldrich). Images were acquired using the 63x
objective on the Zeiss LSM 510 Meta confocal system.

5.3.12

Measurement of ACh secretion

Acetylcholine release was measured using the Choline/ACh Quantification Kit
(Biovision) as previously described [27, 32]. Briefly, atrial tissue was isolated from wildtype and ChAT-ChR2-EYFP mice and incubated in Tyrode’s solution containing 100 µM
pyridostigmine bromide (Sigma-Aldrich; P9797) at 37ºC for 2 hours. The solution was
collected and centrifuged at 10,000 RPM for 5 minutes at 4ºC and the resulting
supernatant was collected and placed on ice. ACh concentration was determined using
the colorimetric Choline/ACh Quantification Kit (Absorbance 570 nm). Each sample was
assayed in duplicate and experiments were conducted using at least 3 mice/genotype.

5.3.13

Heart rate and blood pressure measurement

Systolic and diastolic blood pressures as well as heart rate were recorded from conscious
animals using the CODA tail-cuff blood pressure system (Kent Scientific, Torrington,
CT, USA) as previously described [33].
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5.3.14

Electrocardiography

Radiofrequency telemeters were implanted in wild-type and ChAT-ChR2-EYFP mice
subcutaneously and ECG recordings were obtained as previously described [13]. Heart
rate was recorded continuously over 24 hours to obtain baseline recordings. In addition,
HR recordings were obtained immediately following IP saline injection or following an
acute exercise routine, as previously described [27]. In addition, autonomic regulation of
cardiac function was analyzed through evaluation of heart rate responses following
autonomic blockade using IP injections of atropine (1 mg/kg) and/or propranolol (1
mg/kg).

5.3.15

Statistical analyses

Results for all experiments are provided as mean ± SEM. Either a Student’s t-test or a
one-way ANOVA with a Tukey’s post-hoc test were used to evaluate statistical
differences between experimental groups using Graphpad or SigmaStat. p<0.05 was
considered statistically significant.
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5.4 Results
5.4.1

VAChT levels are increased in failing human myocardium

In order to determine whether the NNCS is present in humans, we used ventricular
extracts from control individuals and patients with non-ischemic dilated cardiomyopathy
(NICM;

Table

5.1)

and

analyzed

cholinergic

markers.

mRNA

levels

of

acetylcholinesterase (AChE) were not altered in control and heart failure individuals (Fig.
5.1A). mRNA level for ChAT were slightly increased in human HF samples compared to
age-matched healthy controls (Fig. 5.1B), although this did not reach significance.
Immunoblot and immunofluorescence confirmed that ChAT protein levels were not
altered in heart failure (Fig. 5.1C, D). In contrast, VAChT mRNA was significantly
increased in HF patients (Fig. 5.1E). Immunoblot analysis indicated that VAChT protein
levels were also increased in heart failure patients when compared to controls (Fig. 5.1F).
The immunofluorescence data suggest that at least part of the increased levels of VAChT
originated in cardiomyocytes (Fig. 5.1G). The VAChT antibody utilized here has
previously been validated in VAChT KO cardiomyocytes and is known to specifically
recognize VAChT in mammalian cardiomyocytes [27].

5.4.2

cChAT mice display altered heart rate regulation and cardiac
remodeling

Previous experiments demonstrated that mice with a cardiomyocyte-specific deletion in
VAChT display ventricular remodeling and delayed heart rate recovery following activity
[27]. However, VAChT is part of the major facilitator superfamily of transporters, which
includes members of the multidrug resistance protein family, and as such can transport
other organic substrates, including choline, which can have distinct physiological effects
[34, 35]. To further test if the previous phenotypes we described in cVAChT mice are
indeed related to lack of ACh release, we utilized cChAT mice and determined whether
these mice present a similar phenotype to cVAChT mice.
We isolated adult cardiomyocytes from cChAT mice and found that ChAT transcripts, as
determined by RT-PCR, were detected in ChATflox/flox but not cChAT myocytes (Fig.
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Table 5.1 – Non-ischemic cardiomyopathy (NICM) patient specifics.
ID#
1"
2"
3"
4"
5"
6"
7"

Diagnosis#
Age#
End#stage#dilated#NICM;#EF#15720%;#s/p#AICD;#HTN#
69#
Dilated#NICM;#calcified#aortic#and#mitral#valves;#IABP#
67#
End#stage#NICM;#hypertrophic#dilated#CM;#inotrope#dependent# 61#
Dilated#CM;#DM2;#HTN;#HLD#
59#
Dilated#NICM;#EF#<15%;#s/p#ICD#
58#
End#stage#dilated#NICM;#s/p#AICD#
56#
End#stage#NICM;#some#LVH;#possible#Dilated#CM#via#MR;#RV#
64#
dysfunction;#Lupus#
EF,#ejection#fraction;#AICD,#automatic#implantable#cardioverter#defibrillator;#
HTN,# hypertension;# IABP,# intra7aortic# balloon# pump;# CM,# cardiomyopathy;#
DM2,# diabetes# mellitus# type# 2;# HLD,# hyperlipidemia;# ICD,# implantable#
cardioverter# defibrillator;# LVH,# left# ventricular# hypertrophy;# MR,# mitral#
regurgitation;#RV,#right#ventricle.#
#
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Figure 5.1 - Human cardiomyocytes express markers of cholinergic system. (A)
mRNA expression for AChE is unaltered in non-ischemic dilated cardiomyopathy
(NICM). No difference in ChAT mRNA (B) or protein level (C) is observed in NICM.
(D) Perinuclear staining for ChAT is observed in cardiomyocytes from both non-failing
and NICM samples. VAChT mRNA (E) and protein (F) levels are increased in NICM.
(G) Punctate VAChT staining is observed in the perinuclear region of cardiomyocytes
and increased in NICM samples. Data are represented as the mean ± SEM. n≥4 mice for
all experiments. *p<0.05.

252

Figure 5.1 - Human cardiomyocytes express markers of cholinergic system.
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5.2A). Staining for ChAT in murine cardiomyocytes showed a pattern that was similar to
the one we previously reported, with mainly nuclear and perinuclear staining of ChAT
(Fig.

5.2B).

This

stained

was

completely

abolished

in

cChAT

mice

by

immunofluorescence analysis (Fig. 5.2B) confirming the elimination of ChAT in isolated
ventricular cardiomyocytes.
Previous experiments showed abnormal heart rate regulation in both cVAChT and
cChAT mice under restraint conditions [27]. Further experiments in this study with
cChAT mice revealed no alterations in heart rate response under baseline conditions over
24 hours in a home-cage environment, as measured via radio-frequency ECG telemetry
(Fig. 5.2C). However, these mutant mice did exhibit delayed heart rate recovery
following intraperitoneal injection of saline, which was used as a stressor (Fig. 5.2D).
Furthermore, as compared to ChATflox/flox animals, cChAT mice exhibited a greater initial
increase in heart rate as well as a delay in heart rate recovery following an acute, low
intensity, treadmill exercise test (Fig. 5.2E). These results are essentially the same as we
previously reported for cVAChT mice.
In addition, similarly to the previously observed phenotype in cVAChT mice, cChAT
animals also displayed an increase in cardiac size (Fig. 5.3A), due to cardiomyocyte
hypertrophy (Fig. 5.3B). Furthermore, ChAT knockout myocytes showed a tendency for
increased expression of β-MHC (p=0.07) and a significant increase in ANP expression
(Fig. 5.3C), both markers of cardiac remodeling. In addition, similar to cVAChT
myocytes, cChAT myocytes also showed a significant increase in mitochondrial
superoxide levels (Fig. 5.3D), indicative of increased oxidative stress and remodeling.
Control experiments confirmed that these molecular changes and cardiomyocyte
remodeling are absent in Myh6-Cre mice [27]. All the phenotypes uncovered in cChAT
mice were also previously observed in cVAChT mice, leading us to conclude that these
alterations are due to either lack of ACh synthesis in cChAT mice or lack of ACh release
in cVAChT mice [27].
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Figure 5.2 - cChAT mice display altered heart rate regulation. (A) ChAT transcript is
expressed in ChATflox/flox myocytes but not in conditional ChAT knockout (cChAT)
myocytes. (B) Immunofluorescence in adult cardiomyocytes confirms deletion of ChAT
at the protein level in cChAT cardiomyocytes. (C) Heart rate over 24 hours in awake,
free moving mice is unaltered between ChATflox/flox and cChAT mice in their home cage.
(D) cChAT mice exhibit a delay in heart rate recovery following gentle restraint and IP
saline injection. (E) cChAT mice exhibit a greater increase in initial heart rate and
delayed recovery to baseline levels following exercise, as compared to ChATflox/flox
controls. n≥7 for all experiments. Data are represented as mean ± SEM. *p<0.05 vs.
control mice.
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Figure 5.2 - cChAT mice display altered heart rate regulation.
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Figure 5.3 - cChAT mice exhibit ventricular remodeling and hypertrophy. (A)
cChAT mice display cardiac hypertrophy, as measured through heart weight (normalized
to tibia length, n=number of cells). (B) Isolated cChAT cardiomyocytes exhibit a
significant increase in surface area, as compared to ChATflox/flox cells (n=number of
mice). (C) Expression of the cardiac stress marker, β-MHC, shows a tendency for
increase in cChAT myocytes while the expression of ANP is significantly increased in
cChAT cardiomyocytes, as compared to control cells (n=number of mice). (D) ROS
levels in cChAT myocytes, as measured using the MitoSOX superoxide indicator, are
significantly increased (n=number of cells; at least 3 mice/genotype). Data are
represented as the mean ± SEM. *p<0.05.
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Figure 5.3 - cChAT mice exhibit ventricular remodeling and hypertrophy.
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5.4.3

cVAChT mice exhibit increased angiotensin II-mediated
cardiac remodeling

Our data suggest that the cholinergic cardiomyocyte system has physiological impact on
heart function in mice. Therefore, our goal was to determine whether cardiomyocyte
VAChT contributes to remodeling under stress. To clarify whether changes in the
expression levels of VAChT, which can effectively regulate ACh release [23-26], could
impact pathological remodeling, we focused our experiments on cVAChT mice
chronically treated with angiotensin II (Ang II). Ang II is a potent vasoconstrictor, which
activates AT1 receptors on vascular smooth muscle cells [36, 37] and can thereby induce
ventricular remodeling by increasing cardiac afterload. Furthermore, Ang II-mediated
signaling has also been shown to directly induce hypertrophy and molecular remodeling
in ventricular cardiomyocytes [38-40]. We chose pharmacological treatment instead of
surgical induction of heart failure in mice in an attempt to produce limited cardiac
dysfunction, in case the lack of VAChT led to worse outcomes.
Ang II treatment did not lead to significantly increased mortality in cVAChT mice, as
compared to control animals (Fig. 5.4A). However, non-invasive analysis of left
ventricular hemodynamics using M-mode echocardiography confirmed a significant
decrease in LV fractional shortening as well as LV ejection fraction in both control and
cVAChT mice following Ang II treatment (Fig. 5.4B, C, D). Importantly, cVAChT mice
exhibited a significantly greater decrease in both LV fractional shortening and ejection
fraction, as compared to Ang II-treated control mice (Fig. 5.4C, D), thus suggesting that
cVAChT mice were more sensitive to Ang II-mediated cardiac dysfunction. Notably,
neither genotype displayed LV dilation following Ang II treatment, as the LV internal
dimensions were similar across genotypes during both diastole and systole (Fig. 5.4E).
The lack of ventricular dilation confirms that we are analyzing the initial stages of
ventricular remodeling in these animals, prior to the onset of heart failure and severe
decline in contractile function.
In order to determine pathological hallmarks in cVAChT mice that may contribute to the
worsened LV dysfunction observed following Ang II treatment, heart weight and
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Figure 5.4 - cVAChT mice exhibit enhanced ventricular dysfunction following Ang
II treatment. (A) No significant difference in survival is observed following Ang II
treatment. (B) Representative images of M-mode echocardiography suggest a greater
decline in cardiac function in cVAChT mice following Ang II treatment, as compared to
control mice. The LV fractional shortening (B) and ejection fraction (C) is significantly
decreased in both VAChTflox/flox and cVAChT mice, with the mutant mice displaying a
more significant decrease in both parameters. (D) The LV internal dimensions during
diastole and systole are not altered in either genotype following Ang II treatment. Data
are represented as the mean ± SEM. n≥7 mice for all experiments. *p<0.05,
****p<0.0001.
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Figure 5.4 - cVAChT mice exhibit enhanced ventricular dysfunction following Ang
II treatment.
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cardiomyocyte surface area were analyzed. VAChTflox/flox control mice displayed an
increase in heart weight following Ang II treatment as compared to saline-treated mice
(Fig. 5.5A). Conversely, cVAChT mice displayed baseline cardiac hypertrophy with
saline treatment alone, as previously described [27]; however, as compared to salinetreated animals, Ang II treatment did not induce a further significant increase in heart
weight in cVAChT mice (Fig. 5.5A). Notably, an analysis of cardiomyocyte surface area,
in situ, revealed that Ang II-treated cVAChT mice exhibit a significantly greater
cardiomyocyte hypertrophic response than Ang II-treated control mice (Fig. 5.5B).
Since chronic Ang II exposure can lead to increased reactive oxygen species (ROS)
production and cardiomyocyte death [41-43], we analyzed changes in the myocardium.
Further analysis revealed genotype-dependent changes in oxidative stress, as measured
by the levels of oxidized proteins in the myocardium. Specifically, under baseline
conditions with saline treatment, there was an increase in oxidative stress in cVAChT
mice, as compared to control mice (Fig. 5.5C), consistent with our previous observations
[27]. Furthermore, Ang II treatment led to a greater increase in oxidative stress in the
myocardium in cVAChT mice as compared to Ang II-treated control mice (Fig. 5.5C).
In addition to the changes in oxidative stress, Ang II-treated cVAChT mice displayed a
greater disruption of myocardial structure, as compared to VAChTflox/flox control mice
(Fig. 5.5D). In order to determine the potential for ECM remodeling, Trichrome C
staining was performed to analyze collagen deposition. In VAChTflox/flox mice, no fibrosis
was observed following treatment with Ang II; however, in cVAChT mice, prominent
fibrosis due to increased interstitial and perivascular collagen deposition was observed
(Fig. 5.5E). Together, these results suggest that decreased levels of VAChT in
cardiomyocytes, without alterations in the parasympathetic nerves [27], can negatively
influence cardiac remodeling in response to a pathological insult.
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Figure 5.5 - cVAChT mice display increased ventricular hypertrophy and
remodeling. (A) Ang II treatment led to a significant increase in HW/TL ratio in
VAChTflox/flox control mice while cVAChT mice did not display cardiac hypertrophy. (B)
Ang II treatment led to a significant increase in cardiomyocyte hypertrophy in both
genotypes; however, an even greater hypertrophic response was observed in cVAChT
mice. (C) Oxidative protein levels were increased following Ang II treatment. cVAChT
mice displayed higher levels of protein oxidation than the control animals, as evidenced
by quantification of staining intensity. (D) VAChTflox/flox control mice exhibited
myocardial disruption following Ang II treatment, a response that was further enhanced
in cVAChT mice. (E) Trichrome C staining revealed no increase in fibrotic response in
control animals following Ang II treatment; however, cVAChT mice exhibited both
interstitial and perivascular fibrosis. Data are represented as the mean ± SEM. n≥4 mice
for all experiments. Letters indicate significant differences among groups (p<0.05).
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Figure 5.5 - cVAChT mice display increased ventricular hypertrophy and
remodeling.
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5.4.4

Increased VAChT expression does not disturb cardiac
function

Although decreased levels of VAChT in either nerve terminals [13, 30] or
cardiomyocytes [27] seem to influence cardiac remodeling, whether increased VAChT
levels may affect cardiac function is unclear. Therefore, we used a newly described
mouse line overexpressing VAChT using BAC transgenics (ChAT-ChR2-EYFP) for these
experiments [44]. This particular line was generated to express channelrhodopsin-2
(ChR2) in cholinergic neurons using a ChAT BAC; however, because the VAChT gene is
present in the first intron of the ChAT gene, the transgene leads to VAChT
overexpression [25]. Previous experiments showed an approximately 25-fold increase in
VAChT mRNA levels in the brain; however, there was only a 3-5 fold increase in protein
levels, depending on the brain region in this mouse line [25]. Because expression of the
gene is regulated by the endogenous promoter regions in the BAC, we first confirmed
whether the atria of ChAT-ChR2-EYFP mice overexpressed VAChT. Due to the fact that
the ChR2 protein is tagged with EYFP, we performed fluorescent immunohistochemistry
to confirm the expression of the BAC transgene in atrial tissue. Immunostaining
confirmed the expression of EYFP in cholinergic neurons, which were specifically
labeled with the cholinergic marker CHT1 (Fig. 5.6A). qPCR analysis revealed that
expression of the transgene in the heart led to a modest, but significant, increase in
VAChT expression (Fig. 5.6B). Furthermore, immunostaining of atrial tissue confirmed
an increase in staining for VAChT thus suggesting an increase in VAChT protein levels
in ChAT-ChR2-EYFP mice (Fig. 5.6C). Notably, EYFP was not present in ventricular
cardiomyocytes, thus suggesting that the BAC transgene is not expressed in these
cardiomyocytes (Fig. 5.6D). It is possible that BAC transgene expression may be
regulated differently in neuronal vs. non-neuronal tissues. Since the BAC was not
expressed in ventricular cardiomyocytes, VAChT would not be upregulated in these cells.
Therefore, we measured ACh release from atrial tissue, which contains cholinergic nerve
terminals and cell bodies, using a colorimetric assay to quantify ACh secretion [27] and
confirmed that the increase in VAChT expression led to a significant increase in ACh
release (Fig. 5.6D). The increase in ACh release follows the modest increase in VAChT
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Figure 5.6 - Characterization of VAChT expression and ACh release in ChATChR2-EYFP hearts. (A) The BAC transgene containing ChR2-EYFP is expressed in
CHT1-labelled cholinergic neurons in the atria of ChAT-ChR2-EYFP mice. (B) VAChT
expression is significantly increased in ChAT-ChR2-EYFP hearts, (C) ChAT-ChR2-EYFP
atria exhibit greater staining for VAChT, as compared to the wild-type mice. (D) Staining
for ChR2-EYFP is absent in isolated, ventricular cardiomyocytes suggesting a lack of
BAC expression in these cells (scale bar=25 µm). (E) ACh release is significantly
increased in ChAT-ChR2-EYFP atria. Data are represented as the mean ± SEM. *p<0.05
vs. control, ***p<0.001 vs. control. n=at least 3 mice/genotype for all experiments.
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Figure 5.6 - Characterization of VAChT expression and ACh release in ChATChR2-EYFP hearts.
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levels. Therefore, it seems that the ChAT BAC used here is not as effective in increasing
the expression of VAChT in parasympathetic neurons as it is in the brain.
In order to determine whether this modest increase in systemic cholinergic tone leads to
physiological changes in these mice, we performed tail-cuff analysis to measure blood
pressure and heart rate. No difference in either heart rate or blood pressure was observed
between the two genotypes, as measured using the CODA tail-cuff system (Fig. 5.7A).
Electrocardiographic analysis was also performed using radio frequency telemeters to
analyze heart rate responses under both baseline conditions as well as following
administration of pharmacological agents to determine whether there was autonomic
dysregulation in these mice. The baseline heart rate in ChAT-ChR2-EYFP mice, as
measured over 24 hours, did not differ from the control counterparts (Fig. 5.7B).
Furthermore, the response to an IP injection of saline was not altered in transgenic mice
(Fig. 5.7C), suggesting that the stress-related response to handling was not affected by the
modest increase in cholinergic tone. In addition, in order to measure autonomic
imbalance in these mice, we gave a bolus dose of various pharmacological drugs and
monitored the HR response in these animals. There was no difference in heart rate
response between the control and ChAT-ChR2-EYFP mice following administration of a
bolus dose of the muscarinic receptor antagonist, atropine (Fig. 5.7D), the β-adrenergic
receptor antagonist, propranolol (Fig. 5.7E), or atropine and propranolol together (Fig.
5.7F). These data suggest that there is no major difference in autonomic regulation of
heart rate. Furthermore, the intrinsic heart rate in ChAT-ChR2-EYFP mice is also
unaltered, as evidenced by the heart rate response following inhibition of all autonomic
regulation. In contrast, when the ChAT-ChR2-EYFP mice were subjected to an acute,
low-intensity treadmill test, the initial increase in heart rate following the exercise was
significantly reduced as compared to control counterparts (Fig. 5.7G), suggesting that
under increased physiological stress overexpression of VAChT may play a role.
To determine whether this increase in cholinergic tone leads to changes in left ventricular
hemodynamics, we used the Millar catheter technique to assess cardiac function in live
animals. Analysis of LV parameters in anesthetized animals was done
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Figure 5.7 - Heart rate response to exercise is attenuated in ChAT-ChR2-EYFP mice.
(A) No difference in blood pressure or heart rate is observed between wild-type and
ChAT-ChR2-EYFP mice. (B) Heart rate over 24 hours in awake, free moving mice is
unaltered between WT and ChAT-ChR2-EYFP mice in their home cage. (C) Heart rate
recovery following gentle restraint and IP saline injection is similar in WT and ChATChR2-EYFP mice. The heart rate response of both wild-type and ChAT-ChR2-EYFP mice
is similar following a bolus dose of atropine (D), propranolol (E) or atropine and
propranolol together (F). (G) The initial increase in heart rate following exercise is
attenuated in ChAT-ChR2-EYFP mice as compared to wild-type controls. n≥7 mice for
all experiments. Data are represented as the mean ± SEM. *p<0.05 vs. control mice.

269

Figure 5.7 - Heart rate response to exercise is attenuated in ChAT-ChR2-EYFP mice.

A

B

C

D

E

F

G

270

under both baseline conditions and following the administration of isoproterenol (0.5 µg
i.p.). All of the hemodynamic parameters measured using the Millar technique were
similar between the wild-type and ChAT-ChR2-EYFP mice, both under baseline
conditions as well as following a bolus dose of isoproterenol (Table 5.2). These results
suggest that, under baseline conditions, at least without the presence of an external
stressor, modest increased cholinergic tone due to increased VAChT expression does not
alter LV function.
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Table 5.2 – Hemodynamic parameters for wild-type (n=7) and ChAT-ChR2-EYFP
(n=7) mice under baseline and following isoproterenol stimulation.
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5.5 Discussion

Substantial data suggest that increasing cholinergic signaling in both animal models of
HF as well as human patients can reduce morbidity and mortality associated with
ventricular dysfunction. In an animal model of heart failure, conjunctive treatment with
vagal nerve stimulation and β-blockade therapy has been shown to improve cardiac
contractility and animal survival [45, 46]. Furthermore, both cardiac remodeling and
mortality were reduced in animal models of HF following chronic treatment with the
cholinesterase inhibitor, donepezil [47, 48]. Finally, increasing extracellular ACh levels
through

administration

of

a

peripheral

quaternary

cholinesterase

inhibitor,

pyridostigmine, led to greater vagal control of the heart and reduced ventricular
dysfunction in rats with HF [49]. Importantly, enhancing cholinergic tone also appears to
have positive consequences in human HF patients. A clinical trial investigating vagal
stimulation via an implantable system led to an improvement in their NYHA class score
as well as a decrease in LV end-systolic volume [50]. Additionally, in a nationwide
cohort study in Sweden, the use of cholinesterase inhibitors in Alzheimer’s disease
patients led to a 34% reduction in risk of myocardial infarction and death [51].
The mechanisms through which treatment with cholinesterase inhibitors can induce
protective effects have yet to be explored. However, it is likely that at least some of the
positive effects observed in response to increased cholinergic activity are due to enhanced
signaling of the cardiac NNCS. The notion that cardiomyocyte-derived ACh serves a
protective role in cardiac disease is supported by data presented here which suggest that
VAChT is upregulated in cardiomyocytes from failing human myocardium. To the best
of our knowledge, this is the first report to not only demonstrate the existence of a nonneuronal cholinergic system in human cardiomyocytes, but also to report an increase in
VAChT expression in heart failure. This increase in VAChT levels in human patients
with NICM and HF hints at the possibility that ventricular myocytes may be able to
increase cardiac ACh secretion. We propose that this increase in VAChT is not
deleterious, and may help to offset some of the remodeling in heart failure. Obviously,
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this modest increase in VAChT expression does not seem to be enough to prevent
remodeling.
We utilized mice lacking the ability to produce ACh (cChAT) and confirmed that
cardiomyocyte ACh is essential in maintaining cardiac homeostasis, similar to the
previously observed phenotype in cVAChT mice [27]. These experiments strongly
suggest that the phenotypes previously observed in cVAChT mice are essentially due to
lack of ACh secretion. In order to further dissect the importance of the NNCS in cardiac
remodeling, we chronically treated cVAChT mice with Ang II. Chronic treatment with
Ang II led to enhanced remodeling characterized by increased oxidative stress and
myocyte hypertrophy. However, LV dysfunction was more pronounced in VAChTdeleted mice. This was likely due to increased disruption of myocardial structure and
increased fibrotic response compared to control mice, both of which contribute to
decreased ventricular compliance. The increased cardiac remodeling and hypertrophy
observed in cVAChT mice following induction of cardiac disease suggests that the
NNCS plays a critical role in attenuating the ventricular remodeling response.
Importantly, analysis of pathological remodeling was performed at 1 month following
Ang II infusion. This time point was selected in order to determine the importance of the
NNCS in the early stages of ventricular remodeling, prior to the onset of heart failure.
Control animals did not display enhanced ECM remodeling and fibrotic response
following Ang II treatment. In fact, the myocardial structure appeared to be similar to that
observed in saline-treated animals. These data suggest that, in the absence of
cardiomyocyte-derived ACh, disruption of the myocardium is accelerated following
activation of initial neurohumoral responses. Importantly, there is a distinct possibility
that the increased oxidative stress observed in cVAChT mice leads to cardiomyocyte
death, which may serve as a precursor for the accelerated ventricular remodeling and
dysfunction associated with chronic Ang II infusion. The molecular mechanisms that
regulate this enhanced remodeling response have yet to be elucidated and will be pursued
in future studies.
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In agreement with the current study, previous work from other groups has also confirmed
the importance of the NNCS in cardiac disease. Studies have shown that ChAT KO HL-1
cells, derived from murine atrial cardiac tissue, exhibit decreased viability in response to
chemical hypoxia, likely due to decreased levels of cellular ATP in these cells [52].
Furthermore, these cells appear to be more sensitive as acute treatment with
norepinephrine leads to greater production of reactive oxygen species (ROS) as well as
increased apoptotic response in ChAT KO cells [52]. Conversely, overexpression of the
enzyme responsible for the synthesis of ACh, choline acetyltransferase (ChAT-Tg),
specifically in cardiomyocytes, attenuates ventricular remodeling and increases survival
following myocardial infarction [20]. These data further highlight the importance of the
cardiac NNCS in the regulation of cardiac function, especially following induction of
stress, including ischemia.
Although the data presented here suggest that myocardial cholinergic signaling might be
increased in human HF, it is unclear whether this contributes to the decline in cardiac
function or played a protective role. ChAT-ChR2-EYFP mice were utilized to determine
whether increased cholinergic signaling led to adverse cardiac effects. Due to the BAC
driven overexpression of VAChT, these mice do not seem to fully recapitulate the
overexpression phenotype we observed in humans. First, it seems that the BAC is not
expressed in isolated cardiomyocytes (Fig. 6D); therefore, VAChT may not be
upregulated in the ventricles of these animals. Moreover, the level of overexpression in
cholinergic parasympathetic nerve terminals is much less than what we previously
reported in the brain [25]. For example, we have previously observed a 20-fold increase
in VAChT mRNA levels in the brain, whereas we only detected a 50% increase in
expression in the heart (Fig. 6B). Nonetheless, ACh release in atrial tissue follows the
increase in VAChT levels, providing a way to follow the consequences of moderately
increased levels of ACh release. Interestingly, we observed no changes in inotropy,
chronotropy or autonomic regulation of heart rate in these animals. These data suggest
that, under physiological conditions, enhancing cholinergic signaling does not alter
cardiac function. However, in the presence of physiological stress, increased cholinergic
tone can attenuate exercise-induced increase in heart rate. This blunted response to
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activity suggests that increased ACh signaling in the heart may lead to greater control of
the heart under conditions of increased sympathetic drive, as seen in the disease state.
Since enhancing cholinergic signaling in models of HF yields positive results, future
studies will utilize these ChAT-ChR2-EYFP mice to analyze the progression of
ventricular remodeling following induction of cardiac disease.
Importantly, our data indicate that cardiomyocyte-secreted ACh plays a critical role in
regulating the onset and progression of LV dysfunction in mice. It is possible that, in
cardiac disease, the expression of markers of the cholinergic system in cardiomyocytes is
upregulated, which would help to restore cholinergic signaling to baseline levels
following vagal withdrawal. In addition, cardiomyocyte ACh may counteract the effects
of increased sympathetic drive, which is observed in heart disease. The fact that human
cardiomyocytes display increased expression of VAChT in HF gives further support to
this notion and may provide a mechanism through which enhancing cholinergic tone in
animal models and human patients can have its beneficial effects.
Notably, a global increase in VAChT expression, and thus ACh release, does not lead to
adverse consequences in mice but rather serves to offset sympathetic signaling under
conditions of physiological stress. These results serve as an important precursor to the
clinical use of cholinesterase inhibitors in heart failure patients. The safety of
cholinesterase inhibitors is well characterized in Alzheimer’s disease patients; therefore,
modulation of cholinergic signaling may serve as an unexplored clinical avenue for
treatment of cardiac disease in humans.
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Chapter 6

6.1 Summary of Major Findings

A decrease in vagal-mediated cholinergic signaling is observed in the failing
myocardium; however, the exact role of cholinergic signaling in the regulation of cardiac
function was unclear. In this thesis, we sought to determine whether alterations in
neuronal and/or non-neuronal cholinergic signaling leads to changes in cardiac
homeostasis, in particular inotropic and chronotropic responses as well as transcriptional
regulation. Furthermore, our goal was to elucidate whether ACh signaling plays a role in
delaying the progression of cardiac remodeling under pathological conditions.
Chapter 2 of this thesis was designed to identify molecular alterations associated with
deficient systemic cholinergic signaling. The mice utilized in Chapter 2 presents a global
reduction of approximately 70% in levels of the vesicular acetylcholine transporter
(VAChT). Our laboratory previously reported that these mice display cardiac dysfunction
and a phenotype similar to heart failure [1]. Importantly, many of the functional and
molecular changes associated with reduced VAChT expression (VAChT KDHOM mice)
could be attenuated with the use of pyridostigmine, a peripheral cholinesterase inhibitor
[1]. These data suggested that lack of ACh secretion was, in fact, the driving force that
led to changes in ventricular function. As such, we further characterized the molecular
alterations in these mice due to deficient cholinergic signaling. A microarray analysis was
performed using cardiac tissue and we identified numerous transcriptional changes,
including changes in genes that regulate fatty acid synthesis. Furthermore, we identified
an increase in reactive oxygen species (ROS) in cardiomyocytes from mice with
decreased ACh secretion, which may partially be due to the transcriptional changes
observed here. Finally, we utilized another model of autonomic dysfunction with
enhanced adrenergic signaling and observed similar transcriptional changes as those
observed with cholinergic deficient mice. The data presented here further implicate
autonomic imbalance as a main contributor to cardiac dysfunction.
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As previously mentioned, parasympathetic innervation of the ventricles is very sparse,
where it is mainly restricted to the cardiac conduction system [2-4]. Interestingly,
previous studies suggested that ventricular cardiomyocytes also express prototypical
markers of the cholinergic system, which may act to regulate ventricular function [5, 6].
In Chapter 3, we discovered that murine cardiomyocytes posses the machinery to produce
and secrete ACh. Furthermore, cardiomyocyte-derived ACh was able to prevent
hypertrophy and molecular remodeling in cardiomyocytes in response to hyperadrenergic
stimulation, in vitro. Specifically, preserving extracellular ACh levels through treatment
with cholinesterase inhibitors led to decreased cardiomyocyte hypertrophy in response to
isoproterenol treatment, reduced expression of cardiac stress markers, decreased NFAT
nuclear translocation and decreased peak systolic calcium as compared to isoproterenol
treatment alone. Together, these data provide support to the concept that ACh secreted
from cardiomyocytes may act in an autocrine/paracrine fashion to offset the deleterious
effects of enhanced sympathetic signaling in cardiac disease.
In Chapter 4, we determined whether this non-neuronal system identified in isolated and
cultured cardiomyocytes plays a role in regulating cardiac function. We observed that the
cardiac non-neuronal cholinergic system (NNCS) is critical in regulating heart activity
and remodeling, in vivo. In fact, inhibition of ACh secretion from cardiomyocytes
through selective deletion of VAChT resulted in delayed heart rate recovery following
physiological stress, including exercise, as well as significant ventricular remodeling.
Under basal conditions, cardiomyocytes lacking the VAChT displayed hypertrophy and
molecular remodeling including activation of the fetal gene program, increased reactive
oxygen species (ROS) production and enhanced peak systolic calcium. The molecular
remodeling observed in these mice resulted in abnormal inotropic responses following a
bolus dose of isoproterenol, which suggests that cardiomyocyte-derived ACh contributes
to the regulation of cardiac function under stress. These data support the notion that the
cardiac NNCS is critical in regulating physiological responses, likely by amplifying
cholinergic signaling in the heart. Our experiments also point to the mechanisms by
which ACh is secreted from cardiomyocytes. It has previously been shown that ACh
release from other cell types, including epithelial cells, is dependent on organic cation
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transporters (OCT) rather than VAChT [7, 8]. In cardiomyocytes, we observed that both
pharmacological and genetic inhibition of VAChT prevent ACh secretion thus verifying
this transporter as an essential mediator of ACh release from cardiac myocytes.
Importantly, the VAChT is part of the major facilitator transporter superfamily, and can
transport other organic substrates, which can have distinct physiological effects [9, 10].
As such, mice with cardiomyocyte-specific deletion of ChAT (cChAT mice) were
utilized in Chapters 4 and 5 to confirm that the altered cardiac function observed in
cVAChT mice was due to altered cholinergic signaling. Many of the remodeling
processes and altered heart rate regulation observed in cVAChT mice were also present
in cChAT mice. These data provided definitive evidence supporting the notion that the
observed alterations in cardiac function are due to inhibition of cardiomyocyte-specific
ACh production or release.
Finally, in Chapter 5, we identified that this intrinsic cholinergic system in the heart is
also present in human cardiomyocytes. To the best of our knowledge, this is the first
documentation of the presence of cholinergic machinery in human cardiomyocytes,
which also have conserved expression of prototypic markers of the cholinergic system.
Importantly, this system might be of functional significance in cardiac disease as failing
human cardiomyocytes exhibit increased VAChT expression, which likely leads to an
increase in ACh secretion directly from cardiomyocytes. Importantly, previous data
suggest that parasympathetic tone is downregulated in HF, which contributes to
autonomic dysfunction. However, previous experiments suggest that cardiac sympathetic
nerves transdifferentiate into cholinergic neurons thereby increasing ACh secretion in
heart failure, which leads to decreased mortality [11]. In addition to this previous study,
our data suggest that ventricular ACh secretion may also be increased in human heart
failure. Together, these data indicate that, although compensatory mechanisms may be
activated in HF in order to increase cholinergic signaling, this is still not enough to
completely abolish the ventricular remodeling observed in cardiac disease. Furthermore,
it hints at the possibility that inhibition of ACh secretion may lead to worse prognosis and
outcomes in heart failure.
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Given that VAChT expression was increased in diseased myocardium, we examined
whether a systemic increase in VAChT expression and ACh release leads to altered
cardiac function and adverse effects under physiological conditions. Although our data
suggest that VAChT is not overexpressed in ventricular cardiomyocytes in ChAT-ChR2EYFP mice, we sought to determine whether increased cholinergic signaling in the atria
could alter cardiac function. VAChT overexpression and increased cardiac atrial ACh
secretion did not lead to any significant inotropic or chronotropic differences. These data
suggest that the increase in VAChT expression observed in failing human myocardium
likely plays a protective role rather than contribute to the adverse phenotypes present in
heart failure. In order to further determine the role of the NNCS in the onset and
progression of cardiac disease, we utilized cVAChT mice, which were characterized in
Chapter 4. Chronic angiotensin II (Ang II) treatment led to enhanced cardiac remodeling
and ventricular dysfunction in mice lacking the non-neuronal cholinergic system.
Specifically, cVAChT mice displayed greater defects in ventricular fractional shortening
and ejection fraction following Ang II treatment. Furthermore, pathological responses
were also increased in cVAChT mice, as greater disruption of myocardial structure and
increased fibrotic response were apparent in conditional VAChT knockout mice. These
data provide further support to the notion that the non-neuronal cholinergic system is
crucial in reducing the progression of ventricular remodeling.

6.2 Limitations and Future Studies

The VAChT KDHOM mice utilized in Chapter 2 display a global decrease in VAChT
expression and, therefore, ACh release. This results in a decrease in both parasympathetic
and sympathetic signaling, due to the fact that ACh mediates pre-ganglionic sympathetic
signaling. Moreover, these mice also show a deficit in cardiomyocyte-derived ACh
signaling (Chapter 3). It is possible that the transcriptional alterations observed in cardiac
tissue from VAChT KDHOM mice are due to abnormal sympathetic, parasympathetic
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and/or non-neuronal signaling. However, this mouse line did not allow us to elucidate the
implications of exclusively altering parasympathetic signaling.
Furthermore, decreased systemic cholinergic signaling does not solely lead to decreased
ACh secretion at the level of the heart. Rather, there is significant data suggesting that
vagal signaling can lead to activation of the cholinergic anti-inflammatory pathway,
which can activate α7 nicotinic acetylcholine receptors (α7nAChRs) on macrophages and
inhibit pro-inflammatory cytokine release from these cells, an effect that can be blunted
using selective nicotinic antagonists or α7nAChR knockout mice [12-16]. It is likely that
some of the ventricular dysfunction and pathological responses observed in the VAChT
KDHOM mice is due to defective regulation of this inflammatory response rather than
direct effects of ACh in the myocardium. In support of this notion, there is evidence that
this mouse line presents abnormal anti-inflammatory responses [17]. As such, future
studies will need to be designed to analyze the specific importance of this cholinergic
anti-inflammatory pathway in the regulation of heart disease. To this effect, ventricular
function and pathological remodeling will be analyzed in α7nAChR KO mice via either
left anterior descending coronary artery (LAD) ligation or Ang II infusion. A detailed
analysis of cardiac remodeling in two distinct models of cardiac disease will determine
whether this pathway has a significant impact on progression of heart disease.
Furthermore, it will provide vital information regarding the contribution of the
cholinergic anti-inflammatory pathway in mediating the positive effects of vagal
stimulation.
In Chapter 3, we observed that cardiomyocytes are able to secrete ACh and this intrinsic
cholinergic system may participate in the normal response to adrenergic stimulation.
Although our data suggest that the NNCS has an important physiological function, the
mechanisms that trigger ACh release from cardiomyocytes have yet to be elucidated.
VAChT appears to be present in exocytic vesicles, which are maintained in a pool at the
perinuclear region in cardiomyocytes [18]. It is possible that these exocytic vesicles with
ACh are retained near the nucleus to prevent inadvertent exocytosis of ACh due to
calcium influx during systolic contraction. However, no detailed studies have yet been
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conducted in order to truly explore the mechanisms responsible for triggering ACh
release from cardiomyocytes.
Although this concept has yet to be tested, it is possible that ACh secretion is dependent
on sympathetic signaling, which leads to exocytosis of ACh-containing vesicles. This
notion is supported by the data presented in Chapter 4 which suggest that inhibition of
cardiomyocyte-derived ACh, in vivo, leads to delayed heart rate recovery following
exercise. Increased parasympathetic signaling has long been implicated in heart rate
recovery following physiological stress; however, our data suggest that increased
sympathetic signaling may induce secretion of cardiac ACh, which can act to amplify
parasympathetic signaling and enhance heart rate recovery. In order to test the hypothesis
that sympathetic signaling can mediate ACh release from cardiomyocytes, further in vitro
studies will need to be conducted. Cultured neonatal cardiomyocytes can be subjected to
acute treatment with the β-adrenergic agonist, isoproterenol, and extracellular levels of
ACh can be analyzed.
One of the major changes we identified in Chapter 4 involved significant ventricular
hypertrophy and remodeling due to lack of the non-neuronal cholinergic system in mice.
However, the exact mechanisms that lead to ventricular dysfunction and molecular
remodeling are still unclear. One possibility is that the enhanced heart rate response
observed in these animals is due to increased SAN activity, which results in a pacinginduced pathogenesis model of HF. Under these circumstances, increased chronotropic
responses may be expected to place greater strain on cardiac muscle and activate
pathways leading to ventricular remodeling. Conversely, it is possible that
cardiomyocyte-derived ACh plays a direct role in regulating the function of ventricular
cardiomyocytes and, in the absence of this NNCS system, cardiomyocytes are susceptible
to molecular remodeling. The latter possibility is in agreement with previous work from
another group suggesting that treatment with the cholinesterase inhibitor, donepezil,
preserves cardiomyocyte-secreted ACh and activates ChAT transcription, thereby
increasing ACh production in cardiomyocytes [6]. Furthermore, the authors suggested
that increasing ACh signaling can decrease oxygen consumption and energy metabolism,
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which may serve to preserve myocyte function [6]. In order to determine which of these
possibilities leads to the observed phenotype, cVAChT mice must be chronically treated
with the peripheral cholinesterase inhibitor, pyridostigmine (PYR). In the event that
cVAChT mice exhibit pacing-induced ventricular dysfunction, treatment with PYR may
be able to reverse many of the molecular changes observed in these animals, as seen in
previously published data from our group [1]. However, if the intrinsic cholinergic
system in cardiomyocytes has a direct protective role in the ventricles via
autocrine/paracrine signaling, PYR treatment will produce no positive outcomes due to
the fact that cardiac myocytes lack the ability to secrete ACh.
Irrespective of the specific pathways that lead to the ventricular remodeling observed in
Chapter 4, it is evident that cardiomyocytes from hearts lacking this intrinsic cholinergic
system display baseline molecular remodeling. One potential mechanism for the observed
cardiomyocyte remodeling that has been explored in this thesis involves nuclear
translocation of GRK5, which has been implicated in cardiac hypertrophy [19]. However,
there are likely other mechanisms through which ACh is able to regulate several different
remodeling pathways and downstream functional effects that have not been fully
elucidated in this thesis.
One of these pathways involves changes in calcium signaling in isolated cardiomyocytes
from cVAChT mice. A significant increase in peak systolic calcium levels is observed in
isolated cardiomyocytes, which often results in increased transport of Ca2+ into the
mitochondria where it can lead to mitochondrial Ca2+ overload and increased ROS
production [20]. It is well known that an increase in mitochondrial ROS levels leads to
uncoupling of oxidative phosphorylation, which leads to a decline in ATP production, as
well as cell death [21-23]. Furthermore, this decrease in ATP production, coupled with
the loss of phosphocreatine (PCr), is often seen in cardiac disease and the PCr/ATP ratio
appears to be a strong predictor of mortality [24-27]. Together, these data suggest the
need to determine whether the increased mitochondrial ROS production in cVAChT
myocytes contribute to the observed remodeling and ventricular dysfunction. An in vitro
primary culture model with cardiomyocytes will be necessary to dissect the specific
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mechanisms regulating mitochondrial Ca2+ overload and ROS production and will allow
us to further determine the exact pathways regulated by the cardiac intrinsic cholinergic
system.
In addition, decreased energy production will be an interesting avenue to explore in
cVAChT mice. Both ATP levels as well as cardiac energetic reserves (PCr) are critical to
the maintenance of normal cardiac function. Furthermore, the transcriptional changes
observed in another cholinergic deficient mouse line (VAChT KDHOM) in Chapter 2
suggest that cardiac energetics are regulated by cholinergic signaling. Therefore, future
studies should seek to determine whether decreased ATP production can serve as a
potential mediator of cardiac dysregulation in cVAChT mice.
Throughout our studies, we have shown that cardiomyocytes possess the machinery to
secrete ACh, which has significant functional effects. However, it is still unclear whether
other cell types in the heart are also able to secrete ACh and regulate cardiac physiology
through autocrine/paracrine signaling. It is not improbable that other cell types in the
myocardium are capable of producing extraneuronal ACh. In fact, it has already been
reported that several different cell types generate de novo ACh, including keratinocytes
[28], epithelial cells [29, 30] as well as pancreatic α-cells where non-neuronal ACh
primes β-cells to secrete insulin in humans [31]. It will be important to determine
whether different cell types in the heart possess the machinery to produce ACh and
whether altered ACh secretion from these cells is functionally significant. Cardiac
fibroblasts, in particular, would be a good target as they have been implicated in the
adverse myocardial remodeling that occurs in heart disease [32]. Future studies will
involve isolation of cardiac fibroblasts and analysis of response to external stressors,
including inotropic agents. If these in vitro studies prove promising, it would be
necessary to investigate whether cardiac fibroblasts play a role under both physiological
and especially pathological conditions, in vivo.
In addition to the possibility that other cell types in the heart can secrete ACh, it is also
likely that ACh secretion from cardiomyocytes can modulate ventricular function by
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regulating the actions of other cardiac cell types via paracrine signaling. Although this
possibility has never been explored, it may provide a novel pathway through which
cardiomyocyte-derived ACh has its functional effects, in vivo. Endothelial cells, which
are abundantly present in the myocardium, are one particular cell type that may directly
be affected by cardiac non-neuronal ACh. It’s possible that extraneuronal ACh may bind
to M3 receptors on endothelial cells and induce vasodilation of vascular smooth muscle
cells in ventricular coronary arteries. Although it is technically difficult to determine
whether cardiomyocyte-secreted ACh acts through paracrine signaling in other cell types,
the possibility is certainly enticing. It is important to note that the NNCS is not unique to
the cell types mentioned above. In fact, the NNCS plays an active and important role in
regulating immune function because T-cells are able to secrete ACh, which can then act
in an autocrine/paracrine fashion to inhibit inflammatory cytokine production [33, 34].
In Chapter 5, we show that a systemic increase in VAChT expression does not lead to
any adverse cardiovascular phenotypes. Rather, the mice are relatively normal and also
appear to exhibit greater heart rate regulation in response to physiological stress. The
availability of animal models makes it possible to test the notion that increased ACh
secretion from T cells can enhance cholinergic anti-inflammatory signaling and play a
protective role under pathological states. The mouse line we utilized in Chapter 5, ChATChR2-EYFP, overexpresses VAChT in all tissues where ChAT is expressed, including T
cells. Future studies will look to determine whether increased secretion of this T cell nonneuronal ACh, in conjunction with enhanced cardiac cholinergic signaling, can regulate
the onset and progression of ventricular dysfunction in mice following induction of a
pathological response. Furthermore, since VAChT expression appears to be increased in
human failing cardiomyocytes, it will be interesting to determine whether HF also
correlates with increased ACh production and signaling in the cholinergic antiinflammatory pathway.
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6.3 Significance of Research and Conclusion

Although the exact role of the parasympathetic nervous system in cardiac dysfunction
and heart failure has yet to be completely understood, the data presented in this thesis
highlights the importance of modulating this system in heart disease. Previous data have
made it clear that increasing ACh levels, through either vagal stimulation or
cholinesterase inhibitors, can act through a variety of avenues and reduce cardiac
remodeling in several different models of heart disease. In addition, increasing nonneuronal expression of ChAT specifically in cardiomyocytes has been shown to attenuate
ventricular remodeling. The data presented in this thesis furthers our understanding
regarding the regulation of cardiac function by both neuronal and non-neuronal
cholinergic signaling. Notably, we show that this system modulates cardiac activity not
only under pathological conditions but also in the absence of an external stressor. As
such, the cholinergic system may serve as an important pharmacological target in patients
with heart disease.
Recent efforts to repurpose drugs in cancer and neurological diseases are underway with
the leadership of the NIH [35]. The safety and tolerance of cholinesterase inhibitors are
well known, due to their wide use in Alzheimer’s disease. Therefore, it would be easy to
repurpose this class of drugs for heart disease. Modulation of cholinergic signaling may
serve as a novel, unexplored clinical avenue for the treatment of HF in humans. However,
clinical data on the benefits of cholinesterase inhibitors are still scant. Clinical trials are
certainly warranted in order to test potential benefits of adding cholinesterase inhibitors
to current therapies and evaluate the long-term effects of cholinesterase inhibitors at
different stages of cardiac disease and heart failure.
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